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Pancreatic ductal adenocarcinoma is a malignancy with a very 
dismal prognosis, predicted to become the second leading cancer-
related death in 2030. Available treatments do not contribute to 
improve patients’ life expectancy, with a 5 years survival lower than 
10%. The enormous genetic variability, the dense desmoplastic 
stroma, and the immunosuppressed microenvironment make PDAC 
an unsolved clinical challenge.  
 
Oncolytic virotherapy has been envisioned as a therapeutic 
alternative for clinical management of PDAC. Attenuated viruses, 
orientated to specifically eliminate cancer cells, offer multiple 
advantages over current treatments. The therapeutic viruses self-
amplify upon tumor lysis, propagating to adjacent cells with the 
release of tumor associated antigens that can awake the immune 
system against the tumor. Nowadays, many oncolytic adenoviruses 
are undergoing clinical trials for the treatment of solid tumors, 
including PDAC. 
 
However, patients’ response to oncolytic viruses is lower than 
expected, and their administration as monotherapy is not sufficient 
to abrogate tumor mass. This can be partially attributed to the lack 
of relevant models of pre-clinical screening, performed in in vitro 
systems or in xenografts derived from cell lines that do not 
 
 
recapitulate the genetic heterogeneity of PDAC and its complex 
microenvironment. PDAC organoids are 3D structures established 
from patient tumors that are representative of various features of 
PDAC, displaying inter-patient variability and characterized by an 
easy handling manipulation.  In the current thesis we have explored 
the use of organoids in virotherapy for the screening of personalized 
adenoviral treatments, either as monotherapy or in combination 
with actual gold standard chemotherapy. We identified patient-
specific sensitivities to adenoviruses and showed that oncolytic 
virus response in patient-derived organoids (PDOs) from primary 
tumors might predict metastases sensitivity. The results from this 
part of the thesis contributed to the characterization of the organoids 
as a feasible and personalized model for the pre-clinical study of 
oncolytic adenoviruses. 
 
With the aim to generate oncolytic adenoviruses with improved 
tumor potency and enhanced therapeutic index, we studied the 
influence of the deregulated miRNome in PDAC on adenoviral 
replication. We identified several miRNAs that strongly impacted 
adenoviral propagation.  Furthermore, we approached a miR-222 
sponge design to inhibit miR-222 and the restoration of miR-29c as 
strategies to promote adenoviral replication, exploring some 
mechanistic insights. Studies with the novel oncolytic viruses 
AdNuPAR-E-miR-222-S and ICOVIR15-E-miR29c revealed their 
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1.1 The Pancreas 
The pancreas is an organ located in the upper left abdominal cavity, 
behind the stomach, coming out from the duodenum curvature and 
surrounded by spleen, liver and intestines. Its dimensions range 
between 14 and 20 cm. It is lobulated, yellowish and anatomically 
divided in 3 regions: head, body and tail (Fig 1.1 A). 
This organ is classified as a multicellular gland, with mixed 
exocrine and endocrine functions. It secretes hormones, directly into 
the blood flow, and digestive enzymes into the duodenum by a 
system of ducts. 
The endocrine function is exerted in concrete globular zones inside 
the parenchyma of the organ, the pancreatic islets or islets of 
Langerhans. The islets of Langerhans comprise 4 different cellular 
populations, the α, β, δ and PP cells producing glucagon, insulin, 
somatostatin and pancreatic peptides, respectively, directly released 
in the blood flow. 
The exocrine portion of the pancreas is responsible for the 
production of the pancreatic juice, containing the enzymes required 
for the digestion. The producers are the acinar and ductal cells, 
composing 85% of the pancreatic tissue. The enzymes are 
accurately stored in the apical portion of the acinar cells, and their 
secretion in the intercellular canaliculi is finely tuned by external 
inputs from hormones and nerves. The canaliculi are connected to 
small-intercalated ducts, formed by epithelial ductal cells, which 




converges to the main pancreatic duct, finally entering the 
duodenum via the major duodenal papilla (papilla of Vater). Ductal 
cells release water, sodium and bicarbonate to the ductal canaliculi 
and flow together with the digestive enzymes, generating the 
pancreatic juice. The enzymes are kept in an inactive state until 
their reach the duodenum, where enterokinases cleave the proteins 
generating their active forms (Information adapted from 1,2). 
A B 
 
Figure 1.1. Macroscopical and microscopical organization of the pancreas. A. 
Macroscopic representation of pancreas. B. System of centroacinar cells and ductal cells 
for secretion of digestive enzyme. Adapted from 3. 
 
1.2 Pancreatic cancers and Pancreatic Ductal 
Adenocarcinoma 
The pancreatic parenchyma can give rise to a wide range of 
malignancies, including neuroendocrine tumors, colloid carcinomas 
or medullary carcinomas. However pancreatic ductal 




the organ 4. The preferred location for PDAC tumors is the head of 
the pancreas (70%), followed by body and tail (15% each) 5. 
Depending on the geographical area, the incidence of PDAC can 
change, being environmental factors significantly responsible for 
the development of the pathology. Today, PDAC is considered the 
7th cause of cancer-related deaths worldwide, with a 5-year survival 
rate lower than 10%, highlighting the need to clinically improve this 
very dismal prognosis 6,7. 
1.2.1 Histopathological alteration in PDAC 
Study of pancreatic resections identified a series of lesions in the 
small ducts clearly associated with the development of PDAC, 
named Pancreatic Intra Epithelia Neoplasia (PanINs) 8. 
PanINs are pre-malignant lesions with a diameter of less than 5mm, 
arising from small intralobular ducts of the pancreas and with 
different grades of cellular and architectural atypia. PanIN-1 is a 
low-grade lesion, which does not present atypia yet, but can be 
characterized by a flat (PanIN-1A) or papillary (PanIN-1B) 
epithelium. Molecular characterization identifies the presence of K-
Ras mutations and telomeres shortening in PanIN-1, classifying 
these alterations as PDAC initiators. PanIN-2 is characterized by 
moderate cytological and architectural transformation and CDKN2A 
inactivation. Mutations characterizing aggressive PDAC tumors are 
acquired during the PanIN-3 grade, in which the majority of cases 
present with loss of TP53 and SMAD4. The term PanIN-3 is often 




atypia both at cellular and architectural level is already present (Fig 
1.2) 9–11. 
Recent recommendations from international experts raised the 
consensus to classifying PanIN lesions in two groups, low-grade 
and high-grade, categorizing PanIN-2 as low-grade (Fig 1.2) 12. 
Other pre-malignant histological alterations encountered in patients 
and associated to the development of pancreatic cancers are the 
intraductal papillary-mucinous neoplasm (IPMN) and mucinous 
cystic neoplasm (MCN). However, these lesions are associated to 
PDAC with less incidence and their characterization is not as 
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Figure 1.2. Evolution of preneoplasic PanIN lesions from normal tissue. Image adapted 
from 12. 
 
Preneoplastic lesions can take up to 10 years to evolve to PDAC, 
meaning that a diagnosis at preliminary stage would be extremely 
helpful in the management of this malignancy. However, PDAC is 




invading circumstantial organs and thus being unresectable. 
Advanced PDAC is characterized by the appearance of a dense 
stromal component, a phenomenon called desmoplasia, proliferating 
ductal structures, accompanied by severe atrophy of acinar cells, 
inflammatory foci and surrounded by PanIN structures. These 
tumors acquire a plethora of extra genomic changes, permitting 
incredible levels of proliferation, inhibition of apoptosis, 
chemoresistance and ability to migrate and invade (information 
from Pancreatic Cancer, Methods and protocol 2008, Gloria H Su 
editor). 
1.2.2 Molecular characterization of PDAC tumors 
One of the main difficulties in PDAC management is its great 
molecular heterogeneity. The early driving mutations of KRAS, 
TP53, CDKN2A, and SMAD4 are widely characterized (Fig 1.2) 13–
15. 
• KRAS is altered in more than 90% of PDAC, initiating in 
low grade PanIN. The most recurrent alteration is a point 
mutation in the 12th codon of the gene, resulting in a 
constitutive activation of the protein. KRAS belongs to the 
RAS superfamily, encoding a small GTPase protein 
regulating proliferation, differentiation, survival and 
migration. Once mutated, the GTPase activity is abolished, 
leading to constitutive activation of downstream pathways. 
• CDKN2A is a tumor suppressor gene, encoding both 




deletions mostly affect only p16INK4A functions 15. The 
primary function of this protein is a tight regulation of G1/S 
checkpoint of cell cycle, by phosphorylating CDK4 and 
CDK6. Loss of p16INK4A lets pancreatic cancer cells 
proliferate without control. 
• TP53 is tumor suppressor factor, present in the cell as a 
latent form. It is activated after damage in the genome, 
enabling cell cycle arrest and permitting eventual gene 
repair or driving cells to apoptosis. Main mutation of p53 
resides in its DNA binding domain, leading to its 
accumulation in the nucleus. Loss of TP53 is generally the 
consequence of CDKN2A alteration, probably induced by 
the accumulation of damaged DNA inducing a selective 
pressure for the tumor progression. It is mutated in 85% of 
PDAC patients. 
• SMAD4 is the co-transcription factor responsible for 
activation of TGF-β canonical pathway. It is lost in high 
grade PanINs, before the development of advanced 
carcinoma. It is mutated in 55% of PDAC. 
Besides these common alterations, the rest of the genes harboring 
mutations can be encountered among PDAC patients with a 
frequency lower than 5%. 
Recently, large scale molecular analysis provided a more detailed 
classification of PDAC, identifying subclasses of PDAC tumor 




their mRNA expression profile, and the composition of the tumor 
16,17. A consensus nomenclature has been recently proposed 4, 
recognizing the following 4 subtypes: 
• Quasi Mesenchymal (QM-PDA) or squamous, due to a high 
presence of genes overlapping with other squamous tumors 
• Immunogenic progenitor: classical PDAC, characterized by 
decreased tumor cellularity and strong immune infiltration 
• Pure classical progenitor: classical PDAC tumor 
• Exocrine like or Aberrantly Differentiated Endocrine 
Exocrine (ADEX): characterized by a transcriptional 
program more similar to normal differentiated pancreas 
This classification defines PDAC tumors with distinct biology and 
can help to identify subtype-specific therapeutic vulnerabilities. 
1.2.2.1 Altered molecular pathways relevant for this study 
The plethora of genetic mutations in PDAC impacts the core of 
many signaling pathways 18.  We briefly summarized those relevant 
for this study. 
 
 
Notch Signaling Pathway 
This embryonic signaling pathway has the control of the stem cells’ 




pathway is common to many PDACs samples. A family of 4 trans 
membrane proteins (Notch 1-4) acts as cellular receptor. Upon 
binding to its ligands Jagged 1-2 (JAG1-2) or Delta like (Delta 
1,3,4), there is a conformational change in the Notch receptor that 
exposes the protein to intracellular proteases. A first cleavage from 
ADAM family protein of metalloproteinases, and a second from γ 
secretase complex, release the intracellular domain of Notch 
(NICD). Once in the nucleus, NICD interacts with RBPJ/CSL, 
initiating the transcription of target genes such as: HES (Hairy 
Enhancer of Split), HEY (HES related to YRPW), cyclin D1, p21, 




According to literature, Notch pathway is one of the major 
pathways responsible for chemoresistance and maintenance of 
cancer stem cell population inside the PDAC tumor bulk 22. 
Figure 1.3. Schematic Representation of Notch Signaling Pathway. Image from Nowell 





This pathway is physiologically related to embryonic development, 
with implications in morphogenesis and proliferation of many 
organs. However, it is also one of the early-altered pathways in 
PDAC. 
The Wnt family is composed of 19 different ligands, acting in a 
canonical or non-canonical pathway, having as direct effector the β-
catenin. The canonical pathway is regulated by an on/off system, 
whose activation depends on Wnt ligand binding to its 
transmembrane receptor frizzled (FRZD). In the absence of this 
interaction the degradation complex APC/Axin/GSK-3β tightly 
controls β catenin levels, and upon phosphorylation, marks the 
molecule for proteasomal degradation. When Wnt binds to FRZD, a 
series of conformational changes lead to the dishvelled protein 
(DSH) recruitment to the FRZD receptor, where it is required to 
inhibit APC/Axin/GSK-3β activity23,24. Then, β catenin is 
accumulated in the cytoplasm and migrates to the nucleus, where 
upon binding TCF/LEF transcription factors initiates cell fate 





Figure 1.4. Schematic representation of Wnt/b catenin signaling pathway. Image from 
26 
In PDAC the over activation of this pathway is considered an early 
event, already detected in PanINs. The main tumorigenic activity 
has been linked to resistance to apoptosis and maintenance of a 
CSC population, likely responsible for gemcitabine resistance 27. 
Urokinase type plasminogen activator receptor (uPAR) 
The uPAR/uPA system is a major regulator of the extracellular 
matrix (ECM) remodeling. The binding of uPA activator to the 
receptor uPAR leads to the cleavage of the zymogen plasminogen 
present in the ECM, generating the protease plasmin 28. Plasmin 
removes by proteolytic cleavage ECM components and activates the 
metalloproteinases (MMP) for matrix remodeling (Fig 1.5).  The 
uPA/uPAR complex is also involved in signal transduction and 





Figure 1.5. Regulation of cell signaling by uPA/uPAR. Image from 31 
 
The upregulation of uPAR gene is well described and common to 
many cancer types, including PDAC. High expression of this 
molecules has been related to dismal prognosis 32, and the main 
effects provoked by this upregulation are linked to EMT 
transformation and progression through a metastatic phenotype 29,33. 
Many studies linked the upregulation of these molecules to the 
acquisition of a CSC phenotype. 
1.2.3 PDAC microenvironment 
PDAC is one of the most stroma-enriched cancers, where stromal 
cells outstand tumor cells number, ranging from 50 to 80% of tumor 
population 34. Widespread fibrotic desmoplasia, composes the 
PDAC tumor microenvironment (TME) 35. 
The desmoplastic reaction is characterized by the recruitment and 
activation of cancer associated fibroblasts (CAFs), remodeling of 




and fibronectin, and recruitment of regulatory immune cells, 
conferring an immunosuppressed environment 36,37. 
CAFs were first thought to be originated from pancreatic stellate 
cells, mesenchymal-like cells resident in normal pancreas; however, 
their origin from mesenchymal stem cells, bone marrow derived 
stem cells and endothelial cells have been well documented 
(reviewed in 37). In the last years, their role in PDAC progression 
has been better understood, defining subtypes of CAFs inside 
tumors, with different aggressive phenotypes. The first 
characterization of a normal and activated stromal subtypes was 
performed by Moffit and collaborators 38. The discovery of two 
different subpopulations of CAFs, defined as inflammatory CAFs 
(iCAFs) and myofibroblast (myCAFs), endowed with pro-
tumorigenic and tumor-restraining properties, respectively39, 
identified these cells as a key factor for PDAC evolution and 
treatment (Fig 1.6).  
 
Figure 1.6. Different Populations of Cancer Associated Fibroblasts existing in PDAC 




Besides CAFs, more factors must be taken into account in TME. 
PDAC is considered a non-immunogenic tumor, due to the ability to 
mask its own tumor antigens from the immune system. This is 
related to the secretion of immunosuppressive cytokines and other 
molecules, transmitting inhibitory signals to immune cells. Several 
studies highlight how PDAC TME is mainly populated by 
immunosuppressive cell types, such as regulatory T cells or 
myeloid-derived suppressor cells, with very low infiltration of 
Cytotoxic T Lymphocytes (CTL) 34,36 (Fig 1.7). 
 
Figure 1.7. Composition of the PDAC tumor microenvironment. Image from 41 
 
1.2.3.1 Pancreatic cancer stem cells 
Similarly to normal tissues, preserving a reservoir of adult stem 




tumor initiating cells (TICs), has been described as a part of the 
cellular component in a variety of tumors 42. This small percentage 
of cells is endowed with tumor initiating potential, self-renewal and 
ability to reconstitute the tumor 43. This low-differentiated 
subpopulation has been associated with increased resistance to 
cytotoxic agents, such as gemcitabine, due to the overexpression of 
efflux pumps (ABC transporter), antioxidative agents and 
antiapoptotic proteins (Fig 1.8) 44. 
A strong reactivation of the embryonic signaling pathway, such as 
hedgehog, Notch and Wnt, is a common feature of CSC. However, 
the molecular characterization of this subpopulation is still highly 
incomplete 45. The divergence of molecular markers encountered is 
variable, stressing the probability of the existence of more than one 
population with plasticity within the pool of CSCs (Fig1.8) 43.  
 




Remarkably, the PCSC population establishes strong 
communication with the desmoplastic TME of PDAC. The 
interaction between CAFs and PCSC has started to be characterized, 
revealing the presence of a tight crosstalk with the secretion of pro-
tumorigenic cytokines (IL-6, IL-8…) and chemokines stimulating 
CSCs properties 46. Intervening in this crosstalk can provide novel 
development for future therapies. 
1.2.4 PDAC treatment 
PDAC is a complex malignancy, highlighting the importance of a 
multidisciplinary team in patients’ management 47. Surgery still 
remains the only cure for patients affected by this malignancy. 
However, the number of patients arriving at diagnosis with a 
resectable PDAC is of 10-20%. Instead, the number of individuals 
diagnosed with a borderline resectable (BRPC) or locally advanced 
pancreatic cancer (LAPC) ranges around 30-40% of cases. 
Remaining patients (50-60%) already present metastatic or systemic 
disease at diagnosis 14. 
Surgery alone is not sufficient, since the number of relapses within 
the year after surgery is around 90% of operated patients. Then, the 
best strategy consist on the administration of adjuvant therapies 
based on gemcitabine + capecitabine, following surgery, resulting in 
a 5 years-survival of 30% 48. An emerging strategy for BRPC or 
LAPC is the administration of neoadjuvant therapies that can reduce 
the tumor mass from a local advanced stage to a resectable tumor. 
In this scenario, the mixed regimen of FOLFIRINOX (Oxaliplatin, 




of gemcitabine + albumin bounded paclitaxel (nab-Paclitaxel) are 
the chemotherapies of choice (reviewed in 49). 
In advanced non operable PDAC, depending of the physical status 
of the patient, either FOLFIRINOX, for those with a general good 
health status, or gemcitabine + nab-Paclitaxel, for the rest, are 
administered 50–52. Overall survivals of 9,9 and 7,9 months, 
respectively, were reported in a recent study gathering clinical 
routine data across Europe 53. 
 
PDAC patients’ life expectancy is still very low. Despite the good 
knowledge about the molecular and pathological alterations, the 
targeted therapies against PDAC have not led to results comparable 
to actual standard of care. Nowadays, immunotherapies are 
promising and are giving good results in many cancers. However, 
the immunosuppressed environment of PDAC is probably the 
reason why any clinical success has been reported yet for this 
neoplasia (reviewed in (54)). 
 
1.3 microRNAs 
MicroRNAs are a huge class of single strand RNA molecules 
composed of 22-23 nucleotides, able to regulate gene expression at 
post-transcriptional level. Described for the first time in C. Elegans 
55, their presence in many eukaryotic organisms has been 
documented. These small RNA molecules are involved in all 




thus having a key role in the evolution towards pathological status, 
such as cancer56,57. In 2010, the number of miRNAs claimed in the 
human genome was 70058; nowadays, thanks to high throughput 
sequencing techniques and analysis, miRBase release 22.1 accounts 
for 4719 known human miRNAs. 
1.3.1 microRNAs biogenesis and regulation 
The process of miRNA production is tightly regulated, involving 
huge number of factors, responsible either for miRNA processing or 
modulation. Mature miRNAs come from different sources; the most 
abundant ones, and the first to be discovered, localize in intronic 
regions. They are processed co-transcriptionally, before splicing, 
from RNA polymerase II 56,59. Intronic miRNAs are usually 
processed following the canonical pathway of miRNA biogenesis. 
The canonical pathway involves a first transcriptional step inside 
the nucleus, followed by molecule exportation and processing in the 
cytoplasm. Intronic miRNAs are processed by RNA polymerase II, 
which generate a pri-miRNA, characterized by one or more stem 
loop structures with 3’ and 5’ tails, reaching more than 1 Kb length. 
A single stem loop is composed of an upper stem of 22 nt long, in 
which the future mature miRNA is localized, and a lower stem of 
11 nt long, ending in overhang 3’ and 5’ extremities 59. As a 
distinctive feature of RNA polymerase II transcription, pri-miRNAs 
are capped and polyadenylated, like mRNAs, and from the same 
transcriptional unit more than one microRNAs can originate 58,60. A 
dual protein complex called the microprocessor captures pri-




RNAse III enzyme, and DGCR8 (DiGeorge Critical Region 8), its 
cofactor. 
Briefly, the pri-miRNA structure ending in a loop is recognized by 
DGCR8, whose binding will permit the cleavage performed by 
Drosha. After that, a 65-70 nt stem loop is released, known as the 
pre-miRNA. The cut performed by Drosha leaves a signature of a 2-
nucleotide overhang at the 3’ end of the pre-miRNA 60. Additional 
proteins finely tune the process, either acting over the efficiency of 
the process (helicases) or modulating the activity of the 
microprocessor via post-transcriptional modification 
(phosphorylation, sumoylation, ubiquitination) 57,61. 
The pre-miRNA is exported to the cytoplasm with the help of the 
GTP dependent Exportin 5 (XPO5). GTP to GDP hydrolyzation 
mediated by XPO5 releases the dsRNA structure (Winter et al., 
2009). Once in the nucleus, the nuclease Dicer, with the help of 
double stranded RNA binding proteins TRBP and PACT, recognize 
the 3’ overhang of the pre-miRNA and generates a cut 22-25 nt 
downstream, resulting in the removal of the stem loop and the 
generation of a dsRNA duplex 56. 
The formation of this small duplex is determinant for the assembly 
of the RNA-induced silencing complex (miRISC), formed by the 
union of the duplex with the AGO proteins. In humans, 4 AGO 
proteins have been discovered, showing preferences for RNA 
duplexes characterized by mismatches in the nucleotides through 
the positions 8-11. Dicer is essential for the duplex charging on the 




thermodynamically stable of the two strands is selected to form the 
mature miRISC complex, and it will receive the name of the guide 
strand. This complex is the responsible for the binding to target 
mRNA, which is recognized by base-pair complementarity to the 
guide strand of the miRNA previously charged in the AGO protein. 
The other strand, known as passenger strand, is unwound and 
released with the help of endonucleases and ATP hydrolyzing 
proteins (Process resumed in fig 1.9) 59,60. 
Besides canonical pathway, other routes independent from Drosha 
have been listed for miRNAs. MiRNAs having origins from small 
introns spontaneously assume a structure resembling pre-miRNA 
and are directly recognized by XPO5 and transferred to the 
cytosolic compartment. In other cases, pre-miRNAs can originate 
from short hairpins directly transcribed by RNA pol II, or from non-
coding-RNAs, such as t-RNAs and snoRNAs (Fig 1.9). These are 
Drosha independent, but their processing still depends on Dicer 





Figure 1.9. Canonical and non-canonical biogenesis of miRNAs and formation of 




1.3.2 Target recognition 
Study of the pairing of miRNAs with their target genes led to the 
identification of principles useful for target recognition or 
prediction. It is well established that the most determinant region 
for target recognition is the seed sequence, a 6 nt long sequence 
located at the 5’ of the miRNAs, including nucleotide from 2 to 7 62. 
The seed sites on the mRNA and the seed sequence on miRNA pair 
via Watson Crick complementarity, determining an interaction 
called canonical. Besides canonical interaction, extra nucleotides 
pairings can take place, depending if the 1st and 8th nucleotide 
preceding and following the seed, respectively, are involved in the 
target recognition 63. Pairings admitting wobbling or bulged sites 
inside the seed sequence have been described, especially in 
mammals. This results in a less strong inhibitory interaction, and it 
is often helped by the presence of extended complementarity at the 
3’ end of the miRNA seed sequence 64,65. 
The preferred region for these interactions is identified in the 
3’UTR of an mRNA, although binding sites inside the codifying 
sequence or regulatory motifs have also been encountered. Within 
the 3’UTR, the miRNA interacts with a variety of RNA Binding 
Proteins (RBPs), whose interactions and abundance will determine 
the post-transcriptional regulation of the mRNA. In general, genes 
with stable expression are characterized by very short 3’UTR, 
limiting the interaction with inhibiting miRNAs and RBP, whereas 
short-living genes have longer 3’UTR, permitting tight and precise 




towards its end, whereas in the short one seed sites have been 
encountered 15-20 nt away from stop codons 68. In general, the 
presence of more than one seed sites enhances the strength of 
interaction, leading to best target inhibitions. 
1.3.3 Regulation of mRNA translation 
The recognition of the miRISC complex and the seed site on a 
target mRNA leads to a destabilization of mRNA, first inhibiting 
translation and then causing target degradation. 
Secondary structure of mRNA is fundamental to understand the 
process of miRNA silencing. It is well established that 5’ end of the 
mRNA is immediately capped during transcription, whereas the 3’ 
end of the sequence is formed by a long polyA tail, bound to the 
PolyA binding protein (PABP). The cap and the PABP interact via a 
molecular bridge composed by the proteins eIF4E, directly 
recognizing the cap, eIF4G, a scaffold protein, and eIF4A, a RNA 
helicase. All these proteins organize the mRNA in a circular 
structure promoting ribosome binding and translation 68. 
MiRISC complex disrupts this organization through sequential 
steps. The miRNA resides inside the AGO protein in a stretched 
conformation, where only the seed sequence is exposed for mRNA 
target identification 66. Upon recognition, the protein GW182 
mediates the disruption of mRNA structure. The molecular bridge 
between PABP and eIF4E is interrupted and mRNA linearized. The 
polyA tail is now exposed to cellular nucleases, recruited by the 




digest the exposed polyA of the mRNA, which is in turn submitted 
to a decapping process by exonuclease XRN1 and finally degraded 
(Fig 1.10). 
 
Figure 1.10. Translational repression induced by the action of the miRISC complex. 
Image from 69. 
1.3.4 miRNAs and cancer 
Considering their regulatory properties, since the very beginning of 
their discovery miRNAs were studied for participation in 
carcinogenesis. The first evidences arrived with the discovery of 
miR-15/miR-16 deregulation in chronic lymphocytic leukemia. The 
loss of these miRNAs was associated to a frequent deletion in 
chromosome 13, present in about 70% of cases 70. 
Successive studies classified chromosomal loss or amplification as 
one of the driving events for miRNA downregulation or 




cause for miRNA deregulation came from studies demonstrating 
that the pro-tumorigenic MYC and TP53 genes acted as important 
regulators of miRNAs expression. MYC has been demonstrated to 
activate miR-17-92 pro-tumorigenic cluster 74, responsible for E2F 
regulation and progression through cell cycle. On the other hand, 
MYC negatively regulates tumor suppressive miRNAs, such as 
miR-26, miR-29 and let-7 family, favoring tumorigenesis 75. 
TP53 acts by regulating miRNAs involved in cell cycle and 
apoptosis, processes that become misbalanced as a consequence of 
TP53 mutation 73. Other mechanisms of miRNA deregulation are 
linked to epigenetic silencing or activation, and defects in miRNA 
biogenesis machinery. Deletion in Dicer and Drosha has been 
linked to an accelerated tumor progression in vivo, and mutations 
along the pathway of miRNA biogenesis are related to enhance risk 
of cancer 72,73.Accumulation studies on cancers’ miRNome defined 
lists of miRNAs whose expression changes in malignancies. A 
widespread underexpression of miRNAs in tumor tissue is 
observed, although upregulation of certain miRNAs is also detected. 
Whereas the location of the tumor and its stage are the main 
determinants of the deregulation, some miRNAs are permanently 
altered in many cancers 76–78. 
1.3.4.1 miRNAs and PDAC 
The first description of the PDAC-associated miRNome is from 
2007. Szafranska and collaborators gathered miRNA-related data 
from normal pancreas, chronic pancreatitis, PDAC tumors and cell 




between normal and transformed tissues 79. Nowadays, there are 
plenty of studies integrating data and listing miRNAs associated to 
PDAC malignancies.  Discrepancies between studies are mainly due 
to different type of samples and analysis. However, there are 
miRNAs whose role has been well studied and constitute part of the 
PDAC deregulated miRNome 80–82. 
Downregulated miRNAs of interest in this study: miR-29c. 
The miR-29c belongs to a family of miRNAs composed of three 
mature members, miR-29a, miR-29b and miR-29c encoded in two 
genetic clusters. MiR-29c is located in the chromosome 1, in a 
cluster with miR-29b. The expression of this family is widespread 
down-regulated among cancers exerting a control over ECM 
deposition83. In PDAC, a deregulation of the whole family is 
observed, linking this loss to the progressive accumulation of 
fibrosis in KRASG12V pancreata of KC mice and human PDAC 
tumors, stressing the importance of miR-29s in remodeling tumor 
stroma 84. Specific studies on the role of miR-29c showed that the 
re-introduction of this miRNA led to an enhanced gemcitabine-
induced apoptosis in PDAC pre-clinical models 85. Furthermore, 
miR-29c avoids β catenin accumulation into the nucleus leading to 
inhibition of Wnt/β catenin signaling. This phenomenon 
demonstrated to revert self-renewal ability and CSC-like properties 
of PDAC cells 86. 
Moreover, miR-29c may have an active role in regulating host-
pathogens interactions, especially in response to viral infections by 




Upregulated miRNAs of interest in this study: miR-222 
The overexpression of miR-222 has been described among gastric 
cancers88. Specifically, the upregulation of the whole cluster 
comprising miR-221 and miR-222 has been reported, and related to 
poorer survival in PDAC patients89. These miRNAs are located in 
the X Chromosome, sharing an identical seed sequence and with 
extremely high sequence complementarity. MiR-221 and miR-222 
are separated by 727 bp, transcribed by the same promoter and thus 
presenting comparable expression profiles 90. MiR-221 and miR-
222 regulate p27 and p57, respectively, favoring progression 
through G1/S phase of cell cycle. The upregulation of these 
miRNAs in PDAC cells induces resistance to apoptosis 91 and 
confers tumor-remodeling properties by inducing MMP, favoring 
tumor dissemination and spread of metastases 92. 
The interaction of this cluster with adenoviral infections 
demonstrated to be important. Zhao and collaborators described a 
constant diminution of miR-221 in adenovirus-infected lung 
fibroblast 93. Similarly, downregulation of miR-222 showed 
increased adenoviral oncolysis in prostate cancer cells, revealing an 
inhibitory role of this miRNA on adenoviral fitness 94. 
1.4 Patient-derived organoids (PDOs) 
Recent advances in cell culture technologies permitted the 
introduction of a 3D model recapitulating human physiological and 
pathological conditions: the organoids. These are 3D-multicellular 




characteristics, which can self-organize and divide in a manner 
similar to in vivo, simulating the architecture and functionality of 
native organs 95–97. 
 
Organoids were introduced for the first time in 2009 by Dr. Clever’s 
group, with the discovery that intestinal cells expressing Leucine-
reach repeat containing G-protein coupled receptor 5 (Lgr5), a 
marker of adult stem cells (aSC), formed organized 3D structures 
when cultured in Matrigel under specific stimuli 98.Organoids have 
been then introduced in many research fields, to model human 
development and diseases “in a dish”.  
 
These 3D structures can be developed either from pluripotent stem 
cells (PSC), and more interestingly from adult stem cells (aSCs) of 
many tissues, including colon, intestine, pancreas, stomach, liver, 
prostate and kidney (reviewed in 95,99). Interestingly, the presence of 
a subpopulation of cancer stem cells residing in tumors enabled the 
generation of organoids from transformed tissue of different tumor 
types, opening novel insights in cancer research 100–102. 
1.4.1 Organoids and cancer 
The generation of tumor-derived organoids opened a new field in 
cancer research, uncovering clues in cancer development and 
biology, together with accelerating the discovery of new 
compounds and introducing personalized therapies 103. 
 
Tumor-derived organoids overcome many limitations presented by 




based on the use of classical 2D cell lines, Genetically Engineered 
Mouse Models (GEMMs) and patient-derived xenograft (PDX) 
104,105. Although 2D cell lines are easy to propagate in culture, they 
are submitted to strong in vitro selection, leading to the loss of 
tumor molecular characteristics. GEMMs and PDXs better 
recapitulate tumor histo-architecture, mutational landscape and 
phenotypic diversity, serving as more reliable models for the study 
of tumor biology and therapeutic testing. However, they are 
expensive and time consuming, limiting preliminary drug screening 
95,106. 
Instead, organoids have the intrinsic ability to represent individual 
patient’s characteristics, resembling histo-architecture of tumor of 
origin. Interestingly, tumor-derived organoids can be cryopreserved 
and propagated for many passages, and unlike cell lines, remain 
genetically stable. The establishment of a culture is easy and briefly 
accomplished 101,107,108. With an intermediate cost between cell lines 
and PDX, it is likely that organoids will become the preferred tool 





   Figure 1.11. Advantages and disadvantages of actual PDAC pre-clinical models. 
 
Considering all these benefits, organoids are nowadays applied in 
cancer research to deep insight cancer biology and novel therapeutic 
approaches. Their main applications will be described as follows. 
Organoids for cancer modeling 
Cancer is a pathological state induced by a progressive 
accumulation of mutations. The possibility to genetically 
manipulate healthy organoids by CRISPR/Cas9 technology permits 
the study of single mutation-contribution to the development of 
malignancies (reviewed in 104,108).  Colorectal cancer (CRC) is the 
best case of accumulating alterations; studies managed to recreate in 
vitro single cell-gene mutations, identifying additive effects in 




109. Following these pivotal studies in CRC, analogous experiments 
were performed in esophagus110,  gut111 and pancreas112, generating 
stepwise progression of malignant organoids from non-transformed 
tissues (reviewed in104). 
 
Mutational processes behind cancer can be further studied with 
tumor-organoids biobanks. Organoids can be generated from 
resected tumors at different stages, including metastasis, broadening 
inside the role of mutations in cancer development and exploring 
different genomic landscapes (Fig 1.12). Moreover, organoids can 
help to elucidate the heterogeneity among sub-clonal populations 
within the same tumor mass. Roerink and collaborators individuated 
parallel mutational processes co-existing inside a CRC tumor, 
describing subpopulations resistant to treatment, likely responsible 
for therapies failure113. 
 
Considering the emerging role of organoids in the study of genetic 
landscapes of cancer, their unique generation from resected tumors 
can be limiting. For cancers such as PDAC, where only 10-20% of 
patients undergo surgery, the introduction of organoids from 
different cancer stages is required. Recently, the derivation of 
organoids from fine needle biopsies permitted the study of more 
preliminary or more advanced stages of tumors, generating novel 







Organoids for personalized drug screening 
The high structural and genetic analogies presented by tumor-
derived organoids with their tumor of origins make them a superior 
model in the identification of novel anti-cancer therapies and 
personalized treatment (fig 1.12). 
 
Although organoids have not been directly implied in drug 
development yet, small scale drug screening suggested promising 
results 104. Organoids biobank have been explored for the discovery 
of novel druggable targets, favoring the identification of new altered 
molecules for pharmacological inhibition 100. Moreover, the 
possibility to derive organoids from healthy livers can help in the 
management of drug-associate toxicity, responsible for failure of a 
big number of treatments starting clinical trials 104. 
 
The use of organoids for personalized drug screening have been 
introduced since their very beginning, identifying different grade of 
sensitivity among PDOs 100,116. However, until recently, the 
cytotoxicity observed in organoids in vitro was not compared to 
patients’ response in the clinic. In the last two years, studies in CRC 
and PDAC demonstrated matching sensitivities between patients 
and their derived organoids, suggesting the predictive value of this 
system in terms of drug response115,117,118. Interestingly, the 
possibility to derive organoids from patient’s metastasis can help to 




time frame determine the most adequate approach for patients with 
advanced diseases 117,118. 
Considering the validity and predictivity of the system, it is likely 
that in the following years organoids will become a determinant tool 
for prompt clinical decision making. 
 
Figure 1.12. Possible applications for organoids in cancer research. Image from 104 
1.4.1.1 PDAC-derived organoids 
The introduction of organoids in cancer research has been 
particularly beneficial for those malignancies characterized by high 
mortality rate, such as PDAC. With a 5 years survival lower than 




major clinical problems7. The great genetic diversity among 
patients, not represented in cell lines, but strongly respected in 
organoids, stimulated the interest on this tool for PDAC research. 
Huch and collaborators generated organoids from pancreatic tissue 
for the first time in 2013. Like for intestinal organoids, they 
demonstrated that upon pancreatic injury, ductal cells were 
activated with a concomitant expression of Lgr5 marker and 
upregulation of Wnt signaling119, required for tissue 
remodeling120,121. 
Information gathered with the organoid model in PDAC has 
demonstrated the structural and genetic features shared between 
primary PDAC tumor and its derived PDOs107,122,123. Others have 
proved the value of PDAC organoids to identify the contribution of 
specific genetic mutations towards the development of the 
malignancy 112. 
 
The unmet clinical need to identify efficacious treatments for PDAC 
patients resulted in the generation of a biobank of 69 PDOs, derived 
from surgeries, fine needle biopsies and post-mortem autopsies, 
with primary tumors and PDAC metastasis to screen for 
therapies115. Whole genome sequencing identified common 
mutations between primary tumor and PDO, and transcriptomic 
analysis permitted the classification of PDAC tumors in classic and 
basal-like subtypes, according to the actual nomenclature 4. In this 
work, the concept of “pharmacotyping” was introduced for the first 




observed drug sensitivity. Interestingly, when treated with actual 
gold standards, organoids derived from tumors with high cellularity 
mirrored the outcome observed in their corresponding patients, 
dividing individuals in responders and non-responders. 
 
The publication of this study in 2018 pointed towards organoids as 
a novel rationale to guide personalized therapeutic regimens in 
PDAC. However, there are also some limitations to current 
organoids technology, being the most relevant the lack of stromal 
elements in PDOs cultures. Since the PDAC organoids community 
is highly aware of this limitation, efforts to establish conditions for 
cultures of organoids with CAFs and/or T-cells have been 
described39,124. 
 
However, considering the importance of the desmoplastic reaction 
in PDAC tumors, further investigation is needed to the 
establishment of 3D cultures involving PDOs, and recapitulating the 
tumor microenvironment. This would evolve in the generation of 
more predictive screening models. 
 
1.5 Oncolytic Virotherapy 
Oncolytic virotherapy is an emerging cancer therapy that takes 
advantage of replication-competent viruses to selectively destroy 
cancer cells (Fig 1.13). The interest of viruses as possible agents for 
tumor destruction originates in early 1900s, with the observation of 




the birth of cell culture in 1950s, many studies evaluated the activity 
of different viruses on tumor cells, resulting in clinical trials. 
However, since the use of wild type viruses showed systemic 
toxicities in many patients and transitory clinical benefits, the 
interest of viruses as cancer weapons was abandoned (reviewed in 
125–127). The idea of introducing tumor selectivity to a virus was first 






Figure 1.13. Schematic Representation of the concept of oncolytic virotherapy. 
 
Since then, both RNA and DNA viruses have been genetically 
modified to obtain tumor selectivity and higher potency 129–131. 
Oncolytic viruses (OV) are now designed to replicate and kill tumor 
cells, leaving normal cells unharmed. Lysis induced by viral 




new cancer cells, and liberate tumor-associated antigens, that can be 
recognized by T cells, engaging the immune system against the 
tumor (Fig 1.13)132,133. 
An attenuated adenovirus serotype 5, Oncorine (H101) has been 
authorized since 2005 in China for head and neck carcinomas 134.  
However, the first virus worldwide approved as virotherapy from 
both the Food and Drug Administration (FDA) in the USA and the 
European Medical Agency (EMA) in Europe was the T-VEC in 
2015 135–137.  T-VEC is an attenuated herpes simplex virus (HSV-1) 
modified for the expression of granulocyte-macrophage colony 
stimulating factor (GM-CSF) transgene, promoting antitumor 
immunity 138. It is nowadays used in clinic as monotherapy for 
advanced stages melanomas. 
Following T-VEC approval, a big number of oncolytic viruses have 
been armed with transgenes with characteristics that can 
complement viral activity. Herpes viruses, vaccinia viruses, 
picornaviruses, retroviruses and adenoviruses are undergoing phase 
I/II clinical trials, alone or in combination with drugs, bringing new 
horizons in the treatment of incurable tumors 132,136,139. 
1.6 Oncolytic adenoviruses 
Following its discovery in 1953 140, studies of adenoviruses 
elucidated intrinsic characteristics making them attractive 
therapeutic agents. Adenoviruses are not associated to serious 
pathologies (i), their genome is well known and easy to manipulate 




integrate inside the genome (iv), can be produced at high titers (v) 
and are able to activate immune responses upon cell lyses (vi) 141–
143. The sum of these properties makes this virus largely explored in 
clinic, being nowadays in 51 clinical trials for cancer treatment 
(source: https://clinicaltrials.gov). 
 
1.6.1 Adenoviral Biology 
Adenoviruses belongs to the adenoviridae family, infecting 
eukaryote cells and classified in 7 different groups, from A to G. 
Nowadays, 57 different serotypes of adenovirus have been 
described 144,145. Among the human adenovirus, the group C, 
especially serotype 2 and 5 are the best studied and mostly applied 
for therapies. 
1.6.1.1 Adenoviral genome structure and dynamics of expression 
Adenovirus C serotype 2 and 5 present a dsDNA genome of 35-36 
KB length, encoding more than 40 proteins. Given its limited 
dimensions, adenoviral genes are efficiently organized in 
polycistronic transcription units, with overlapping genes (Fig 1.14 
A). The perfect temporal organization of the adenovirus permits a 
sequential expression of its genes to gradually take over host cells, 
permitting viral DNA replication and maturation 146,147. 
Depending on when they are expressed during the life cycle, 





• Immediate early: E1A. Existing in 4 different splicing 
isoforms, it is determinant for the manipulation of host cell 
environment and the expression of the early genes. The conserved 
regions (CR) 1-4 of E1A establish more than 4000 protein 
interactions, suppressing cellular innate immunity and forcing host 
cell to enter the S phase of cell cycle. E1A CR3 trans-activates E1B, 
E2, E3 and E4 early genes 147,148. 
• Early: E1B, E2, E3 and E4 continue with the remodeling of 
the cellular environment and induce adenoviral DNA transcription. 
E1B interferes with cellular mRNAs accumulation and protein 
degradation, repressing interferon-stimulating genes (ISG) and 
favouring viral RNA transcription and splicing 149. E2 encodes for 
the viral replication machinery, composed by the DNA binding 
protein (DBP, E2A), adenoviral polymerase (AdPol, E2B), and pre 
terminal protein (pTP – E2B) 146,147. E3 produces multiple spliced 
proteins contributing to the suppression of the anti-viral response. 
E4 encodes at least 7 proteins with functions involved in DNA 
replication and host-cell manipulation 150,151. 
• Intermediate: the small genes IX and IVa are transcribed at 
intermediate point of infection, independently of late transcripts 
expression. They have a role in DNA packaging into mature virions 
and facilitate the activation of the major late promoter (MLP) 146,151. 
• Late: the activation of these genes defines the second phase 
of adenoviral infections and takes place after viral DNA replication 
has started.  The late genes (L1-L5) are alternatively spliced and 
polyadenylated from the same 28000 Kb transcript under the 




packaging proteins, permitting the encapsidation of viral DNA and 
consecutive formation of mature virions 146,151. 
Besides these genes, two smalls non-coding RNAs have been 
described: small virus-associated RNA (VA-RNA) I and II, located 
inside MLP transcription unit, but independently transcribed by 
cellular RNA polymerase III. They can interfere with cellular 
miRNA processing and stimulate viral genome replication al late 
time of infections (Fig 1.14 A)151,152 
1.6.1.2 Virion Structure 
X-ray crystallography, and later electron microscopy, unveiled the 
adenoviral structure, consisting of a non-enveloped icosahedral 
capsid (Fig 1.14 B). The hexon (a trimer of polypeptide II) forms 
the 20 facets of the structure, and in each vertex the penton-base 
protein (pentamers of polypeptide III) stabilizes the structure. The 
penton works as base for the fiber (trimmers of protein IV), which 
protrudes from the vertex and determines attachment to cell 
surfaces. The viral capsid is further cemented by the presence of 
minority protein (IIIa, VI, VIII, and IX), stabilizing the facets153–155.  
To fit in this 900 A diameter-structure, the 36KB genome of the 
adenovirus is tightly packed with viral DNA binding proteins156, the 
basic proteins VII, V, µ Iva2 and terminal protein µ. The adenoviral 
genome is wrapped around protamine-like protein VII, main 
responsible for DNA condensation within the physical dimension of 
the capsid151,153,157. The process of genome packaging inside the 
capsid generates young virions, that need to be proteolytically 







Figure 1.14.Concepts of basic adenoviral biology. A. Schematic representation of Ad5 
genome structure. B. Schematic representation of Adwt virion structure. Image adapted 
from 158. 
 
1.6.1.3 Adenoviral infectious cycle 
An adenoviral infection begins when the fiber terminal domain, 
termed knob, interacts with the epithelial receptor CAR (Coxsackie-
Adenovirus Receptor). Following this first attachment, the penton 
base recognizes cellular integrins, mainly aνβ3/aνβ5, thanks to the 
presence of an RGD motif 145,152. This determines the virion 
internalization in cellular endosomes, with a clathrin-dependent 
mechanism. The acid pH present inside the endocytic compartments 
triggers modification in the adenoviral capsid that leads to 
disassembly of the more external structural proteins, resulting in 
endosome lyses and adenoviral escape to the cytosol 159,160. Capsid 




adenoviral trafficking through cellular microtubules until reaching 
the nucleus. At the nuclear pore complex, viral DNA is released 
from the virion and imported in the cellular nucleus with the help of 
the nuclear pore complex. Once in the nucleus, the host 
transcriptional machinery starts to produce early viral mRNAs, 
followed by viral genome replication, expression of structural 
proteins and virions assembly. In 36 hours, the adenoviral life cycle 
is completed, leading to yields of hundreds of thousands of virions, 
which will lyse the cell and propagate to adjacent cells (Fig 1.15). 
 
 
Figure 1.15. Schematic representation of adenovirus lytic cycle. Image from 161 
1.6.1.4 miRNAs and viral infection 
There is increasing evidence that miRNAs play important roles in 




pro-viral or anti-viral activities. Moreover, viral infections can 
modulate the cellular miRNome with changes induced either by the 
virus, to promote a proviral environment, or by the antiviral cellular 
response, to limit the viral life cycle (reviewed in 162,163). 
 
Initial studies analysing miRNA expression in response to 
adenovirus infection were carried out in human laryngeal epithelial 
cells (Hep2) with Ad3 164. The authors described a total of 36 
upregulated and 44-downregulated microRNAs in infected cells, 
compared to the control condition. They observed a group of 
miRNAs upregulated at 6h PI, which gradually diminished with 
propagation of infection. Studies from Zhao and collaborators, in 
lung fibroblast cells defined fluctuating microRNA levels at 
different steps of Ad2 infection 93. At early phase of infection (0 to 
12 h PI), upregulation of miRNAs that favor cell growth arrest and 
an antiviral signaling were detected, suggesting that in the early 
onset of the infection, the miRNAs amount is modulated by the cell, 
trying to counteract the virus infection93,162–164. With the start of 
adenoviral DNA replication, from 12 hours PI, many miRNAs 
started to be downregulated, favoring the expression of molecules 
inducing progression through cell cycle, mainly transcription 
factors. At 24h PI the virus has the complete control of the cell, and 
by 36h PI a large majority of miRNAs are downregulated, inducing 
sustained viral replication escaping any control exerted by the cell. 
1.6.2 Design of oncolytic adenoviruses 
Adenoviruses do not present a natural tropism for replication in 




provide tumor selectivity. Nowadays, oncolytic adenovirus design 
is oriented to obtain tumor specificity and augment their potency. 
1.6.2.1 Strategies to enhance tumor-targeting 
Three major different strategies can be exploited to specifically 
direct adenovirus towards tumor cells, involving transcriptional and 
post-transcriptional processes. 
 
1.6.2.1.1 Tropism alteration 
The main receptor responsible for adenoviral attachment on cell 
surface is the CAR receptor. However, its downregulation is 
common among cancers165,  and a re-direction of the fiber-host 
surface interaction towards more common receptors can improve 
tumor-targeting. Adenovirus 5 fiber tropism can be switched to Ad3 
or Ad35 fiber, that recognize DSG2 and CD46 receptors, 
respectively, upregulated in many cancers 166,167. An alternative is 
the introduction in the capsid of targeting peptides recognizing 
other molecules than CAR. The insertion of an RGD motif in the 
fiber knob permits adenoviral recognition through cellular integrins, 
highly expressed in cancer cells, broadening tumor transduction 168. 
 
1.6.2.1.2 Control of viral gene expression 
A widely explored strategy to control viral gene expression is the 
insertion of a tumor-specific promoter regulating E1A expression. 
Different oncolytic adenoviruses have been generated using 
promoters of upregulated genes in cancer, including 




169–171. Some of these regulatory elements have been further 
modified to be chimeric promoters with sequences responding to 
deregulated signaling in cancer. In this line, our group generated an 
oncolytic adenovirus with the uPAR promoter and three SPS 
sequences that respond to Notch activation signals, enhancing the 
tumor-specific regulation of E1A 172. Others, have modified the 
natural adenoviral E1A promoter by the introduction of binding 
sites for the E2F transcription factor, altered in many tumors 173. 
 
Viral gene expression in tumors has also been post-transcriptionally 
regulated by miRNAs 174. MiRNAs differential expression between 
transformed and normal tissue has been used to improve tumor-
targeting by insertion of miRNA-complementary sequences in the 
3’UTR of viral genes, resulting with detargeting activity of the virus 
in normal cells 175–177. The insertion of a multiple miRNAs - 
controlled circuit in an oncolytic virus permitted the tight 
expression of viral genes and immune effectors, leading to high 
selective viruses with superior tumor-killing efficacy 178. 
 
Recently, the insertion of CPE (cytoplasmatic polyadenylation 
elements) regulatory sequences at the 3’ UTR of E1A permitted the 
selective activation of viral genes transcription in transformed cells. 
The differential expression and activity of the CPE binding proteins 
between normal and cancer cells provided a new paradigm of 





1.6.2.1.3 Manipulation of viral genes 
Viral genes can induce progression through G1/S phase bypassing 
the molecular control exerted by p53 and pRb. Mutations of both 
molecules in cancers have been exploited as a mean to increase 
adenoviral tumor selectivity. 
 
E1B, together with E4Orf6, binds and re-localizes p53, favoring 
adenoviral genome replication 149. ONYX-15 and H101 oncolytic 
adenoviruses have been engineered with a mutation in the E1B-55K 
gene, avoiding p53 sequestration in normal cells, but favoring 
adenoviral genes transcription in cancer cells where p53 is inactive 
180. 
E1A CR2 region recognizes and binds pRb, leading to the release of 
E2F and favoring cell cycle progression.  The 24bp deletion in this 
E1A region restricts viral replication to cells that have constitutively 
active the retinoblastoma pathway, avoiding pRb binding in non-
transformed cells 181. 
1.6.2.2 Strategies to enhance adenoviral potency 
Adenoviruses can be armed with transgenes to augment their 
potency. Engineered transgenes can provide additional functions, 
such as improving viral spread through the stroma or facilitating the 
activation of the immune system. The introduction of ECM 
remodeling factors, including hyaluronidase 182, DNAseI 183 or 
metalloproteinases 184 demonstrated higher grade of adenoviral 
diffusion in desmoplasic PDAC tumors. VCN-01, an attenuated 




in combination with gemcitabine and nab-paclitaxel for the 
treatment of advanced PDAC 185,186. 
 
To stimulate patients’ immune system against the tumor, oncolytic 
adenoviruses are being modified to express cytokines, chemokines 
187, tumor associated antigens 188 or bi-specific t-cell engagers 
(BiTE), inducing T-cell recognition of the tumor 189. 
 
1.6.2.2.1 miRNAs modulation to boost adenoviral potency 
 
Recently, mechanistic insights among adenoviral infection, cancer 
and microRNAs identified these ssRNA molecules as an easy 
handling tool to enhance adenovirus potency 94,190. 
 
Overexpression of miR-26b triggered stronger adenoviral-related 
cell death and spreading to adjacent cells in prostate cancer cells, 
suggesting miR-26b as a sensitizer of oncolysis in this cancer 94. In 
PDAC, our group has recently shown that miR-99b and miR-485 
act as enhancers of adenoviral oncolysis through increased 
adenoviral fitness leading to improved antitumoral activity in vivo 
190. 
Despite the recent findings of miRNA sensitizers, the impact of 
over-expressed miRNAs in cancers on adenoviral oncolysis has not 
yet been explored. In the current work we have addressed this point 
and studied the oncolytic effects of sequestering candidate 





























The general goal of this thesis has been to progress oncolytic 
adenovirus therapy for PDAC, by the incorporation of novel 
preclinical models to test for patient-specific responses and the 
generation of oncolytic adenoviruses with enhanced therapeutic 
index. 
  
The two main objectives have been the following: 
 
i) Evaluate patients-derived organoids (PDOs) technology as a 
platform to screen for personalized virotherapy in vitro  
 
1) Establishment of a battery of PDOs from PDAC and normal 
pancreatic tissues, and evaluation of their applicability in the 
study of adenoviral infection; 
 
2) Screening of a battery of PDOs to identify individual 
sensitivities to virotherapies, and the effects derived from 
the combination with chemotherapy; 
 
3) Study virotherapy-responses in metastasis originated from 
PDOs xenografted in mice; 
 
(ii) Improve oncolytic adenovirus potency by modulation of 
miRNAs deregulated in PDAC  
 
4) Screening of aberrantly expressed miRNAs sensitizing viral 





5) Generation of a miRNA sponge-adenovirus and evaluation 
of its oncolytic effects in vitro and in vivo; 
 
6) Modulation of miRNA levels with the THZ1 transcriptional 
inhibitor, and assessment of the effects of its combination 
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3.1 DNA Manipulation 
3.1.1 Plasmid DNA isolation from prokaryotic cells 
Bacteria can be used as a vector to amplify DNA exogenously 
inserted in the form of a plasmid. This process is called 
transformation and permits the plasmid replication together with 
bacterial DNA. In this way, great quantity of vector can be 
produced. 
3.1.1.1 Small scale isolation of plasmid DNA 
Minipreparations (miniprep) were used to obtain small amount of 
plasmid DNA (30-50 µg) from liquid bacterial culture. This 
purification was based on DNA precipitation in the presence of salts 
and isopropanol. 
Transformed bacteria containing the DNA of interest were grown in 
Luria Broth’s (LB) medium with the appropriate antibiotic 
overnight at 32ºC or 37ºC. An aliquot of 1.5 mL of cells was then 
centrifuged and the cellular pellet homogenized in an isotonic buffer 
containing RNAse A (buffer P1), and further lysed with an alkaline 
solution containing SDS (buffer P2). The reaction was stopped by 
the addition of an acid buffer (buffer P3), then incubated on ice for 
20 min and centrifuged (15000 rpm, 10 min) to remove cellular 
debris. Supernatant phase was harvested, and the plasmid DNA 
easily precipitated by the addition of isopropanol and finally 
collected after a second centrifugation. The pellet containing DNA 
was further cleaned up with 70% ethanol. When ethanol was 
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completely evaporated, plasmid DNA was re-suspended in 30 µL of 
Nuclease-free water and stored at -20ºC. 
3.1.1.2 Large Scale isolation of plasmid DNA 
To get larger amount of DNA, an analogous process as the one for 
minipreps was followed. MAXIpreparations (MAXIpreps) were 
used to produce large amounts of high-quality plasmid DNA with 
the help of a commercial kit (Plasmid Maxi Kit – Quiagen). 
Depending on the number of plasmid copies/bacteria (high copies 
or low copies plasmid), 250 mL or 500 mL of LB were required. 
After incubation overnight at 32ºC or 37ºC, LB containing the 
bacteria was pelleted at 6000 g for 15 minutes. Cell lysis was then 
performed following manufacturer’s protocol. 
3.1.2 Isolation of genomic and viral DNA from cells 
Genomic DNA from cultured cells or organoids was isolated with 
the help of a commercial kit (Blood DNA Isolation Mini Kit – 
Norgen Biotek), following manufacturer’s protocol.  When cells 
were infected with adenovirus, the viral DNA was obtained together 
with the chromosomal DNA of infected cells. 
3.1.3 DNA quantification 
The amount of DNA in a sample and its purity was determined by 
spectrophotometer absorbance (Nanodrop -Thermo Scientific). 
Nucleic acids absorb at 260 nm, and this wavelength was used to 
trace their concentration according to the Lambert-Beer Law. 
Materials and Methods 
54
Besides concentration, following absorption ratios have to be taken 
into account: 
• 260/280: values around 1.8 were considered optimal, 
meaning purity of nucleic acids. Values lower than 1.8 
indicated strong contamination from proteins or phenols that 
absorb at 280nm. 
• 260/230: ratio used as additional measurement of purity, 
assessing for salts contaminant. Pure nucleic acids values 
used to range from 2 to 2.2. 
3.1.4 DNA digestion 
Pure DNA can be digested with bacterial endonucleases, also 
known as restriction enzymes (RE) that recognize specific sequence 
on endogenous DNA and introduce a cut in these loci. Digestion 
with RE in this study was used for two different aims: 
• Cloning strategies: RE helped to cut a specific DNA 
fragment from a vector (e.g. a plasmid), to locate it in a new 
backbone previously cut with the same RE. Products of 
digestions were generally analyzed by agarose gel 
electrophoresis, and the desired band purified for further 
cloning. Purification was performed after agarose 
dissolution with a commercial extraction kit (QIAquick Gel 
Extraction Kit – QUIAGEN). 
• Plasmid DNA pattern recognition: once a new plasmid 
was obtained, or commercially purchased, the fidelity of the 
sequence was tested by RE digestion. 
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3.1.5 DNA amplification via Polymerase Chain reaction 
(PCR) 
PCR allows for the specific amplification of DNA fragments by the 
activity of the DNA polymerase of Thermophilus aquaticus (Taq 
Polymerase), working at high temperatures (72ºC). To amplify, 
specific oligonucleotides (primers) matching sense and antisense 
strand of target DNA sequences are required. Primers are 20-25 
nucleotides sequences that hybridize to target sequences and 
facilitate the DNA fragment elongation in the presence of 
deoxynucleotides (dNTPs) by the DNA polymerase. To define the 
conditions of the PCR reaction two main factors were considered: 
1) each pair of primers works at a hybridization temperature (Th), 
2) the length of a target sequence influences the duration of the 
elongation phase (Te), amplifying Taq Polymerase at 1Kb/minute. 
PCR phases are summarized as follows: 
 
Initial denaturation 95ºC - 5 minutes 1X 
Denaturation 95ºC - 30/45 s 30-40X 
Hybridization Th (variable) – 
30/45s 
30-40X 
Elongation 72ºC - Te (variable) 30-40X 
Stabilizingfinal 
elongation 
72ºC - 5 minutes 1X 
 
A list of primers used in the study for PCR amplification is 
available in Table 3.1. 
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PCR reactions were conducted with the commercial kit Dream 
TaqTM Hot Start DNA Polymerase (Thermofisher Scientific) and 
dNTPs from 100mM dNTP Set (Invitrogen). When DNA fragments 
were amplified for cloning in plasmids, a DNA-polymerase with 
high-fidelity activity was used (Expand High Fidelity PCR System - 
Roche), in order not to introduce random changes in the nucleotide 
sequence. 
3.1.6 DNA sequencing 
DNA fragments amplified via PCR were sequenced via Sanger’s 
Method. This is based on the incorporation of fluorescently marked 
chain terminating dNTPs to a DNA fragment being elongated in 
vitro. 
Beckman Coulter Genomics and Eurofins Genomics performed 
sequencing reactions, upon delivering template DNA and specific 
primers. The set of primers used for sequencing is listed in Table 
3.1. 
3.2 DNA constructs generation 
3.2.1 Plasmids expressing miRNA sponges 
The plasmid backbone used for miR sponge insertion was the 
miRVec. This is a commercially available plasmid, previously 
modified in the lab by Estela Nuñez to express an eGFP under the 
control of a CMV promoter. The eGFP was completely functional, 
due to the presence of a promoter (CMV), three STOP codons, a 
short 3’ UTR and a polyA tail to permit translation of the protein. 
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This construct was further modified to have an EcoRI restriction site 
at the 3’ end of the eGFP. 
The clonings of the miRNA sponge repetitions were performed in 
this backbone, forming part of the 3’ UTR of the eGFP, by insertion 
in the EcoRI site. 
3.2.1.1 miRNA sponge design 
Sponges were generated with the help of the software miRNA-song 
(http://www.med.muni.cz/histology/miRNAsong/index.php)191. We 
provided to the software the desired miRNA sequence to target, and 
specified the number of sponge repetitions. The software generated 
a combination of sequences working as sponges. We designed 4 
tandem sequences, separated by a different spacer, and with a budge 
between nucleotides 9-12. This was described to increase the 
efficiency of the sponges 192–194. 
For miR-222 sponge, we selected the combination with the lowest 
free energy of duplex (-130 kcal/mol) and the highest number of 
“on-target” sites. For the miR-Scramble sponge, we selected the 
sequence with the highest free energy of duplex (maximum value 
obtained was -30 Kcal/mol) and the lowest number of recognizing 
target sites. We also analyzed the off-targets recognized by both 
miR-222 and Scramble Sponges and we found miRNAs very poorly 
expressed in PDAC. 
To assure the termination of the transcription of the eGFP after the 
sponges, the sequence was terminated with two extra stop codons 
(TAA-TGA) at the 5`of the sequence corresponding to forward 
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primer. Both forward and reverse primers were also endowed with 
sticky ends containing EcoRI recognition sequence to re-establish 
the presence of this RS after cloning. The sponge sequences 
selected were ordered as ssDNA in the sense and reverse orientation 
and are listed in Table 3.2. 
3.2.1.2 miRNA sponge annealing and phosphorylation. 
To anneal ssDNA fragments, they were re-suspended in duplex 
buffer (IDT) at a final concentration of 100µM. Oligos were mixed 
in equal amounts and heated at 94 ºC for 4 min. Then, switching off 
the heat block gradually ramped the temperature down. 
Annealed oligos were then phosphorylated with T4 PNK enzyme, in 
a mix containing T4 ligase buffer enriched with ATP. Reagents 
reacted for 40 min and the phosphorylated annealed products were 
further purified via PCR, and quantified. 
3.2.1.3 Cloning miRNA sponges in the miRVec backbone 
miRVec backbone was digested O/N with EcoRI. The day after, the 
product was run on agarose gel, and the band of the digested vector 
purified. After purification, digested miRVec was submitted to 
dephosphorylation with alkaline phosphatase enzyme (Fast AP), for 
10 min, to avoid re-ligation of extremities. 
Sponges were ligated with miRVec (EcoRI) with the help of T4 
ligase ON. Different molar ratios were used to enhance the chance 
of ligation. 
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Ligated constructs were introduced in DH5α bacterial via heat-
shock transformation, and then plated on LB+Agar+Ampicillin. 
Next morning, colonies were tested for insertion of miR-Scramble 
or miR-222-S sponges by PCR. Three positive clones were 
sequenced and a correct colony was chosen. A schematic 
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3.2.2 Generation of plasmid vectors with sgRNAs for 
miRNA KO 
To express the Cas9 protein and sgRNAs in eukaryotic cells, we 
used the lentiviral vector system lentiCRISPRv2 (Addgene 
catalogue #52961). The different steps needed to clone the sgRNAs 
in the BsmBI restriction site of the lentiviral vector are described as 
follows. 
Figure 3.16. Cloning strategy for the generation of miRVec-eGFP-miR-222-S and miRVec-
eGFP-Scramble. 
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3.2.2.1 Single guide RNA design (sgRNA) 
sgRNAs are responsible for the specificity of the CRISPR/Cas9 
system. The sgRNAs are composed by a single strand RNA 
(ssRNA), complementary to the target sequence, and a trans-
activating crRNA (tracrRNA) that binds to the Cas9 nuclease. The 
sgRNA guides the Cas9 to the region of complementarity where 
target recognition and DNA cut will occur. Since the tracrRNA is 
common to all the sgRNA, for simplicity the specific ssRNA 
sequences are referred as sgRNAs. 
sgRNAs were bioinformatically designed with the help of different 
softwares: 
• MIT Software (http://crispr.mit.edu/); 
• Benchling (https://benchling.com/); 
• Breaking 
Cas(http://bioinfogp.cnb.csic.es/tools/breakingcas/)Oliveros 
et al., 2016) 
Candidate sgRNAs were tested by two or three programs. The 
selected sgRNAs were chosen based on high on-target activity and 
specificity, and low off targets score. The sgRNAs were designed as 
blunted-end sequences to permit ligation in the BsmBI site. Two 
pairs of ssRNAs, close to a PAM sequence, were designed for each 
target, since the theoretical design does not always lead to 
functional guides. The sgRNAs were ordered as ssDNA oligos from 
IDT and further annealed in the laboratory. A list of the sgRNAs 
used in the study is available in Table 3.3. 
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3.2.2.2 ssDNA oligos annealing and phosphorylation 
ssDNA for sgRNA strands were re-suspended in the amount of 
ddH2O recommended by the supplier. ssDNA strands were paired 
together due to their complementarity, with the help of a 
thermocycler. The mixture was first stabilized at 37ºC for 30 min, 
then heated up at 95ºC for 5 min to separate eventual dsDNA 
formed, and gradually ramped down to 25 ºC to favor specific base-
pair recognition (5ºC/min). T4 PolyNucleotide Kinase (T4 PNK – 
New England Biolabs) was added to the mixture to favor dsDNA 
phosphorylation and permit further ligation with the 
unphosphorylated lentiCRISPRv2. 
After reaction, sgRNA Fw and Rv were diluted 1:500 and 1:1000 in 
ddH2O. For a stoichiometric reason the sgRNA was present in 
lower quantity than the plasmid in the reaction to permit a 
productive ligation (the plasmid was 600 times the length of the 
duplex of sgRNAs). 
 
1 µL sgRNA Fw 100µM 
1 µL sgRNA Rv 100µM 
1 µL 10X T4 Ligation Buffer (with ATP) 
6.5 µL ddH2O 
0.5 µL T4 PNK 
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3.2.2.3 LENTICRISPRv2 digestion and dephosphorylation 
The plasmid was incubated for 3 h with the enzyme Esp3I (BsmBI, 
ThermoFisher Scientific) together with FastAP (Thermo sensitive 
Alkaline Phosphatase – ThermoFisher Scientific), to 
dephosphorylate the vector and avoid re-ligation. These enzymes 
could be used in the same master mix, since they worked well 
together using the buffer from Esp3I. 
5 µg lentiCRISPRv2 
3 µL Esp3I 
3 µL FastAP 
6 µL 10X Esp3I buffer 
0.6 µL DTT 100 mM 
Up to 60 µL H20 
 
When the digestion was completed, the product was run on a 0.8% 
agarose gel, and a band of approximately 12000Kb and one of 2000 
Kb were visible. The 12000Kb band was isolated and purified using 
QIAquick gel extraction KIT (QIAGEN). 
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3.2.2.4 sgRNA ligation into lentiCRISPRv2 and selection of 
positive colonies 
Two different ligation mixtures were set up at two sgRNA dilutions. 
The ligation reaction was incubated O/N at 4ºC with T4 ligase 
(Roche). A control ligation reaction, containing ddH2O instead of 
annealed sgRNA was performed in parallel. 
X µL Digested lentiCRISPRv2 (50ng) 
1 µL Oligo Duplex (1:500/1:1000) 
1 µL 10 X Ligase Buffer 
Up to 11 µL ddH2O 
1 µL T4 Ligase 
 
The products of ligation were transformed in DH5α bacteria strain 
via heat-shock transformation. After recovery, bacteria were seeded 
in LB+AGAR+Ampicillin plates, and the day after grown colonies 
were selected for plasmid DNA extraction with miniprep protocol. 
First, a PCR with lentiCRISPRv2 hybridizing primers was 
performed, and positive bands sequenced. A colony with the correct 
sequence was selected. A schematic representation of the process 
can be found in Fig 3.2. 
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3.3 RNA manipulation 
3.3.1 RNA extraction and retro transcription to cDNA 
Total RNA was isolated from adherent cell lines, organoids and 
patient’s tissues using miRNeasy mini Kit ®(QUIAGEN), which 
permits obtaining both mRNAs and small RNAs, such as miRNAs. 
Cells were disrupted with the help of QIAzol lysis reagent and RNA 
was purified following manufacturer’s protocol. In the case of 
tissues, disruption and homogenization were facilitated by the use 
of a 20G needle. 
To avoid contamination of genomic DNA, purified RNA was 
treated with DNAse, DNA-free TM DNA removal kit (Invitrogen), 
Figure 3.17. Schematic representation of sgRNAs cloning in lentiCRISPRv2 vector 
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as described by manufacturer. Quality and quantity of extracted 
RNA were measured with Nanodrop. 
• For mRNA, 500 µg of total RNA was used for 
complementary DNA (cDNA) synthesis with polyA primers 
by Primescript TM RT Reagent KIT (Takara) in a final 
volume of 20µL, following manufacturer’s protocol. 
• For miRNAs, due to their smaller size, the use of specific 
probes was required. These are stem loops that, upon 
melting at high temperature, recognize the miRNA to which 
they are complementary to and permit retro transcription to 
cDNA. The resulting cDNA fragment is then long enough to 
permit adhesion of primers for qRT-PCR. MiRNA retro-
transcription was performed on the amount of 3 µg of total 
RNA, and the reverse transcriptase and stem-loop primers 
used are commercially available from Applied Biosystem 
(TaqMan MicroRNA Reverse Transcription Kit, TaqMan 
MicroRNA assay). 
3.3.2 RNA Expression 
Expression of mRNAs and miRNAs were quantified via qRT-PCR 
in a Viia7 Real time PCR system (Applied Biosystem), using 
specific primers for mRNAs and TaqMan probe for miRNAs. 
3.3.2.1 Gene expression analysis 
To analyze gene expression, abundance of cDNA was quantified via 
qRT-PCR. cDNA is directly proportional to the amount of mRNA 
for a gene of interest in the sample analyzed, giving a direct 
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measurement of its expression. An un-specific dye commercially 
available (the LightCycler® 480 SYBR Green I Master Mix – 
Roche Applied Science) intercalates into double strand DNA during 
the amplification with specific primers. This reaction was 
performed in a 384 well plates in a thermocycler capable to detect 
fluorescence from samples (Viia7 Real Time PCR System – 
Applied Biosystems). Evolution of fluorescence across the PCR 
cycles allowed for the calculation of the initial amount of cDNA of 
the gene of interest. This was quantified via ∆Ct method and always 
relativized to a housekeeping gene, which expression did not 
change within the different conditions. The hypoxanthine 
phosphoribosyltransferase 1(HPRT) was used in most of the 
analysis as housekeeping gene. The reaction mixture was prepared 
mixing 5µL of Master Mix 2X, 0.3 µL of specific primers (10µM) 
and 3.7 µL of H2O. To the mixture, 1 µL of cDNA was added for 
each well. Reactions were performed in triplicates.  Primers are 
listed in Table 3.4. 
3.3.2.2 miRNAs expression analysis 
MiRNAs expression was quantified via qRT-PCR based on 
TaqMan assays, in a Viia7 thermocycler. TaqMan assays (TaqMan 
MicroRNA Assay – ThermoFisher) combine primers and hydrolysis 
probes that recognize the miRNA’s cDNA and emit fluorescence 
when the fluorophore is cleaved and thus separated from the 
quencher by the exonuclease activity of the polymerase.  TaqMan 
probes permit quantitative measurement of the fluorescent product 
during the cycles of the PCR. Reaction mixture was prepared as 
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follows and performed in triplicate for each sample: 5 µL Master 
MIX 2X, 0.5 µL TaqMan miRNA assay 20X, 1.5 µL of reverse 
transcription product and 3µL of Nuclease-free-water. MiRNAs 
expression was quantified using the ∆Ct method, relativizing to the 
ribonuclear RNA (rRNA) RNU6B. A list of the commercial probes 
used is available in Table 3.5. 
 
3.4 Eukaryotic cell lines manipulation 
3.4.1 Cell lines. Maintenance and culture conditions. 
All the cell lines used in this study were adherent and grew as 2D 
cultures. They were maintained in a humidified incubator at 37 ºC 
with 5% of CO2. All the cell lines were grown in DMEM 
(Dulbecco’s Modified Eagle Medium), supplemented with 10% of 
inactivated fetal bovine serum (iFBS), 100 U/mL penicillin, 100 
µg/mL streptomycin, and 2mM L-glutamine. All the cell lines were 
split twice a week to assure their wellness and avoid cell 
overgrowth. 
A-549: human cell line derived from a lung adenocarcinoma. 
Mainly used for recombinant adenoviral production due to their 
high efficiency in amplification of this virus. Cells kindly provided 
by Dr. Ramon Alemany (IDIBELL - Institut Català d’Oncologia, 
Barcelona). 
HEK-293 ICO: Human Embryonic Kidney 293 cells, derived from 
embryonic kidney cells immortalized via introduction of 5’ of 
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adenoviral genome including E1A. Due to their easiness in 
transfection, this cell line is used in the first step of recombinant 
adenovirus production, as well as for the generation of replication-
deficient adenoviruses. Cells kindly provided by Dr. Ramon 
Alemany (IDIBELL - Institut Català d’Oncologia, Barcelona). 
HEK-293 T/17: highly transfectable cell lines derived from 
parental HEK293 with the introduction of SV40 antigen. Due to this 
characteristic, they were mainly used for transient transfection and 
for lentiviral generation. Purchased from ATCC (CRL-11268). 
ASPC-1: pancreatic cancer adenocarcinoma cell line derived from a 
xenograft in nude mice generated from cells from an ascites of a 
patient with pancreatic cancer. Purchased from ATCC (CRL-1682). 
Used in Dr. Goel’s laboratory, Baylor Charles A Sammons Cancer 
Center, Dallas (TX). 
Capan-1: pancreatic cancer cell line derived from a liver metastasis 
obtained from a patient affected from PDAC. Purchased from 
ATCC (HTB-79). Used in Dr. Goel’s laboratory, Baylor Charles A 
Sammons Cancer Center, Dallas (TX). 
CP-15 Luc: human cell line expressing firefly luciferase. The 
parental line came from a human pancreatic ductal adenocarcinoma 
xenografted in athymic mouse 196 then stably transduced with a 
retrovirus expressing firefly luciferase. Cells were then selected 
with hygromycin, and after the generation of clones, tested for 
luciferase expression. This line was generated in our laboratory. 
MIA PaCa-2: human cell line derived from a pancreatic ductal 
adenocarcinoma. Acquired from ATCC (CRL-1420). 
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PANC-1: human cell line derived from a pancreatic ductal 
adenocarcinoma. Acquired from ATCC (CRL-1469). 
3.4.2. Transient Transfection 
Transfection is the process that permits non-permanent introduction 
of genetic material inside eukaryotic cells. It is a fast and easy way 
to have a primary assessment of plasmid constructions. 
Cells were transfected by DNA co-precipitation with calcium 
phosphate (CalPhos Mammalian Transfection Kit- Clontech). 
HEK-293T cells were seeded the day before transfection at a 
density of 300.000 cells/well in a MW6 plate. Depending on the 
construct, a different amount of plasmid DNA was transfected, 
following manufacturer’s protocol (from 0.2 to 1 µg).  The DNA 
was mixed with CaCl2 in a Vortex and a phosphate buffer HBS 
solution was added drop by drop. After 15 minutes of incubation, 
the solution containing the DNA/phosphate crystals was added to 
cells. The day after, transfection media was replaced with fresh one 
to remove the precipitates, due to their long-term toxicity. 
3.4.3 Lentiviral transduction 
3.4.3.1 Generation of stable KO/KD in PDAC cells via 
lentiCRISPRv2 transduction. 
To generate PDAC cells with specific miRNA KO we used the 
lentiCRISPRv2 (Dr. Feng Zhang – purchased from Addgene) vector 
containing Cas9 and engineered with sgRNAs 197targeting miRNAs. 
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Lentiviruses are RNA viruses requiring a series of genes (Gag, Pol, 
Rev, Env, Tat) to be produced. Once lentivirus enters the cells, its 
RNA genome is retrotranscribed to dsDNA and this can integrate 
randomly inside the genome. We used 2nd generation lentiviruses to 
generate infective particle transfected to HEK-293T cells 198. 
The three plasmids were: 
• Envelope Plasmid: containing env, codifying for the viral 
glycoprotein of the capsid of the Vesicular Stomatitis Virus 
(VSV) 
• Packaging Plasmid: containing gag, pol, rev and tat genes, 
responsible for retrotranscription of viral RNA, 
incorporation in the host genome and production of 
structural proteins; 
• Transfer Plasmid: containing the transfer DNA: 
lentiCRISPRv2 + sgRNA. LentiCRISPRv2 also contains 
the Cas9 protein and the LTR and PSI packaging sequences 
at its extremities, to permit final viral particles formation. 
Semi-confluent (60-70%) p100 plate of HEK-293T cells were 
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Envelope plasmid (pVSV-G) 3.4 µg 
Transfer plasmid (lentiCRISPRv2) 9.8 µg 
Packaging plasmid (p8.91) 6.3 µg 
Cacl2 2 M 86.8 µL 
ddH2O Up to 700µL 
 
The transfection method was performed with the calcium phosphate 
technique. Transfection medium was replaced with fresh one the 
morning after. Two days following change of medium, the 
supernatant containing viral particles was filtered to remove cell 
debris, and transferred to PDAC cells. PDAC cells were incubated 
with the virus for two days and then puromycin selection was added 
(4-8 μg/mL, depending on the cell line). After selection, cells were 
checked for genome editing in the desired genomic locus. All the 
miRNAs targeting were verified by sequencing (primers used for 
sequencing listed in table 3.1; sequencing on appendix 8.1). 
TaqMan probe assays were used to evaluate target miRNA 
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Figure 3.18. Schematic Representation of lentiviral transduction of PDAC cells for the 
generation of CRISPR/Cas9 KOs. 
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3.4.3.2 Selection of KO clones for candidate miRNAs 
To generate individual cell clones, the initial pool was diluted up to 
1 cell/well in a 96MW plate. For this, 100 cells were diluted in 10 
mL of medium, and 100 µL were added to each well. Cells were 
grown for at least 10 days, and then visible colonies were 
trypsinized, and transferred to a bigger plate (p60) for further 
analysis. 
 
3.5. Patient-derived pancreatic organoids (PDOs) 
Between 2015 and 2019 tumor and healthy pancreatic samples from 
PDAC patients undergoing surgery in the Hospital Clinic were 
collected, upon signed informed consent. The Hospital Clinic 
Ethical Committee approved the study. 
3.5.1 Organoids generation from human pancreatic tissues 
After surgical operation, the tissue was immediately collected and 
submitted to anatomo-pathological evaluation by a qualified 
medical doctor. Fragments from both healthy and transformed 
pancreatic tissues were preserved at 4ºC in advanced DMEM/F12 
(Gibco), supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin, 2mM L-glutamine and 1 M HEPES. Tissue was 
immediately processed or within the next 24h. A list of materials 
required to initiate the protocol is listed in Table 3.6. 
Materials and Methods 
73
The procedure to obtain organoids is summarized as follows 
(adapted from 101,199): 
 
1. The tissue was placed under the tissue-culture hood in a 
sterile p60 plate and minced to small pieces with a surgical 
knife; 
2. When fragments reached dimensions around 1-2mm, 2mL of 
digestion solution were added (see Table 3.6) and 
everything transferred to 15 mL falcon tube. The tube was 
filled up to 7 mL with digestion media and incubated at 
37ºC, 450 rpm shaking with 30º of inclination. 
3. Tissue digestion was checked every 30 min. When the 
digestion media become turbid, we moved to culture hood. 
4. The digestion medium was pipetted up and down with a 5 
mL serological pipette, to let the undigested tissue 
precipitate. The medium with digested cells was transferred 
to a p100 plate containing 10mL of wash medium, in order 
to dilute digestion medium (Wash 1). 
5. Extra fresh digestion medium was placed with not digested 
pancreatic tissue and returned to the shaker at 37ºC. 
By placing the p100 plates containing wash 1 under the microscope 
we checked for ducts, resembling stalks of grape.  If great majority 
of cells has a round-shaped form, the solution was generally 
discarded. If a considerable number of ducts was observed, we 
moved to next steps from a to e. For normal pancreatic tissues, 
ducts would be picked after 2nd-3rd wash, whereas for tumor tissues 
they were obtained after longer digestions, generally discarding the 
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first washes. This was due to the different stiffness of the tumor 
compared to the normal tissue, which was always easier to digest. 
 
a. For higher success rate, ducts could be picked to 
enrich the culture in ductal cells rather than acinar 
cells. Plate was located under microscope at 10-20X 
magnifications and with the help of pipette manually 
picked one by one. 
b. When 100 ducts or more were picked, and collected 
in 15mL falcon tube, wash medium was added on the 
top and centrifuged at 300g for 5 minutes. 
c. The medium was aspirated and cleaned again with 
wash medium by centrifuging. The pellet obtained, 
in this case P1, could be either directly seeded or 
placed on ice waiting for more ducts from following 
digestions. We generally preferred to seed directly 
after pelleting, to avoid too long wait that could 
affect cell viability. 
d. To properly seed ducts, a mixture 20%: 80% of cells 
with medium: Matrigel was prepared. Wash medium 
in the tube containing the pellet was aspirated and 
only the amount required for seeding was left in the 
tube (eg to seed 6 wells in a 24MW plates 60 µL of 
wash media were maintained in the falcon). Matrigel 
was then added (for 6 wells, 240 µL of Matrigel 
were required), mixed to obtain a homogeneous 
solution and seeded in 24MW plates. 
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e. We incubated at 37ºC for 20 min, on the top of a pre-
warmed flask, and when Matrigel was solid, 500 µL 
of complete culture medium were added. 
6. Remaining tissue incubated with digestion medium was 
checked every 30 minutes - 1 hour and when cells were 
liberated in the solution, it was processed as P1 to obtain 
Pellets P2, P3, P4 …). 
7. The digestion process was ideally stopped when no more 
tissue was seen by naked eye or when sufficient cells were 
obtained. Tumors highly resistant to dissociation were 
submitted to an extra round of digestion with Tryple trypsin 
(not requiring inactivation with FBS). Tissue was incubated 
with 3-4 mL of Tryple for a maximum of 15 min at 37ºC, 
diluted with wash media to stop the Tryple and centrifuged 
at 300g for 5 minutes. 
8. Pellet was processed and seed as described in d. 
3.5.2. Organoids follow up after seeding 
Two days after seeding, the organoids started budding. They were 
maintained in culture by changing medium every 3 days. When they 
reached confluence (70-80%), generally after 7-10 days, they were 
passaged. Before the first passage cultures, medium was 
supplemented with a Rho Kinase inhibitor (to avoid single cell 
death for anoikis, due to the lack of adherence to an external 
matrix). All the organoids generated from tumor tissues survived for 
more than 20 passages. Healthy tissue derived organoids could be 
maintained up to 10 passages. 
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3.5.3. Organoids culture routine 
Organoids were split once a week at a 1:4 or higher dilutions, 
depending on the confluence, and seeded in 24MW plates with 
matrigel (see 3.5.2). The passage Medium was DMEM F12 
(Gibco), supplemented with 100U/mL penicillin, 100 µg/mL 
streptomycin, 2mM L-glutamine and 1 mM HEPES. After seeding, 
fresh growth medium was added, and replaced 4 days later. 
3.5.3.1 List of organoids used in the study 
IDIT1: PDAC organoids directly derived from patient’s fresh 
tissue. Kindly provided by Dr. Hans Clevers (Hubrecht Institute, the 
Netherlands). 
IDIT2: PDAC organoids directly derived from patient’s fresh tissue 
sample. Kindly provided by Dr. Hans Clevers (Hubrecht Institute, 
the Netherlands). 
IDIT3: PDAC organoids directly derived from patient’s fresh tissue 
sample. Kindly provided by Dr. Hans Clevers (Hubrecht Institute, 
the Netherlands). 
IDIT4: pancreatic tumor organoids derived from CP-15 pancreatic 
adenocarcinoma tumor. A biopsy from the original tumor was 
propagated in nude mice; afterwards organoids were generated from 
these orthotopic xenografts. 
IDIT5: PDAC organoids derived from patient’s fresh tissue after 
surgical operation in Hospital Clinic, Barcelona. 
IDIT6: PDAC organoids derived from patient’s fresh tissue after 
surgical operation in Hospital Clinic, Barcelona. 
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IDIT7: PDAC organoids derived from patient’s fresh tissue after 
surgical operation in Hospital Clinic, Barcelona. 
IDIS0: healthy pancreas derived organoids, generated from 
digested pancreatic tissue. The tissue was kindly provided by Dr. 
Meritxell Rovira (CMRB Barcelona). 
IDIS6: healthy pancreas organoids derived from patient’s fresh 
tissue after surgical operation in Hospital Clinic, Barcelona (healthy 
portion of pancreas from IDIT6 patient). 
IDIS7: healthy pancreas organoids derived from patient’s fresh 
tissue after surgical operation in Hospital Clinic, Barcelona (healthy 
portion of pancreas from IDIT7 patient). 
3.5.3.2. Preparation of organoids growth medium 
3.5.3.2.1.  Organoids growth medium formulation 
Organoids need a medium enriched in many growth factors, to 
recapitulate gastro-intestinal niche and its stimuli. The components 
required to obtain 50 mL of medium are listed in table 3.7. This 
medium was prepared in the amount of 50 or 100 mL and stored at -
20 ºC for less than one month. 
 
3.5.3.2.2. Conditioned media production 
Wnt3a, Rspondin-1 and Noggin conditioned media were obtained 
from stably transfected cell lines expressing the different genes 
codifying for each of the recombinant proteins. The three cell lines 
were kindly provided by Hans Clevers’ laboratory, Utrecht, the 
Netherlands. 
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• L-Wnt-3a: murine cell lines engineered to produce Wnt-3a 
at high concentration (Willert K et al, Nature 2003). Zeocin 
at 125 µg/mL was used for selection after thawing. 
• HA-R-Spondin1-Fc 293T: HEK-293 stably transfected to 
express murine R-Spondin protein. Zeocin at 300 µg/mL 
was used for selection after thawing. 
• m-Noggin-Fc 293T: HEK-293 stably transfected to express 
murine Noggin. Geneticin G418 at 500 µg/ml was used for 
selection after thawing. 
 
3.5.2.2.3 TOP/FOP Assay for WNT and Rspo activity 
This assay is based on exploiting molecular mechanisms of Wnt 
signaling, characterized by an ON/OFF state. Briefly, in the ON 
state of the pathway, a ligand member of Wnt family (in this case 
Wnt-3a), binds to its receptor named frizzled (FZD) and to its 
coupled lipoprotein receptor-related protein 5 or 6 (LRP5/6). This 
trimeric complex intracellularly recruits Dishevelled (DSH) and 
Axin, inhibiting β-catenin degradation. Thus, β-catenin migrates to 
nucleus where it recognized TCF / LEF transcription factors for the 
activation of the Wnt-related genes. When the system is OFF, 
meaning no Wnt signaling is transduced, β-catenin is constitutively 
phosphorylated by the kinases GSK and CKIa with the help of the 
scaffold proteins Adenomatous Polyposis Coli (APC) and Axin.  
This amino-terminal phosphorylation of the protein leads to 
proteasomal degradation, and transcriptional activity in the nucleus 
is not observed 24,200. 
Materials and Methods 
79
On the bases, the TOP/FOP assay consists on the transfection of 2 
different plasmids, containing TCF motifs 201 : 
 
• TOP Flash Plasmid: this plasmid contains a minimal HSV 
thymidine kinase (TK) promoter, whose activity is helped 
by the presence of 3 binding sites for TCF. Together, they 
control the transcription of the firefly luciferase (reporter 
gene). When Wnt-3a molecule is enriched in the conditioned 
medium, it binds to TCF binding sites permitting luciferase 
transcription and translation (inducible expression). 
• FOP Flash Plasmid: it is the same construct as FOP flash, 
but the TCF binding sites are mutated. In this way, the 
signal obtained when transfecting this plasmid is the same in 
presence or not of Wnt-3a molecules. It works as an internal 
control for the experiment. 
• pRL-TK vector: this vector contains the Renilla luciferase 
under the control as HSV-TK promoter. It provides low to 
medium levels of Renilla in co-transfected mammalian cells 
(constitutively expressed). It will be the control of 
transfection of the assay (information available on 
Promega.com). 
With this assay both L-Wnt-3a and Rspo conditioned medium 
activity could be tested. Indeed, Rspo can augment the induction 
of transcription of firefly luciferase acting on the promoter 
containing TCF binding sites. 
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Procedure: 
• Day 1: 30.000 cells/well were seeded in triplicate in a 24 
MW plate. 
• Day 2: the combination of plasmids TOP Flash/Renilla or 
FOP Flash/Renilla were transfected by CalPhos mammalian 
transfection kit (Takara). 
• Day 3: normal DMEM 10% was replaced with conditioned 
media or control media to both TOP and FOP conditions and 
incubated for 24 hours (See Table 3.8 for further details on 
media preparation). 
 
Transfection Mix 1 X 
-Flash / FOP-Flash plasmid (400 ng/µL) 0.25 µL 
p-RL TK (100ng/µL) 0.1 µL 
CaCl2 3.1 µL 
H2O 21.55 µL 
Total / well 25 µL 
 
• Day 4: medium was replaced with 100 µL of passive lysis 
buffer from dual luciferase reporter assay kit (Promega), 
diluted 1:5 in water. The plate was frozen for 1 h at -80ºC, 
and then the luciferase signal was detected with the help of 
the kit. 
• Reading the assay: 10 µL of the lysate were transferred to 
the 96MW white plate together with 30µL of Luciferase 
Activation Reagent (LARII) and the reaction was analyzed 
in a luminometer (Synergy - Biotek). After the first read, 
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luciferase was stopped and renilla activated by the addition 
of the buffer STOP and GLO. 
For each well, we calculated the ratio luciferase/renilla 
*1000, called relative luminescence unit (RLU). It is a direct 
measurement of the luminescence recorded during the assay. 
The RLU ratio of TOP/FOP transfected conditions needed to 
be higher that 30-fold to be used for the production for 
organoids growth (see fig 3.4). 
 
 
3.6. Drug treatments 
Drugs used in this study alone or in combination with the 
adenovirus are listed below: 
• Gemcitabine (Gemzar, Lilly CO) this chemotherapeutic 
agent was used in combination with AdNuPARmE1A at 2.5 
Figure 3.19. Example of the output of a TOP/FOP assay for the evaluation of WNT and Rspo 
conditioned media activity. 
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ng/mL. We prepared a stock at 10µg/mL by diluting 
purchased gemcitabine in saline solution. Stock was 
maintained up to 2 months at room temperature. Work 
solution was prepared fresh every day in DMEM 10%. 
• Nab-Paclitaxel (Abraxane – Cell gene): used in combination 
with AdNuPARmE1A at 100 nM. This drug was purchased 
as powder stable at RT and prepared fresh at every use, due 
to its fast degradation once resuspended. A 10mM stock in 
saline solution was prepared on the day of the experiment. 
Then, working concentration was prepared in DMEM 10%. 
• THZ1: CDK7 inhibitor, purchased as a powder from 
MedChem Express. It was reconstituted in DMSO to obtain 
a 1 mM stock. For every experiment, serial dilutions were 
prepared starting from this stock, diluting in fresh DMEM 
10%. 
3.6.1 Evaluation of Synergism 
Eventual existing synergisms between the treatments analyzed were 
calculated with the following formula: 
 
CI= (CA,X/ICX,A) + (CB,X/ICX,B) 
 
CA,X and CB,X are the concentration of one of the treatment required 
to induce 50% of mortality in combination. ICX,A and ICX,B are the 
combination for a single agent to achieve the same effects when 
administered alone 202. If the value of the Combination Index 
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calculated for the two treatments was lower than 0.8, the 
combination treatment was considered synergistic. 
3.7. Adenovirus manipulation 
3.7.1 List of adenoviruses in this study 
In this study, both replication-deficient (lacking E1A) and 
replication-competent adenoviruses have been used. All the 
adenoviruses backbone described were previously generated in the 
laboratory, except for AdNuPAR-E-miR222-S and AdNuPAR-E-
Scramble that have been generated during this thesis. 
• AdGFP-LUC: reporter adenoviruses, lacking functional 
replicative genome. It includes an enhanced GFP (eGFP) 
gene under a cytomegalovirus (CMV) promoter in sense 
strand, and a CMV-leaded firefly luciferase gene in 
antisense. This virus was kindly provided by Dr Alemany’s 
laboratory 203. 
• Ad5wt: normal adenovirus serotype 5 with no 
modifications. 
• Adwt-E: replication competent Ad5wt, modified by the 
insertion of an eGFP gene after the fiber unit (L5) as an 
extra splicing acceptor for mayor late promoter (MLP). M. 
Rovira previously generated this virus in the lab. 
• ICOVIR15: Oncolytic adenovirus kindly provided by Dr 
Alemany’s lab 173 . In this adenovirus, E1A transcription is 
under a double system control: an E1A modified promoter 
with 8 E2F binding sequences and a SP1 binding sequence 
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plus a 24bp deletion in the E1A gene to redirect E1A 
transcription towards Rb/p16 altered pathway. Moreover, it 
bears an RGD motif inserted in the fiber gene 204. 
• ICOVIR15-E:  ICOVIR15 backbone, with an eGFP gene 
introduced in late after the fiber unit (L5) as an extra 
splicing acceptor of MLP. Previously generated in the lab by 
M. Rovira. 
• ICOVIR15-E-miR29c: ICOVIR15 backbone modified by 
the insertion of a sequence codifying for the pre-miR-29c, 
including both 5p and 3p of the mature miRNA. The 
fragment, including the premiR sequence leaded by a 
cytomegalovirus (CMV) promoter, was inserted in a region 
between E4 and right ITR, in which viral genes would not 
be affected. 
• AdNuPARmE1A:Oncolytic adenovirus previously 
generated in the lab by Ana Mato 172 . In this adenovirus, 
E1A transcription is kept under control of a promoter 
consisting of the fusion of an uPAR minimal promoter with 
Notch Responding sequences (SPS elements). Both 
pathways are over activated in PDAC cells, comparing to 
normal cells. In this way, E1A will be expressed only the 
cells having highly active Notch signaling and high uPAR 
transcriptional activity. 
• AdNuPARmE1A-E: AdNuPARmE1A parental backbone 
endowed with an eGFP gene inserted in late, as another 
splice site of MLP. Previously generated in the lab by Carlos 
Lopez. 
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• AdNuPAR-E-Scramble: AdNuPARmE1A backbone, 
modified with a CMV driven eGFP containing in the 3’UTR 
4 target sites for a scramble sequence of a mixture of 
putative miRNAs. This construct has been inserted between 
E4 and right ITR of the virus. 
• AdNuPAR-E-miR222S: AdNuPARmE1A backbone, 
modified with a CMV driven eGFP containing in the 3’UTR 
4 target sites for hsa-miR-221/222. 
3.7.2 Generation of AdNuPAR-E-miR-222-S / Scramble 
genomes 
3.7.2.1 pAdZ system 
These viruses were generated with the pAdZ system, developed in 
2008 by Richard J. Stanton 205, and further modified by R. Alemany 
206. They provided a rapid, high-throughput method for genetic 
engineering of adenoviral genomes, only requiring a one-step 
recombination. 
This is possible thanks to a particular E.Coli strain, SW102, which 
contains a bacterial artificial chromosome (BAC) with the 
adenoviral genome in which the RpsL-Neo cassette is inserted. This 
BAC contains basic resistance to the antibiotic chloramphenicol. 
Briefly, the system is based on two principles: 
 
1) SW102 strain is endowed with phage λ recombination 
genes. These are silent at 32ºC but are activated by shifting 
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the bacteria at 42ºC for 15 min. These genes permit 
recombination between sequences having 40bp of identity. 
 
2) Presence of RpsL-Neo Cassette: by homologous 
recombination, the RpsL-Neo cassette can be inserted in the 
adenoviral genome amplifying, its sequence with 40bp of 
homology arms for the adenoviral region of interest. The 
RpsL-Neo cassette confers sensitivity to streptomycin and 
resistance to kanamycin, and upon its insertion, the bacteria 
will grow in kanamycin + chloramphenicol. Once this 
fragment is inserted in the adenoviral genome, this can be 
further replaced by a gene or sequence of interest, by a 
second homologous recombination. When RpsL-Neo is 
replaced, SW102s will grow in streptomycin and 
chloramphenicol. 
3.7.2.2. Generation of fragments containing CMV-eGFP-miR-
Scramble/ miR-222-S and homologous recombination in 
pAdNuPARmE1A-RpslNeo E4 
CMV-eGFP-miR-Scramble and CMV-eGFP-miR-222-S were 
amplified with primers hybridizing at the 5’ and 3’ of the plasmid 
sequence (primers miRNA cua, listed in table 3.1). Besides 
recognizing miRVec sequence, those primers were characterized by 
overhanging sequence homology with the adenoviral genome, in the 
region between E4 and R-ITR. In this way, PCR amplification of 
miRVEC-CMV-eGFP-miR-Scramble/miR-222-S with the 
described primers would generate a 1600bp fragment having 40 bp 
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extremities homologous the adenoviral genome. Thus, according to 
pAdZ system, this short homology should permit recombination 
between the RpsL-Neo cassette contained in the adenoviral 
backbone and our fragment. The primers were designed to clone the 
fragment in an antisense direction in the adenoviral genome 
pAdNuPARmE1A-RpslNeo E4. 
Following recombination, colonies growing on LB + Agar + 
Chloramphenicol (12.5 µg/mL) + streptomycin (5mg/mL) were 
picked and cultured in liquid medium containing the indicated 
antibiotics. Colonies were further tested by PCR and restriction 
analysis and finally confirmed by Sanger sequencing. 
3.7.3. Amplification of adenovirus in eukaryotic cell lines 
3 µg of pAdZ plasmids pAdNuPARmE1A-E-Scramble and 
pAdNuPAR-E-miR222-S were transfected with SuperFect reagent 
(QUIAGEN) to a p60 plate of HEK293 ICO cells. pAdZ plasmids 
codify for Sce-I endonuclease, which permits genome linearization 
inside the cells. 
Five to 10 days after transfection the cytopathic effect was observed 
and cells and media were collected and homogenized by 3 x 
freeze/thaw cycles to release viral particles. Solution was 
centrifuged at 600g -10 min to eliminate cellular debris. This 
supernatant containing virus was called P1 homogenate. 
1/10 of P1 was added to a p100 plate of A549, growing in DMEM 
10%. Again, when cytopathic effect was observed, both cells and 
medium were collected and submitted to freeze/thaw cycles to 
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generate P2. With 1/10 of P2 2 p150 plates of A549 cells were 
infected, and collected when evident cytopathic effect was 
observed, about 3-4 days later and generate P3. Before performing 
the final infection (P4), a preliminary trial was performed on 3 p150 
a549 plates to determine the optimal dose of infection, with 250, 
500, 750 µL of P3. Then, 500 µL of P3 (established dose after 
trials) was used to infect the final production of 15 p150 A549 
plates for the viral stock. This step was performed growing cells in 
a 2% FBSi supplemented DMEM. When cells appeared cytopathic, 
they were harvested for final purification. Cells were centrifuged 
300 g for 5 min and their pellet was submitted to freeze/thaw cycles 
before purification. P4 Freeze/thaw cycles were operated by the 
resuspension of the pellet in a 5 mL volume of PBS ++ (PBS 
containing CaCl2 0.68mM and MgCl2 5mM). 
3.7.4 Purification of Adenoviruses 
Adenoviral particles are purified by Cesium Chloride (CsCl) 
gradient centrifugation. 
Day 1. A gradient containing 1.5, 1.35, 1.25 g/mL of CsCl solutions 
was prepared (from bottom, to the top), and the viral homogenate 
was added on the top of the tube. A first ultracentrifugation was 
performed at 35000 rpm for 2 h in a swinging SW40Ti rotor. 
After the centrifuge, two bands of adenoviral particles could be 
observed between 1.35 and 1.25 CsCl layers. The upper band 
corresponded to empty viral capsids and thus removed. The lower 
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band was collected and submitted to a second ultracentrifugation for 
24 h at 35000 rpm in a continuous gradient of CsCl 1.35 g/mL. 
Day2. Two bluish bands were observed in the continuous gradient, 
the upper band was discarded and the lower band, containing the 
full viral particles collected. 
To eliminate CsCl, PD-10 desalting columns (GE Healthcare) were 
used. Viruses were eluted from columns with PBS++ (PBS 
containing CaCl2 0.68mM and MgCl2 5mM) and kept in PBS ++ 
with 10% glycerol for storage at -80ºC in 2, 50 and 100 µL aliquots. 
3.7.5 Titration of adenovirus 
In this thesis three different titration methodologies have been used. 
Adenoviruses introduced in the section 4.1 have been titrated by 
plaque forming units (pfu/mL), whereas in section 4.2 and 4.3 by 
infective forming units (IFU). When Adwt was used alone (section 
4.2) it was administered as vp/mL. 
3.7.5.1 Physical quantification of viral particle by 
spectrophotometry 
Viral DNA was quantified by measuring its absorbance at 260nm 
wavelength. 
Different adenoviral dilution (1/5, 1/10, 1/20) were prepared from 
viral stock in lysis buffer (Tris-HCl pH7.4 10mM, EDTA 1mM, 
SDS 0.1%) and incubated 10 min at 56ºC. DNA was quantified at 
Nanodrop 100 (ThermoScientific) and the viral titer was 
extrapolated from the following formula: 
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vp/mL = DO260 ·dilution factor · 1.1 ·1012 
3.7.5.2 Titration by plaque-forming unit (pfu/mL) 
Viral titration by plaque forming units considers the functional 
ability of the virus to infect the cells. It determines the number of 
infective particles (plaque-forming units) by detecting the late 
adenoviral protein expressed inside the cells with an 
immunostaining for the viral hexon, 18-20 hours following 
infection. 
HEK293 ICO cells were infected with a series of adenoviral 
dilutions in a final volume of 200µL and incubated for a period of 
18-20 h. The day after, cells infected by the virus were stained with 
an anti-hexon antibody (coming from a cellular hybridoma). 
Visualization was realized by recognition with a fluorescently 
marked secondary anti-mouse antibody. 
Positive cells were directly counted under a fluorescence 
microscope (IX51 – Olympus) or photographed for posterior 
manual counting (ImageJ). The viral titer was determined with the 
following formula: 
Pfu/mL= # stained cells ·dilution factor ·0.1 mL 
3.7.5.3 Titration by viral infectious units (IFU) 
This titration quantifies the viral genomes inside the cells 4 hours 
after infection. 
A549 cells were used for this titration: 50000 cells/well were plated 
in 24MW plates in a final volume of 500µL. Next day, 1/100 and 
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1/1000 of the viral dilutions were prepared and used to infect the 
cells with 10µL of the dilution, in triplicate. Four hours later, cells 
were washed three times with PBS and collected upon 
trypsinization. Viral and cellular DNAs were extracted with a 
commercial kit, and the number of viral genomes/cells determined 
via qPCR using specific primers for hexon and albumin (Adhexo, 
Albumin, see table 3.1). The number of viral genomes was obtained 
by interpolation with a standard curve. 
3.8 Functional Assay 
3.8.1 MTT assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) is a colorimetric assay based on the conversion of 
thiazolyl blue tetrazolium bromide into insoluble blue formazan by 
metabolic active cells. The formazan deposits can be dissolved in 
DMSO and quantified at 560nm with a spectrophotometer as an 
indirect measurement of cell viability. 
Cells were incubated with a battery of adenoviral doses for 3, 5 or 7 
days. At the end of the treatment, culture medium was replaced by 
MTT solution at a concentration of 7.5mg/mL, dissolved in DMEM 
10% medium. Cells or organoids were incubated for 30 minutes or 
2 h, respectively. Medium containing MTT was replaced with 
DMSO, to dissolve precipitated crystals. In the case of organoids, 
an intermediated step was performed between MTT and DMSO 
with 2% SDS (in ddH2O). 30 µL of SDS were added to each well 
and incubated for 1 hour at moderate shaking. Then, 100 µL of 
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DMSO was added. Absorbance was measured at a wavelength of 
560 nm in a spectrophotometer (Synergy HT – BioTek), as a direct 
indication for cell viability. 
Results are expressed as percentage of cell viability compared to an 
uninfected or untreated control (MOCK -100% viability). Using 
GraphPad Prism software, the values were transformed to 
logarithmic and then fitted to a sigmoid curve via a nonlinear 
regression (% viability vs viral dose or drug concentration). The 
ID50 values, representing the amount of virus or drug required to 
inhibit 50% of cell growth, were extrapolated from dose-response 
curves and plotted independently. 
3.8.2 Colony formation assay 
Adenoviral infection was performed as explained in 6.4.3.1, at the 
indicated doses (ranging from 102 to 104 pfu/well). Five days later, 
the infected organoids were collected, mechanically disaggregated 
and seeded in a new 96MW plate split with a 1:2 ratio. Twenty-four 
hours later, only the organoids not infected with virus, or with a low 
viral progeny inside, were able to reassemble and form a new round 
shaped organoid. The number of organoids with a round shape and 
with a diameter larger than 20 µM were counted and plotted. 
3.8.3 Methylene Blue staining 
Cells were incubated with methylene Blue dye (Sigma Aldrich) for 
1 min. Then, the excess of dye was removed by washes with H2O 
and plates were dried at RT for 1 hour. Stained cells correspond to 
the number of cells alive previous to the treatment. 
Materials and Methods 
93
3.8.4 Viral Yield assay 
50000 cells/well for PANC-1 and 100000 cells/well for MIAPaCa-2 
and CP15-Luc were seeded in 24 MW plate. The day after, cells 
were infected with the different adenoviral doses in 500 µL of 
medium. Four hours later, wells were washed three times with 
sterile PBS to remove adenoviral particles that did not enter the 
cells. At this point some cells were collected to assess for viral 
entry. Seventy-two hours after infection, supernatant or total cell 
extracts were harvested, centrifuged at 400g 5 minutes to remove 
cell debris, and used for genomic DNA extraction with commercial 
kits. In the case of total cell extracts 3 freeze and thaw cycles were 
performed before centrifugation. 
For organoids, two confluent wells of organoids were infected with 
50.000 pfu/well. Five days later, organoids were harvested, 
centrifuged and cellular pellet suspended in 300 µL of Advanced 
DMEM F12 medium. The cell suspension was submitted to three 
freeze and thaw cycles to release viral particles contained inside the 
cells. Lysates were centrifuge at 600g for 5 minutes and medium 
containing viral particles was harvested. Two hundred µL of the 
lysate were used for genomic DNA extraction. 
Viral DNA was quantified by specific primers recognizing 
adenoviral hexon (Adhexo) and cellular albumin. The amount of 
viral DNA/cell was extrapolated by interpolation in a standard curve 
of known concentrations. 
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3.8.5 eGFP detection 
eGFP expression was determined via 3 alternative methods: 
• mRNA quantification via qRT-PCR (specific primers 
detailed in table 3.1) 
• Flow cytometry: eGFP intensity was detected in cells with 
the help of a flow cytometer, Attune  Acoustic Focusing 
Cytometer (Applied Bioscience). Cells were harvested by 
trypsinization and analyzed, using mean fluorescence 
intensity (MFI) as parameter. 
• Microscope imaging: eGFP expression was visualized in a 
fluorescent microscope emitting at wavelength of 480nm. At 
the indicated times, cells or organoids were analyzed in 
Olympus IX51 for fluorescence emission. 
 
3.9 Animal Manipulation 
 
All the animal’s procedure met European`s guidelines 86/609/EEC 
and were revised and approved by the ethical committee of the 
University of Barcelona. 
Animals were housed in plastic cages in controlled environmental 
condition of temperature (22 ± 2º), humidity (60%) and light, with 
water and food ad libitum. 
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The animals used in the study were immunosuppressed Athymic 
Nude Fox1 nu/nu mice, purchased from ENVIGO at the age of 6 
weeks (ranging from 20 to 30 gr). 
 
3.9.1 Subcutaneous tumor model 
Subcutaneous tumors were generated either from human cell lines 
or organoids in Athymic Nude Fox1 nu/nu immunosuppressed mice 
to escape rejection of the human inoculated cells. 
For PANC-1, 2·106 cells/tumor were injected in each mouse flank 
with the help of a 29G needle. Before implantation, cells were 
washed twice with PBS to remove FBSi, and then the desired 
number of cells was re-suspended in an appropriate volume of 
DMEM (not supplemented), mixed 1:1 with Matrigel (Corning®). 
One hundred μL of this solution was injected into each flank. 
For the generation of subcutaneous tumor from IDIT1 organoids, 
5·105 cells/flank were inoculated. 
Following injection, tumors were measured twice a week with a 
digital caliper. The volume was calculated by measuring the length 
(D) and width (d) of the tumor, and applying the following formula: 
Tumor Volume = (D · d2   ·  π) / 6 
Once the tumor reached 100 mm3, adenoviral treatment or saline 
solution as a control were administered to the assigned group of 
animals. Animals were euthanized at the end of the experiment and 
tumors were isolated and stored at -80º, for molecular analysis of 
DNA/RNA/protein, or transferred to a 4% PFA solution, for 
histological studies. 
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3.9.2 Orthotopic tumor model 
An orthotopic tumor model consists in the implantation of cells in 
the tissue of tumor origin. This model takes advantage of the organ 
microenvironment, and more faithfully recapitulates tumor 
histology and architecture and at long-term generates metastases. 
In this study we generated orthotopic tumor models by implanting 
5·105 cells from disaggregated organoids, in a mixture 1:1 of PBS: 
Matrigel. 
Briefly, 30 minutes before the operation animals received the 
analgesic meloxicam Metacam ® (Boheringer Ingheleim). Then, 
nude mice were anesthetized with a mixture of isofluorane and 
oxygen and placed on their right side. This was cleaned with 
ethanol and a laparotomy at the level of the spleen was performed. 
Spleen and pancreas were gently externalized, and 100μL of 
mixture containing organoids was slowly injected in the head of the 
pancreas. The formation of a small bubble within the pancreatic 
parenchyma assured the correct implantation of the cells. Organs 
were re-introduced inside the abdominal cavity two min later to 
allow for Matrigel solidification. Muscle layer was closed with 
interrupted 4-0 silk sutures and the overlying skin with Autoclips® 
(Stoelting Europe). Iodine solution was applied to the region of 
surgery, and animals were maintained under a heating source. 
Metacam was administered for the next 2 days and autoclips were 
removed 7 days after surgery. 
Tumor volumes was followed by palpation and once reached values 
that limited ethical statements animals were euthanized (2-3 months 
after organoids implantation). Following sacrifice by cervical 
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dislocation, animals were inspected for the presence of metastasis. 
If present, they were collected together with the orthotopic tumor, 
and stored in advanced DMEM F12, for organoids generation, or 
transferred to a 4% PFA solution, for histological analysis. 
3.9.3 Administration Route 
• Intraperitoneal administration: this route was used for 
administration of the analgesic Metacam with a 29G needle. The 
drug was administered at a concentration of 1/2mg/kg, diluted in 
saline solution to reach final volume of 100μL. 
• Intravenous administration: this route was used for systemic 
administration of adenoviruses via tail vein injection. To ease the 
process, animals were immobilized with the help of a restrainer and 
heat light was applied to the tail, to favor vasodilation.  
Adenoviruses were injected at a dose of 5·1010 vp/animal using a 
29G needle. 
3.10 Histological Analysis 
Tissues stored in 4% PFA (paraformaldehyde) were processed to 
paraffin block and further cut to 5 μM sections in the histology unit 
of IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i 
Sunyer). 
Hematoxylin/eosin (H&E) staining of paraffin-embedded sections 
was used to evaluate tissue structure and was performed by the 
Histology Unit of IDIBAPS. 
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3.10.1 Organoids inclusion 
Organoids were dissociated from matrigel by incubation with 1mL 
dispase (1mg/mL). Organoids were collected with PBS and settled 
in an 8mL flat bottom tube. When sedimented, organoids were fixed 
with 4% PFA for 30 min at RT. PFA was removed via decantation 
and washed twice with PBS. Then, organoids were dehydrated 
applying EtOH diluted in ddH2O (25-50-70%). In the last wash of 
70% EtOH organoids were stored at 4 ºC and sent to the IDIBAPS 
histology unit or to Dr. Clevers’ laboratory for inclusion and slides 
preparation. 
3.10.2 Immunohistochemistry (IHC) 
Paraffin-embedded section were deparaffinized and rehydrated with 
pure Xylen followed by solution with EtOh/H2O with increased 
concentration of H2O (4% - 30% - 50% - 100%). Then, samples 
were incubated in sodium citrate buffer (pH 6.0, 10mM) at 95ºC for 
5 min under pressure. Sections were blocked with PBS-Triton 0.3% 
+ 10% FBS + 1% BSA for 90 min to avoid unspecific bindings. 
Then, sections were washed 3 times with PBS, and incubated O/N 
with primary antibodies anti-Cytokeratin 19 or anti-E1A (AntiCK-
19, Abcam 52625, dilution 1:500 in PBS-0.1% BSA; AntiE1A, 
Santacruz Biotechnology sc-25, dilution 1:200 in PBS-0.1% BSA). 
The day after, endogenous peroxidases were blocked with Dual 
Endogenous Enzyme Block (Dako) for 10 min. After 3 X PBS 
washes, the reaction was developed with Dako EnVision + Dual 
Link System-HRP (DAB+) (Dako). Sections were counterstained 
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with Harris hematoxylin (Panreac) and samples visualized at 
NIKON e600 inverted microscope. 
3.11 Bioinformatics analysis 
For the study of miRNA-related characteristics and target genes the 
following bioinformatical resources were used: 
• miRBase: searchable database of miRNAs annotation and 
sequences (Release 22.1). 
• miRWalk: bioinformatics program integrating data from 
different database predicting targets for miRNAs. Data 
matching at least 4 of the considered databases were 
included as targets (miRWalk, miRanda, miRDB, Pictar2, 
PITA, RNA22 and TargetScan). 
• PANTHER-GO: bioinformatics tool clustering targets 
related to a miRNA of interested. It helped with the 
identification of the pathways having more miR-222 
targeted-genes, performing a gene ontology (GO) analysis. 
The predicted pathways having the lowest p-value were 
considered for further analysis (p value from to 10-16 to 10-
5). 
Other softwares applied for sgRNA design or miRNA sponge 
design have been listed in the appropriate sections (3.2.1.1 and 
3.2.2.1). 
Bioinformatics tools not related to miRNA analysis were: 
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• Nucleotide BLAST: tool for alignment of two or more 
sequences. It was used to analyze results from DNA 
sequencing. 
• Unipro uGENE: program that permits visualization of 
FASTA sequences. Useful for plasmids and adenoviral 
genome design. 
3.12 Data representation and Statistical Analysis 
All data obtained in this study are represented as mean ± Standard 
Error of the Mean (SEM). A minimum of 3 replicates and a 
maximum of 6 for experiment were considered. Data are 
represented via GraphPad Prism v5.0. 
Data obtained are treated as non-normal population and differences 
were analyzed with a Mann-Whitney non-parametric test or with a 
Kruskal-Wallis non-parametric test with the help of Graph Pad. 
Differences were considered significative when p-value < 0.05. P 
values were marked with the presence of *: *p<0.05, **p<0.01, 
***p<0.005. 
For in vivo analysis, tumor growth along days was evaluated with 
mixed linear model in R v2.14.1 using package Ime4 (performed by 
Estela Nuñez). Differences within mean were evaluated with 




DNA Primers Forward (5’→ 3’) Reverse (5’→ 3’) Th Application 
Kras GGTGGAGTATTTGATAGTGTA GGTCCTGCACCAGTAATATGC 55 Sequencing 
miR-21 CCACACTCTGTCGTATCTGTG AAGTGCCACCAGACAGAAGG 58 Sequencing 
miR-93 TGAGGGAGACCAGACCCTTT TTCTGCTTCCCCATGAACCT 58 Sequencing 
miR-221 GTCCCAGCATTTCTGACTGTTGG GGCTTGTGGGTGCTATGCCTTC 58 Sequencing 
miR-222 GCTGGATCTCCAGCACCTAAG CCCAAGCCCCAGCTGATAATG 58 Sequencing 




CTGGGAAGGGAAACTGAGTGGG 58 Sequencing 





miRVec_Val CATGGTCCTGCTGGAGTTCG CTTGCCAAACCTACAGGTGG 57 Sequencing 
Step3/4 CCAGAAACGAAAGCCAAAAA TAATGAGGGGGTGGAGTTTG 50 Sequencing 












C CAGCACGCCGCGGATGTCAAAG 58 qRT-PCR 
Albumin GCTGTCATCTCTTGTGGGCTGT GGCTATCCAAACTCATGGGAG 58 qRT-PCR 




















ssDNA for sponges Sponge sequence Final Primer sequence 










































sgRNA Name Forward (5’→ 3’) Reverse (5’→ 3’) 
sgmiR-21 #1 caccgTCATGGCAACACCAGTCGAT aaacATCGACTGGTGTTGCCATGAc 
sgmiR-93 # 1 caccgCTCCAAAGTGCTGTTCGTGC aaacGCACGAACAGCACTTTGGAGc 
sgmiR-221 # 3 caccGCAACAGCTACATTGTCTGC aaacGCAGACAATGTAGCTGTTGC 
sgmiR-222 # 1 caccgACGAAAGACAGGATCTACAC aaacGTGTAGATCCTGTCTTTCGTc 
sgmiR-761 # 3 caccgTGGCAAGCGGAGGAGCAGCA aaacTGCTGCTCCTCCGCTTGCCAc 
sgmiR-3714 # 2 caccgCGGTGATGGAGCACGTCACA aaacTGTGACGTGCTCCATCACCGc 
sgmiR-4713-5p # 5 caccgATTCGACCCTTATGGGAGCC aaacGGCTCCCATAAGGGTCGAATc 






Target gene Forward (5’→ 3’) Reverse (5’→ 3’) 
BPTF CGAAAAGGAGGAATCCGAGAGG CGTAACATCAGGCTCACTCCAGC 
DDX21 TCATCAAGGACGCACTATCATCT CCTTTCAGGGTGATTTCCCTTT 
eGFP AAGATCCGCCACAACATCGA AACTCCAGCAGGACCATGTG 
c-MYC AGTGCATTGACCCCTCAG CCTGCCACTGTCCAACTTG 
HES-1 TGGAAATGACAGTGAAGCAACT GTTCATGCACTCGCTGAAGC 
HPRT GATATAAGCCAGACTTTGTTGGATTTG CTTGAACTCTCATCTTAGGCTTTG 
KPNA-2 CGTCTTCACAGATTCAAGAACAAGG CCTCTTCAGCATCTGGTCATCC 
KRT-19 CTACAGCCACTACTACACGAC CAGAGCCTGTTCCGTCTCAAA 
NOLC-1 TTCCTGCGCGATAACCAACTC CCTGTAACTTTCGCTCTGGGA 
NOTCH-1 ATCCAGAGGCAAACGGAG CACATGGCAACATCTAACCC 
SOX-9 GCCGAGCTCAGCAAGAC TACTTGTAATCCGGGTGGTC 
TCOF-1 CGATAACCAACTCTCAGAGGTGG CTAAGAGGGAAGAGGCATTGG 
uPAR GCCTTAACCGAGGTTGTGTGT CATCCAGGCACTGTTCTTCA 






miRNA Recognizing sequence Assay ID 
miR-21 UAGCUUAUCAGACUGAUGUUGA 000397 
miR-29c UAGCACCAUUUGAAAUCGGUUA 000587 
miR-93 CAAAGUGCUGUUCGUGCAGGUAG 001090 
miR-99b CACCCGUAGAACCGACCUUGCG 000436 
miR-221 AGCUACAUCUGGCUACUGGGUCUC  000524 
miR-222 AGCUACAUUGUCUGCUGGGUUUC 000525 











Materials Receipt / Provenience Used for 
Wash Media DMEM Supplemented with 2% FBS, 1% P/S Digestion media removal 
Digestion Media 
Wash media + Collagenase XI (0.125 mg/mL) + Dispase 
(0.125 mg/mL) 
Tissue digestion and ducts liberation 
Matrigel Corning Matrigel - Phenol Red-free, LDEV-free, 10 mL 
Organoids seeding 
Thaw on ice for 1 hours 
Tryple Select Thermofisher Scientific Final tissue digestion 
Growth media Complete growth medium formulation at 2.3.2.1 Organoids feeding 
75 cm3 flask Jet Biofill Matrigel solidification 









Reagent Concentration Amount in 50mL Healthy Tumoral 
Advanced DMEM F12 - 14 mL to reach 50 mL + + 
L-Wnt3a 2 X 25 mL + + 
Rspondin-1 10 X 5 mL + + 
m-Nogging 10 X 5 mL + + 
B-27 50 X 1 mL + + 
Nicotinamide (NIC) 100 X 500 µL + + 
N-acetyl-Cysteine (NAC) 400 X 125 µL + + 
Primocin 500 X 100 µL + + 
A-485 1000 X 50 µL + + 
h-FGF-10 1000 X 50 µL + + 
h-EGF 1000 X 50 µL + + 
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h-gastrin 1000 X 50 µL + + 
Prostaglandin-E2 (PGE2) 1000 X 50 µL + - 
Y-27632 - RhoK inhibitor 500 X 100 µL 1 week after isolation 


















L-Wnt-3a testing Media proportion X 7 wells (500µL/well) 
L-Wnt-3a control medium 100% DMEM 10% 3.5 mL DMEM 10% 
L-Wnt-3a conditioned medium 50% L-Wnt-3a + 50% DMEM 10% 
1.750 ml L-Wnt-3a + 1.750 ml 
DMEM 10% 
Rspo-1 Testing Media proportion X 7 wells (500µL/well) 
Rspo-1 control medium 10% Advanced DMEM F12 + 90% DMEM 10% 
350l Advanced DMEM F12 + 
3.150ml DMEM 10% 
Rspo-1 conditioned medium 10% DMEM 10% + 90% Rspo-1 




50% L-Wnt-3a + 10% Rspo-1 + 40% DMEM 10% 
1.750ml L-Wnt-3a + 350l Rspo-1 + 
1.4ml DMEM 10% 



























4.1 Organoids as a translational model to screen 
for therapies 
PDAC is one of the major clinical problems in the field of 
oncology. Its survival has not increased in the last 30 years, and the 
only curative treatment remains surgical removal of the tumor 6,207. 
Oncolytic virotherapy has been envisioned as an alternative 
promising approach for cancer treatment, with many viruses being 
tested in clinical trials, either alone or in combination with 
chemotherapies 186,208. 
In vitro oncolytic virus screening is mostly performed in cell lines 
and eventually in mouse xenografts. However, bidimensional 
cultures poorly reproduce the heterogeneity of a tumor, whereas the 
use of patient-derived xenografts (PDX) is often too time-
consuming for guiding in personalized therapies. 
The 3D organoids model has recently shown its potential as a 
personalized medicine application in testing anti-cancer drugs and 
evaluating tumor diversity 116,209. In the current project we have 
evaluated the potential of tumor organoids to help on virotherapy 
treatment decisions. 
4.1.1 Generation of a patients-derived organoids from PDAC 
and healthy tissues 
We obtained healthy and tumor pancreatic tissue, from patients 
diagnosed with PDAC undergoing surgery at the Hospital Clinic of 
Barcelona. Following established protocols 199,210, we obtained 5 
lines of PDAC-derived organoids from  11 PDAC tumors and  8 
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from 16 healthy pancreas, when possible adjacent and matching the 
PDAC tumors. 
Tissues were submitted to mechanical and chemical disruption. 
Following pancreatic ducts release, cells were seeded in matrigel, 
and supplemented with organoids complete medium. (Fig 4.1.1 A) 
Organoids growth was evaluated by their morphologic appearance 
since day 1. We observed an epithelial cell layer with a round-
shaped structure enlarging with days (Fig 4.1.1 B). Established 
tumor derived organoids could be passaged, maintained in culture 
and unlimited propagated. Normal pancreas derived organoids 
ceased to proliferate after a maximum of 10 passages. 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 7 Day 9 Day 20 
B
A








PDAC – derived 
organoids 
Healthy pancreas – 
derived organoids 
 
Figure 4.1.1. Schematic representation of organoids generation. A. After surgery, a 
pathologist examined the tissue and PDAC region was separated from healthy pancreas. If 
available, both tissues were submitted to a preliminary mechanic disruption with the help 
of a surgical blade, followed by enzymatic digestion. When pancreatic ducts were 
observed, cells were seeded in matrigel, further supplemented by medium. B. IDIT4 




4.1.2 Characterization of PDAC-derived organoids confirms 
their malignant origins and ductal phenotype 
Once organoids from PDAC tissues were established, the 
confirmation of their transformed pancreatic origin was assessed by 
molecular characterization of the mutational status of KRAS. This 
gene is mutated in 90% of PDAC tumors, and protein codon 12 is 
the hot-spot mutation. Sequence analysis of the region 196  revealed 
that the seven lines of organoids used in the study (5 lines generated 
by our group plus 2 kindly provided by Dr. Hans Clevers 
laboratory) presented a KRAS mutation (Table 4.1.1), confirming 






Mutation AA Change 
IDIT1 Mutated 12:25398285(-): G/C G12R 
IDIT2 Mutated 12:25398285(-): G/C G12R 
IDIT3 Mutated 12:25398284(-): G/T G12V 
IDIT4 Mutated 12:25398284(-): G/A G12D 
IDIT5 Mutated 12:25398284(-): G/A G12D 
IDIT6 Mutated 12:25398284(-): G/A G12D 
IDIT7 Mutated 12:25398284(-): G/T G12V 




IDIT5, IDIT6 and IDIT7 were further characterized at histological 
and immunohistochemical (IHC) level. H&E staining of whole 
mount organoids were compared to the PDAC tissue of origin, 
showing strong morphologic similarities such as dysplastic cell 
organization and nuclear irregularities. CK19 IHC revealed strong 
immunoreaction of the ductal marker in patient tumors and 
established organoids (Fig 4.1.2 A, B). 
To confirm the ductal origin of organoids, RNA from all PDOs was 
obtained and analyzed for ductal markers expression. Both normal 
and PDAC organoids showed enrichment in SOX9 and CK19 
























Figure 4.1.2. Human PDAC derived organoids maintain characteristics of tumors of 
origin and are enriched in ductal markers. A. Representative histological sections of 
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human pancreatic tumors. Left panels correspond to H&E staining. Right panels show 
CK19 immunoreactivity staining (scale bar 50 μm). B. PDAC derived organoids from 
matching tumors: Bright field images (scale bar 50 μm). H&E staining of organoids and 
CK19 immunoreactivity (scale bar 50 μm). C. qRT-PCR analysis of ductal lineage markers 
(KRT19 and SOX9) from PDAC organoids (n=7), normal pancreas organoids(n=4) 
organoids, tumor tissue of origin (n=4) and adjacent normal pancreas (n=6). Data are 
represented as mean ± SEM; *p<0.5, **p<0.01, ***p<0.05 Mann- Whitney U Test. 
 
4.1.3 Adenoviruses efficiently infect and replicate in PDOs 
We first evaluated whether adenoviruses were able to infect and 
replicate in organoids. To that end, reporter non-replicative 
adenovirus AdGFPLuc and replicative-competent Adwt-E 

















Figure 4.1.3. Schematic representation of reporter adenoviruses used in the following 
experiments. AdGFPLuc is a replication-deficient reporter adenovirus. It contains a double 
reporter genes system composed by an eGFP and a Luciferase, each one encoded by its 
own CMV promoter. Adwt-E is a replication competent Ad5wt, in which an eGFP has been 
inserted after L5 with an extra splicing site acceptor for transcription from the MLP 
promoter. 
 
IDIT4 organoids were infected with high doses of both viruses and 
infection was followed up by eGFP detection under a fluorescent 
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microscope (Fig 4.1.4 A). Outer layers of organoid cultures showed 
susceptibility to adenoviral infection, as shown by eGFP expression, 
in line with what has been previously reported 211. Interestingly, 
whereas eGFP signal was stable at all the time-points analyzed after 
AdGFPLuc infection, fluorescence signal observed by the Adwt-E 
infection dramatically increased after 96h (Fig 4.1.4 A). Presence of 
eGFP in the inner layers of organoids infected with Adwt-E 
suggested viral replication and spreading in PDOs. Positive E1A 
immunostaining confirmed viral replication within the organoid in 
Adwt-E, whereas no staining was detected in the AdGFPLuc-
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Figure 4.1.4. Adenoviruses are able to infect PDAC derived organoids. A. Representative 
images of time-course eGFP expression in IDIT4 tumor organoids infected with 5·105 
pfu/well of AdGFPLuc or Adwt-E (scale bar 100 μm). Images were taken with an inverted 
fluorescent microscope at the indicated time points. Representative images are shown, 
n=3. B. Histological sections of IDIT4 obtained 24 hours PI with AdGFPLuc and Adwt-E. 
Organoids were fixed in 4% PFA and further processed to obtain paraffin-embedded 
blocks. Tissue slides were stained with H&E to visualize morphology or were hybridized 
with anti-E1A antibody for adenoviral detection. 
 
To better characterize the dynamics of adenoviral replication in 
organoids, we set up an experiment in which naïve organoids were 
infected with viral extracts from sequential passages of infected 
organoids. For this, organoids were infected with AdGFPLuc or 
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Adwt-E and on day 5, harvested and submitted to freeze and thaw 
cycles, to release viral particles (Passage1 P1, Fig 4.1.5 A).  The 
lysate was used to infect naïve IDIT4 organoids, generating P2, and 
5 days later the same procedure was applied to generate P3. eGFP 
fluorescence was monitored through all the passages P1, P2 and P3. 
The cultures infected with the replication competent adenovirus 
displayed high fluorescence levels in all the passages, witnessing 
for strong adenoviral replication within the organoids. eGFP 
fluorescence from AdGFPLuc-infected cultures was only detected 
in P1, evidencing the lack of viral replication (Fig 4.1.5 B). We 
further measured the content of viral particles in P1, P2 and P3 
lysates. Quantification of the adenoviral genomes revealed that 
Adwt-E viral DNA was abundant and at similar levels in all the 
passages, whereas AdGFPLuc genomes were only detected in P1, at 






























































Figure 4.1.5. Adenoviruses are able to replicate in organoids and re-infect adjacent cells. 
A. Schematic representation of the experiment. B. Rounds of adenoviral infection in IDIT4 
organoids. Naïve organoids were infected with 5·105 pfu/well of AdGFPLuc or Adwt-E and 
5 days later (P1) were harvested, followed by three cycles of freeze and thaw. 
Supernatants were used to infect fresh organoids and 5 days later (P2) the same 
procedure was repeated to generate P3. GFP expression was visualized at P1, P2 and P3 in 
organoids infected with Adwt-E, but only at P1 in AdGFP-Luc infected organoids (scale bar 
100 μm). Representative images are shown, n=3. C. Quantification of viral genomes 
content in P1, P2 and P3 organoids passages infected with AdGFPLuc or Adwt-E (n=3). 
Supernatants obtained in each passage after freeze and thaw cycles (described in B) were 
quantified via qRT-PCR using specific primers for adenoviral hexon. 
 
 
4.1.4 Oncoselective adenoviruses display viral attenuation in 
organoids from healthy pancreas 
To assess oncoselectivity and potency of adenoviral therapies, two 
different oncolytic viral backbones were used in the following 
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experiments: the AdNuPARmE1A and ICOVIR15 backbones. 
AdNuPARmE1A has been previously generated in our laboratory 
and incorporates SPS sequences responding to NOTCH activation 
and a uPAR promoter, highly upregulated in PDAC, controlling the 
E1A gene 172. ICOVIR15, kindly provided by Dr. Ramon Alemany 
has an E1A modified promoter with 8 E2F binding sequences and a 
SP1 binding sequence plus a 24bp deletion in the E1A gene to 
redirect E1A transcription towards Rb/p16 altered pathway. 
Moreover, it bears an RGD motif inserted in the fiber gene  (Fig 
4.1.6) 168. 
 
With the purpose of studying oncoselectivity, an eGFP was inserted 
in the adenoviral backbones to monitor adenoviral infections. 
AdNuPARmE1A-E and ICOVIR15-E were tested in PDAC 
(IDIT1) and healthy pancreas (IDIS0) derived organoids. Adwt-E 
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Figure 4.1.6. Backbones of the oncolytic adenoviruses used in the following 
experiments. Adwt-E has already been introduced in 4.1.3; Adwt has the same backbone 
without eGFP. AdNuPARmE1A controls E1A replication by the uPAR gene promoter and 3 
Notch responsive sequences, named SPS. ICOVIR15-E presents an E1A promoter with 
additional E2F binding sites plus an SP1 binding site, Δ24 deletion in the E1A gene and an 
RGD motif in the L5 gene. AdNuPARmE1A-E and ICOVIR15-E further encodes for an eGFP, 
inserted in both genomes after L5 with an extra splicing site acceptor for transcription 




Organoids were infected with 5000 pfu/well and eGFP expression 
was monitored 24, 48, and 72 hours PI. Fluorescence in PDOs from 
PDAC tumors similarly increased with time, independently of the 
virus used, according to viral replication and spread within the 
organoid (Fig 4.1.7 A). Interestingly, whereas eGFP expression 
expanded in normal organoids exposed to Adwt-E, infection with 
oncolytic adenoviruses displayed similar eGFP expression at all 
time points assessed, indicating the difficulty of both 
AdNuPARmE1A-E and ICOVIR15-E to replicate in normal tissue 



























































24h 24h 48h 72h  
Figure 4.1.7. OVs selectively replicate in PDAC derived organoids. Organoids were 
infected with 5000 pfu/well of Adwt-E and the oncolytic adenoviruses AdNuPARmE1A-E 
and ICOVIR15-E. Representative images of GFP expression at 24h, 48h and 72h after 
infection of PDAC IDIT1 organoids (A) or IDIS0 normal pancreas organoids (B). 
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To validate healthy PDOs for testing adenoviral selectivity, we 
performed cytotoxicity studies by an adapted MTT assay on two 
healthy pancreas derived organoids. We infected the cultures with 3 
different viral doses and 5 days later cytotoxic effects were 
evaluated. OVs displayed a diminished cytotoxic effect compared to 
Adwt (Fig 4.1.8). At all the analyzed doses, IDIS0 organoids 
maintained superior viability levels when infected with OVs than 
when infected with Adwt. IDIS6 organoids showed high sensitivity 
to viral lysis and differences in viral responses were observed upon 
infection at the low dose of 103pfu/well, where Adwt cultures 
showed significantly increased cytotoxicity. 
Together these results support the oncoselective activity of 
AdNuPARmE1A-E and ICOVIR15-E and validate PDOs as a 
















































Figure 4.1.8. Oncolytic adenoviruses activity is hampered in healthy pancreas derived 
organoids.  Two different healthy pancreas PDOs were infected at the indicated doses 
with Adwt, AdNuPARmE1A and ICOVIR15. Five days later cytotoxicity effects were 
visualized by an adapted MTT assay. Data are represented as mean ± SEM, n≥4; *p<0.5, 
**p<0.01, ***p<0.05, Non parametric Mann- Whitney U Test.  
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4.1.5 PDOs from PDAC exhibit different sensitivity to 
oncolytic adenoviruses 
The idea of introducing organoids as a system for virotherapy 
screening was meant to evaluate potential inter-patient responses, 
what could help to identify patient-specific treatment. To that end, 
we tested the activity of oncolytic adenoviruses AdNuPARmE1A 
and ICOVIR15 (Fig 4.1.6) and compared their potency to that of the 
wild-type adenovirus Adwt in a panel of PDAC organoids. 
As a proof of concept, AdNuPARmE1A and ICOVIR15 were 
screened for cytotoxicity in IDIT1 organoids. Organoids were 
seeded in 96MW plates and infected with 3 different adenoviral 
doses (103, 104, 105 pfu/well). Viability effects were evaluated on 
day 5, showing a dose dependent cytotoxicity for all the 
adenoviruses. Interestingly, IDIT1 organoids appeared more 
sensitive to AdNuPARmE1A. In fact, at the lowest dose, viability 
of the AdNuPARmE1A-infected IDIT1 organoids reached values 
lower than 50%, whereas at the same dose ICOVIR15-infected 
organoids still maintained viability higher than 75% (Fig 4.1.9 A). 
Analogous results were observed in organoid-formation assays. In 
these experiments, the viability of the organoids was indirectly 
measured as their ability to form new organoids once mechanically 
disaggregated, after 5 days of infection. AdNuPARmE1A-infected 
organoids formed significantly less organoids than ICOVIR15-
infected ones at the two doses tested (Fig 4.1.9 B, upper and lower 
panel). 
To investigate if the oncolytic efficacy in organoids could predict 
the in vivo response to the viruses, IDIT1 organoids were 
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subcutaneously injected into the flanks of nude mice. When tumors 
reached 100 mm3, animals received a systemic dose of saline 
solution, ICOVIR15 or AdNuPARmE1A at 5·1010 viral particles 
(vp)/animal. Treatment with both viruses strongly inhibited tumor 
growth, but the antitumor effect was significantly higher in animals 
receiving the AdNuPARmE1A virus, consistent with the in vitro 



















































































Figure 4.1.9. IDIT1 organoids show increased sensitivity to AdNuPARmE1A in vitro and 
in vivo. A. In vitro cytotoxicity of Adwt, AdNuPARmE1A and ICOVIR15 in IDIT1 organoids. 
IDIT1 organoids were infected with the indicated doses and 5 days later, cell viability was 
assessed by MTT assay. Data are represented as mean ± SEM, n>3; *p<0.05, Non 
parametric Mann-Whitney U test. B. Organoids forming capacity of IDIT1 infected 
organoids. IDIT1 organoids were infected with the indicated viral doses and 5 days later, 
cells were harvested, softly disaggregated and re-seed in 96MW plate with a 1:2 dilution. 
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The day after, formed organoids were counted (discriminating for round-shaped 
structures with dimension > 20 μm). Upper panel represents the count for viable 
organoids 24 hour after re-seeding. Data are represented as mean ± SEM, n=6; *p<0.5; 
**, $$, ##p<0.01; * statistic significance compared to MOCK control, $$ compared to 
Adwt, ## compared to AdNuPARmE1A, Non parametric Mann Whitney U test. In lower 
panel, representative images of nascent organoids 24 hours after re-seeding are shown 
(scale bar 100 μm). C. In vivo antitumoral effects of oncolytic adenovirus in IDIT1 
subcutaneous tumors. Tumor-bearing mice were intravenously injected with 5⋅1010 
vp/mice AdNuPARmE1A, ICOVIR15 or saline and tumor growth was monitored for 42 days 
(n=8, ***p<0.005, Differences within means were evaluated with Tukey’s range Test). 
 
Next, we analyzed the cytotoxic activity of AdNuPARmE1A and 
ICOVIR15 in 4 additional PDOs (IDIT2, IDIT4, IDIT5, IDIT6). 
We observed dose-dependent effects, with patient-susceptibility 
differences to adenoviral infections. At the doses of 104 pfu/cell, 
IDIT2 and IDIT6 reached 50% of viability, whereas IDIT4 and 
IDIT5 maintained values higher than 75% (Fig 4.1.10). According 
to these data, two main degrees of viral sensitivity among patients 
could be identified. IDIT1, IDIT2 and IDIT6 patients showed good 
susceptibility to adenoviral infections, with high cytotoxicity at the 
lowest dose applied (Fig 4.1.9A and Fig 4.1.10). IDIT4 and IDIT5 
required highest amount of OVs to reach remarkable cytotoxicity 
(Fig 4.1.10). The differences in adenoviral sensitivity could be 
potentially explained by differential Coxsackie and adenovirus 
receptor (CAR) expression on the surface of the organoids, in line 
with the variability observed in GI tumors and pancreatic cancer 
cell lines 165,212. Comparative analysis of the OVs AdNuPARmE1A 
and ICOVIR15 activities in organoids revealed similar oncolytic 
response to both viruses in IDIT4 and IDIT5 patients.  However, 
AdNuPARmE1A showed enhanced cytotoxicity in IDIT1 and 
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IDIT2 PDOs, (Fig 4.1.9 A, B and Fig 4.1.10) whereas ICOVIR15 
was more potent in IDIT6 PDOs (Fig 4.1.10). 











































































Figure 4.1.10. Oncolytic adenoviruses show patient-dependent sensitivity. Four different 
PDOs cultures were infected with the indicated doses of Adwt, AdNuPARmE1A and 
ICOVIR15, and cytotoxic effects were visualized 5 days later by MTT assay. Data are 
represented as mean ± SEM, n>3; *p<0.05, Non parametric Mann-Whitney U test. 
 
To understand the increased response of AdNuPARmE1A in IDIT1 
and IDIT2 organoids, we analyzed the expression of uPAR and 
HES1 genes, which share regulatory sequences with the virus, as 
well as that of NOTCH1, as a marker of the NOTCH pathway.  We 
performed qRT-PCR analysis in the different organoids and 
observed increased upregulation of the 3 genes in IDIT1 and IDIT2 
organoids (Fig 4.1.11). This result suggests that the higher potency 
of AdNuPARmE1A in these two organoids could be related to the 




Figure 4.1.11. PDAC derived organoids show different level of activation of uPAR and 
NOTCH pathways. mRNA expression of the indicated genes from 5 different PDOs was 
analyzed and results are expressed as 2^DCt. Data are represented as mean ± SEM, n≥4; 
**p<0.01, Non Parametric Mann- Whitney U Test. 
 
4.1.6 Combining viral oncolysis with chemotherapy or 
treatment with miR-99b-armed oncolytic virus increases the 
anti-cancer effects in PDOs 
To further evaluate the benefit of PDOs for testing optimized based 
adenoviral treatments, we studied the effects of combining 
adenovirus with chemotherapy or the use of adenovirus armed with 
transgenes that could synergize with adenoviral activity. 
To ascertain the potential benefit of combining the standard of care 
chemotherapy for PDAC, gemcitabine + nab-Paclitaxel, with the 
AdNuPARmE1A in PDOs, IDIT1 and IDIT2 organoids were 
treated with AdNuPARmE1A and the indicated drugs, alone or in 
combination. Cytotoxicity assays revealed small differences in 
sensitivity to chemotherapy between the two PDOs.  The strongest 
cytotoxicity effects were observed in the combination treatments, 
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reaching similar response in both organoids with viability values of 
25% at the conditions tested (Fig 4.1.12). These results highlight the 

















































































Figure 4.1.12. Combination of adenovirus with gold standard chemotherapy drastically 
decreases viability of PDAC organoids. AdNuPARmE1A sensitive PDAC organoids were 
treated with 100nM nab-paclitaxel, 2.5 ng/ml of gemcitabine or 5000 pfu/well of 
AdNuPARmE1A, alone or in combination and 5 days later cell viability was assessed by 
MTT assay. Data are represented as mean ± SEM **p<0.01, ***p>0.005, n≥4, Non-
parametric Mann-Whitney U test. 
Previous results from our laboratory showed that the reintroduction 
of certain miRNAs, whose expression is suppressed in PDAC, 
could help adenovirus during infections. ICOVIR15-miR99b and 
ICOVIR15miR-485 armed OVs displayed enhanced antitumor 
response in cell lines and xenografts, due to their role in regulating 
viral transcriptional repressors190. In this project we tested the 
activity of these armed oncolytic viruses (Fig 4.1.13 A) in the 
ICOVIR15-sensitive IDIT6 organoids. ICOVIR15-miR99b but not 
ICOVIR15-miR485 showed significantly higher activity than the 
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parental ICOVIR15 (Fig 4.1.13 B), confirming the role of this 
















































Figure 4.1.13. miR-99b rescue improves adenoviral oncolysis in IDIT6 organoids. A. 
Schematic representation of the viruses used in the experiment. ICOVIR15 was already 
detailed in figure 4.7. ICOVIR15-miR-99b/miR-485 have an ICOVIR15 backbone endowed 
with sequences expressing indicated miRNAs under CMV promoter in a region between E4 
and R-ITR. B. IDIT6 organoids were seeded and infected with the indicated doses of 
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adenoviruses. Five days post infection cytotoxicity was visualized by MTT assay. N>4 
*p<0.05, Non parametric Mann-Whitney U test. 
These results further highlight the patient-dependent sensitivity to 
oncolytic adenovirus and provide increased value to the viral 
screening in PDOs. 
4.1.8 Organoids derived from orthotopic tumors and metastatic 
foci in mice mirror responses of patient-PDO to oncolytic 
viruses 
At the time of PDAC diagnosis, very often, distant metastases are 
already present. Thus, it is fundamental that the developed therapies 
could act both in the primary tumors and in the metastatic foci. We 
took advantage of PDOs to generate a personalized model of 
metastases and characterize their response to OVs. 
We implanted a suspension of 5105 cells obtained from 
disaggregation of IDIT6 organoids in the pancreas of athymic nude 
mice. Tumor growth was followed up by palpation and 2-3 months 
later, animals were euthanized and inspected for the appearance of 
primary tumor and metastases (Fig 4.1.14 A). Of 7 animals 
implanted, 6 developed tumors in the pancreas, with metastatic foci 
either in liver or diaphragm. 
Analysis of tumor tissues revealed the presence of glandular 
structures resembling human PDAC lesions, with positive 
immunostaining for the ductal marker CK19 (Fig 4.1.14 B). 
We established organoids from individual tumors and metastases. 
First, we perform a karyotype of the different organoid lines, and 
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compared with IDIT6 before implantation and with healthy 



















Figure 4.1.14. Schematic representation of the in vivo metastasis model experiment and 
histological characterization of tumors and metastasis. A. Athymic nude mice were 
orthotopically implanted with 5•105 IDIT1 or IDIT6 organoids (n=3 for IDIT1, n=7 for 
IDIT6). Tumors in the pancreas and derived metastases were histologically characterized 
and collected for organoids generation. Karyotyping analysis and sensitivity to OA was 
evaluated in organoids. B. H&E and CK-19 staining orthotopic tumor and its derived 
metastasis. 
 
Healthy organoids showed a diploid chromosome number, whereas 
aneuploidy was evident in all the tumor-derived organoids and was 
superior in the metastatic organoids. These showed the highest 
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percentage of nuclei with more than 69 chromosomes, in line with 
the genetic drift likely taking act during the development of 
metastasis. Original IDIT6 PDOs presented an aneuploidy similar to 











Figure 4.1.15. Chromosomal instability analysis in orthotopic tumors and metastases 
derived from IDIT6 implanted organoids. Metaphases were induced in the different lines 
via COLCEMID treatment (0.1 μg/mL) for 24 h. A minimum of 15 metaphases for sample 
was counted. A. Panel shows representative images of the different samples’ karyotypes. 
B. Percentage of ploidy in each group of samples is represented. A karyotype of healthy 




Next, we evaluated the OVs activity on primary tumor derived 
organoids and their corresponding metastasis. Interestingly, we 
observed that ICOVIR15 displayed enhanced cytotoxicity compared 
to AdNuPARmE1A in organoids from all primary IDIT6 tumors 
and their metastatic foci, mirroring what already observed in IDIT6 
original organoids (Fig 4.1.16 A, B). 
A similar experiment was performed on a reduced number of 
animals, orthotopically implanted with IDIT1 organoids. In this 
experiment 2/3 operated animals developed pancreatic tumors 3 
months later, and one of them presented diaphragm metastasis. 
Again, we observed that tumor and metastasis derived organoids 
reproduced IDIT1 PDO behavior, being AdNuPARmE1A the most 
potent of the two adenoviruses (Fig 4.1.16 C). 
 
These results show that oncolytic virotherapy acts similarly in 
primary tumors and metastases, despite the latter having increased 
genomic instability. Interestingly, tumor evolution seems not to 
interfere with viral activity, at least in the tested conditions. These 
findings suggest the predictive ability of PDOs to identify highly 
active oncolytic adenoviruses and in the future could facilitate the 
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Figure 4.1.16. Primary tumor and metastases derived organoids from PDOs implanted 
in nude mice mirror PDOs sensitivity to adenoviruses. A, B, C. Orthotopic tumors and 
metastases derived IDIT6/IDIT1 organoids from 4 or 2 different animals, respectively, 
were infected at the indicated doses with AdNuPARmE1A and ICOVIR15. Five days later 





4.2 Influence of miRNA deregulation in PDAC on 
adenoviral oncolysis 
Altered miRNAs expression in malignancies has been widely 
demonstrated 213,214. These small post-transcriptional regulators are 
involved in all the processes of cancer biology. Their alteration has 
proven fundamental for tumor cells to acquire resistance to 
apoptosis, to induce high cellular proliferation, migration and 
chemoresistance 81,215–218. 
MiRNAs also play important roles in host-virus interactions. 
Recently our group showed that the reintroduction in an adenoviral 
backbone of miR-99b and miR-485, poorly expressed in PDAC, 
facilitated adenoviral oncolysis and improved the antitumor activity 
in mouse models 190. These results suggest that exploiting miRNA 
modulation can be a good strategy to ameliorate the therapeutic 
activity of oncolytic adenoviruses. However, very often in tumors 
miRNAs are highly upregulated. We hypothesized that the cellular 
deregulation triggered by excessive abundance of miRNAs might 
generate a context that would limit adenoviral replication in PDAC. 
In this thesis we have screened for potential miRNA candidates 
upregulated in PDAC and studied whether their normalization by 




4.2.1. Impact of miR-93 and miR-21 removal on adenoviral 
fitness 
In a recent miRNome study of PDAC samples, authors identified 31 
miRNAs significantly upregulated 219. Among those, miR-93 and 
miR-21 were within the group of the most upregulated miRNAs 
(table 4.2.1). We decided to evaluate the impact of miR-93 and 
miR-21 KO on adenoviral infections. 
 
For this, we generated by lentiviral transduction PANC-1 knockout 
cells for miR-93 (PANC-1-miR93 KO) and the corresponding 
control cells modified with a lentivirus containing no sgRNA 
(PANC-1-Ctrl). For the experiments, the pool of PANC-1-miR93 
KO cells and two individual clones were used (PANC-1-miR93 
KO/1, PANC-1-miR93 KO/2). To confirm the genetic knockout, we 
sequenced the miR-93 region and analyzed the expression of the 
miRNA (Appendix 8.1). As shown in fig 4.2.1 A, miR-93 was 






Cohort 2  
(q-PCR) 
microRNA FC vs Healhty FC vs Heahty FC vs Healthy 
miR-21-5p 11.18 7.84 10.20 
miR-93-5p 2.75 6.59 77.77 
Table 4.2.1. Expression levels of miR-21 and miR-93 in PDAC (data from 219). 
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individual clones (right graph). Next, we tested the cytotoxic 
response of the generated cells to adenoviral infection.  For this, 
cells were incubated with serial dilutions of Adwt adenovirus and 7 
days later viability was evaluated. The pool (Fig 4.2.1 left panel) 
and the different clones (Fig 4.2.1 right panel) of PANC-1-miR93 
KO cells showed a shift to the right in the dose-response curves, 
indicating that knockout cells were less sensitive to adenoviral 
oncolysis. Moreover, the ID50 values of miR93 KO cells were 
clearly superior to that of control cells, confirming its reduced 
sensitivity to viral killing (Fig 4.2.1 C). We assessed viral 
production 48h after adenoviral infection in PANC-1-miR93 KO 
and PANC-1-Ctrl cells and observed that viral progeny was 
diminished in all the PANC-1-miR93 KOs (Fig 4.2.1 D). Similar 
results were observed in MIA PaCa-2-miR93 KO cells, although the 
loss of sensitivity was less evident (Fig 4.2.2 B, C), in line with the 
observation that some residual miR-93 expression was present in 























































































































































































Figure 4.2.1 Effects of miR-93 KO in PANC-1 cells. A. Evaluation of miR-93 expression. 
Both pool KO (left) and clones KO/1-2 (right) were analyzed via qRT-PCR using TaqMan 
specific probes. Results are represented as FC with PANC-1-Ctrl, n=1. B. Viability Curves in 
miR93 KO (left) and miR93 KO/1-2 (right) after 7 days of treatment with Adwt. 5000 cells 
were seeded and the day after infected with serial dilutions of Ad5wt. Results were 
visualized 7 days later by MTT assay. C. ID50 values for PANC-1 Ctrl, miR93 KO (left) and 
miR93 KO/1-2. Data were extrapolated from viability curves by non-linear regression with 
the help of GraphPad Prism v5.0. D. Viral yield assay evaluating viral particles contained in 
total cell extracts 48 hours after infection. 50000 cells/well were seeded and the day after 
infected with 1 IFU/cell. 48 hours later cells were scraped and both cellular and 
supernatant were collected and analyzed for viral particles in the lysate. N>3, data are 






































































Figure 4.2.2 Effects of miR-93 KO in MIA PaCa-2 cells. A. Evaluation of miR-93 expression. 
MIA PaCa-2 miR93 KO were analyzed via qRT-PCR using TaqMan specific probes. Results 
are represented as FC with Mia PaCa-2-Ctrl, n=1. B. Viability Curves in MIA PaCa-2-miR93 
KO and MIA PaCa-2-Ctrl after 7 days of treatment with Adwt. 5000 cells were seeded and 
the day after infected with serial dilutions of Ad5wt. Results were visualized 7 days later 
by MTT assay. C. ID50 values for MIA PaCa-2-Ctrl and miR93 KO. Data were extrapolated 
from viability curves by non-linear regression with the help of GraphPad prism v5.0. N=3, 
data are represented as mean ± SEM. 
Altogether these results indicate that the cellular reshaping of miR-
93 create conditions that influence adenoviral activity. However, 
miR-93 downregulation seems to hinder viral replication. 
 
Next, we evaluated the effects of miR-21 modulation in adenoviral 
oncolysis. PANC-1-miR21 KO and PANC-1-Ctrl cells were 
generated as already described. Sequencing of the genomic region 
containing the miRNA and further qRT-PCR quantification in KO 
and control cells showed reduced or null miR-21 expression in the 
pull of KO cells and in the individual clones KO/1, KO/2, 
respectively (Fig 4.2.3 A, Pool: left panel, clones: right panel). The 
effects of Adwt cytotoxic activity on miR-21 KO PANC-1 cells 
were evaluated after 7 days of infection. MiR-21 removal 
negatively impacted adenoviral activity in PANC-1 KO/1 and 2, 
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displaying ID50 values 10 and 5-fold higher than control cells, 
respectively (Fig 4.2.3 B, C right panels). No differences in 
adenoviral ID50 were observed between PANC-1-Ctrl and PANC-
1-miR-21 KO pool, in line with the residual miRNA expression 
observed in this line (Fig 4.2.3 A, B, C left panels). Again, we did 
not observe any differences in adenoviral activity in MIA PaCa-2-
miR-21 KO (Fig 4.2.4 B, C), in line with the presence of some 
residual miR-21 levels (Fig 4.2.4 A). 























































































































































Figure 4.2.3 Effects of miR-21 KO in PANC-1 cells. A. Evaluation of miR-21 expression. 
Both pool (left) and clones (right) were analyzed via qRT-PCR using TaqMan specific 
probes. Results are represented as FC with PANC-1-Ctrl, n=1. B. Viability Curves in 
miR21KO pool (left) and miR21 KO/1-2 clones (right) after 7 days of treatment with Adwt. 
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5000 cells were seeded and the day after infected with serial dilutions of Ad5wt. Results 
were visualized 7 days later by MTT assay. C. ID50 values for PANC-1 Ctrl, miR21 KO (left) 
and miR1 KO/1-2 (right). Data were extrapolated from viability curves by non-linear 
regression with the help of GraphPad prism v5.0. N>3, data are represented as mean ± 
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Figure 4.2.4 Effects of miR-21 KO in MIA PaCa-2 cells. A. Evaluation of miR-21 expression. 
MIA PaCa-2-miR21 KO cells were analyzed via qRT-PCR using TaqMan specific probes. 
Results are represented as FC with Mia PaCa-2-Ctrl, n=1. B. Viability Curves in MIA PaCa-
2-miR21 KO and MIA PaCa-2-Ctrl after 7 days of treatment with Adwt. 5000 cells were 
seeded and the day after infected with serial dilutions of Ad5wt. Results were visualized 7 
days later by by MTT assay. C. ID50 values for MIA PaCa-2-Ctrl and miR21 KO. Data were 
extrapolated from viability curves by non-linear regression with the help of GraphPad 
prism v5.0. N=3, data are represented as mean ± SEM. 
 
4.2.2 Identification of new miRNA candidates 
Previous results evidenced that removal or downregulation of 
specific miRNAs was modulating adenoviral activity. To identify 
whether any of the most upregulated miRNAs in PDAC could 
interfere with adenoviral oncolysis we moved to a hypothesis-
driven strategy. 
We selected miRNAs upregulated in PDAC (a shortlist from the top 
30 from 219) that could regulate genes participating in two 
significant aspects of the virus-host interactions. From both aspects, 
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we selected relevant molecules and, by bioinformatics prediction, 
we identified the presence of candidate PDAC upregulated miRNAs 
target sites in their 3’ UTR. The two virus-host interactions 
considered are listed below: 
 
1) Upon adenoviral infection, cells undergo an immunogenic 
cell death (ICD), characterized by the emission of 
immunostimulatory damage-associated molecular patterns 
(DAMPs). DAMPs generation is mediated by the c-
GAS/STING pathway, the main sensor of dsDNA inside the 
cytosol, critical for activating interferon responses (reviewed 
in 220,221). Recent reports showed that miR-93 contributes to 
the establishment of an immunosuppressor tumor 
microenvironment by downregulating the expression of c-
GAS 222.  We observed impaired adenoviral cytotoxicity in 
cells KO for miR-93, which could be linked to augmented c-
GAS in the cell, easing adenoviral recognition. In this 
scenario, we hypothesized that miRNAs controlling 
inhibitors of the c-GAS/STING pathway could influence 
adenoviral infections, and that the inhibition of these 
miRNAs could improve oncolysis. Thus, we elaborated a 
shortlist of upregulated miRNAs in PDAC acting on target 
genes that are inhibitors of the c-GAS/STING pathway. 
However, miRNAs not having targets in this pathway were 
also considered for further analysis, with the condition that 




2) Adenoviral infections induce massive changes in host cells, 
some of whom consist in the enrichment of proteins aiding 
adenovirus during its replication process 223. Reyes and 
collaborators published a list of molecules whose amounts 
are strongly enriched along the course of an adenoviral 
infection, co-localizing with adenovirus during its 
replication inside the cells. We hypothesized that those 
proteins could be necessary for the adenoviral replication 
cycle and that upregulated miRNAs targeting these genes 
could interfere with viral activity. In consequence, we 
elaborated a shortlist of upregulated miRNAs in PDAC that 
target the expression of such genes. 
 
Considering common miRNAs fulfilling both criteria, or at least the 
second criteria targeting a minimum of 3 genes, we end up with a 
final list identifying 4 miRNA candidates: miR-222, miR-761, miR-
3714, miR-4713 (Fig 4.2.5, table 4.2.2, Appendix 7.2). 
 
miRNAs  










Figure 4.2.5 Schematic representation of the hypothesis-driven strategy for the 





4.2.3 Impact of miR-222, miR-761, miR-3714 and miR-4713 
on adenoviral activity 
We generated PANC-1 KO cell lines for all the identified miRNAs 
by CRISPR/Cas9, as previously described. Genomic alterations 
were validated by DNA sequencing and miRNA expression analysis 
(Fig 4.2.6, Appendix 7.1). Infection of the 4 PANC-1 KO cell lines 
with serial dilutions of Adwt demonstrated variability in the 
cytotoxic response. PANC-1-miR-761 KO and PANC-1-miR-4713 
KO showed right-shifted dose-response curves, resulting in Adwt 
increased ID50 (Fig 4.2.7 A upper panel, B), suggesting that 
downregulation of these miRNAs was interfering with viral activity.  







microRNA FC vs Healhty FC vs Heahty FC vs Healthy 
miR-761 2.00 2.19 3.13 
miR-3714 2.49 1.76 3.58 
miR-4713-5p 3.84 2.19 26.29 
miR-222-3p 
FC =2.70 224; 
FC = 32 225 
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Figure 4.2.6 miRNA expression in miRNA PANC-1 KO cells engineered by CRISPR/Cas9 
editing. miRNA expression was detected via qRT-PCR using specific TaqMan probes. 
Values are represented as 2^-ΔCt. N≥1, Data are represented as mean ± SEM.**p<0.001, 
Non Paramentric Mann Whitney U test.  
 
Interestingly, Adwt ID50 values were significantly reduced in 
PANC-1-miR-222 KO and PANC-1-miR-3714 KO cells compared 
to PANC-1-Ctrl, suggesting that downregulation of these miRNAs 
in PDAC tumors could facilitate viral activity (Fig 4.2.7 A lower 
panel, B). However, despite being highly abundant in PDAC 
tissues80, miR-3714 expression in PANC-1 cells was barely 
detectable. Thus, we discarded this miRNA and considered only 
miR-222 for further characterization. 
We generated MIA PaCa-2-miR222 KO cells (Fig 4.2.8 A), and 
similarly to PANC-1-miR-222 KO, we observed increased 
sensitivity to adenoviral infection in the miR222 KO cells, when 
compared to MIA PaCa-2-Ctrl cells. We detected a shift to the left 
in the Adwt dose-response curve (Fig 4.2.8 B) that resulted in 
decreased ID50 values (Fig 4.2.8 C).  Next, we assessed viral 
particles production in PANC-1 and MIA PaCa-2-miR222 KO cells 
by infecting with Adwt or with the tumor-selective virus 
AdNuPARmE1A (introduced in section 4.1). Quantification of viral 
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particles released 72 hours PI evidenced increased viral yield in the 
KOs cells, with the highest number of particles produced with Adwt 
infections (Fig 4.2.9). This result endorsed what was observed in 
the cytotoxic assay, and supported the idea of inhibiting miR-222 to 
























































































































































Figure 4.2.7 Cytotoxic effects of Adwt in miRNA PANC-1 KO cells. A. Viability Curves in 
PANC-1 miR761 KO, PANC-1 miR4713 KO, PANC-1 miR222 KO, and PANC-1 miR3714 KO 
after 7 days of treatment with Adwt. 5000 cells were seeded and the day after infected 
with serial dilutions of Ad5wt. Results were visualized 7 days later by MTT assay. B. ID50 
values for KO cell lines. Data were extrapolated from viability curves by non-linear 
regression with the help of GraphPad Prism v5.0. N>3, Data are represented as mean ± 
SEM. . **p<0.01, Non parametric Mann-Whitney U test. 
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Figure 4.2.8 Cytotoxic effects of Adwt in miR-222 KO in MIA PaCa-2 cells. A. miR-222 
expression in MIA PaCa-2-miR222 KO cells analyzed via qRT-PCR using specific TaqMan 
probes. Results are represented as FC with Mia PaCa-2-Ctrl, n>3. B. Viability Curves in MIA 
PaCa-2-miR222 KO and MIA PaCa-2-Ctrl after 7 days treatment of with Adwt. 5000 cells 
were seeded and the day after infected with serial doses of Ad5wt. Results were visualized 
7 days later by MTT assay. C. ID50 values for MIA PaCa-2-Ctrl and miR222 KO. Data were 
extrapolated from viability curves by non-linear regression with the help of GraphPad 
prism v5.0. N>3, Data are represented as mean ± SEM. **p<0.01 Non parametric Mann-
Whitney U test. 
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Figure 4.2.9 Viral release in PANC-1 and MIA PaCa-2 miR222 KOs. 50000 PANC-1 and 
150000 MIA PaCa-2 cells were seeded and the day after infected with 1 (PANC-1) or 2 
(MIAPaCA-2) IFU of either Ad5wt or AdNuPARmE1A.  Four hours later, cells were washed 
three times with PBS and 500 μL of fresh medium were added to each well. Seventy-two 
hours after infection supernatants were collected and the amount of viral particles 
present were detected by qRT-PCR with adenoviral hexon specific primers. **p<0.01, Non 




MiR-222 is located in the short arm of the X chromosome, as part 
of a cluster region in tandem with miR-221. Both miRNAs share the 
seed sequences, are separated only by 727 bp (Fig 4.2.10) and have 
common transcriptional regulators, leading to similar alteration 












Figure 4.2.10 Schematic representation of miR-222 location in the human genome. Both 
sequences of miRNAs in the cluster are represented. Seed sequence is highlighted in red 
and sequence identity in blue. TATA BS meaning TATA box binding site. 
 
Considering these features, we checked if the increased sensitivity 
to Adwt in PANC-1-miR222 KO was specific of miR-222 and 
independent of miR-221. Expression analysis of miR-221 content in 
PANC-1-miR222 KO showed similar miRNA levels in KO and 
PANC-1-Ctrl cells (Fig 4.2.11 A), witnessing miR-222 KO 
specificity. 
Since miR-221 and miR-222 shared the seed sequence, very likely 
the inhibition of miR-222 through a sponge construct would also 
downregulate miR-221 content. With this in mind, we explored the 
effects of inhibiting miR-221 in adenoviral activity. PANC-1-
miR221 KO cells were generated and confirmed by DNA 
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sequencing (Fig 4.2.11 B, Appendix 7.1). When cells were 
challenged with a battery of Adwt dilutions, the cytotoxic response 
was similar in miR221 KO and Ctrl cells (Fig 4.2.11 C), indicating 





































































Figure 4.2.11 Influence of miR221 KO on adenoviral oncolysis. A. Evaluation of miR-221 
expression in PANC-1 cells KO for miR-222. B. Validation of miR-221 KO in PANC-1 cells. 
After sgRNA insertion, double or triple peaks can be observed, meaning that genetic 
editing led to a mixture of rearrangement. C. Cytotoxicity assay in PANC-1-Ctrl and PANC-
1-miR221 KO. 5000 c/w were seeded and the day after infected with serial dilution of 
Adwt, ranging from 0 to 50 vp/cell. Results were visualized 7 days later by MTT assay. Left 
panel represents viability curves, right panel represents ID50 values. ID50 values were 
extrapolated from viability curves by non-linear regression with the help of GraphPad 
Prism v5.0. N=3, data are represented as mean ± SEM. 
4.2.4 Generation of miR-222 sponges 
Previous results supported the idea that miR-222 inhibition could 
facilitate adenoviral activity. One of the strategies developed to 
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inhibit miRNAs, are the so-called miRNA sponges. These are 
artificial constructs containing miRNAs binding sites, mimicking 
the target sequences on mRNAs and acting as miRNA decoy. 
Optimal miRNA sponges are generally constituted by 4-8 repeated 
tandem sequences with complementarity to the miRNA of interest, 
and separated by 4 nt. Introduction of a buldge in the nucleotides 
between the position 9-12 of the sponges demonstrated to increase 
the sequestration activity of the constructs226,227. 
We designed miRNA sponges as 4 tandem repeats of the sponge 
sequences separated by 4 random nucleotides spacers 175,194,227. The 
sponge sequence consisted of a 21 nucleotide sequence with a 
bulged region in nucleotides 9 to 12 flanked by 9 and 8 nucleotides 
of perfect complementarity to miR-222 226. Scramble control 
sequence and miR-222 sponge sequences were generated with the 
miRNA song software 228(Fig 4.2.12 A). 
Among the sequences predicted by the software to work as miR-222 
sponge sequence, we selected the one characterized by the lowest 
energy score, meaning high affinity, and the highest number of 
target sites, selecting 4 target sites/sponge sequence. The affinity 
prediction of this sequence was equivalent for both miR-221 and 
miR-222. Some miRNA off-targets with very low affinity were 
identified for miR-222 sponge (miR-370-3p, miR-3692-5p, miR-
4731-5p, miR-6861-5p, miR-147b, miR-1301-3p), however their 
expression is poor in PDAC, reducing their potential interference. 
For the selection of the Scramble sponge we used the same software 
and picked up a sequence that recognized individual target sites 
having high-energy score and that were not expressed in PDAC. 
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To evaluate the sponge’s activity, we cloned both constructs in the 
3’UTR of the eGFP gene controlled by a CMV promoter in the 
miRVec vector, generating miRVec-eGFP-miR222-S and miRVec-
eGFP-Scramble (Fig 4.2.12 B).  HEK-239T cells were transfected 
and eGFP expression was analyzed as a surrogate of sponge 
functionality. Visualization of eGFP 48h later under a fluorescence 
microscope revealed very low eGFP expression in miRVec-eGFP-
miR-222-S transfected cells, compared to cells receiving miRVec-
eGFP-Scramble (Fig 4.2.12 C). The result was confirmed in 
quantification analysis by flow cytometry (Fig 4.2.12 D). Low 
eGFP expression in miRVec-eGFP-miR-222-S transfected cells was 
also detected by eGFP mRNA quantification (Fig 4.2.12 E). The 
sponge effect resulted in a reduced expression of miR221 and 













































































































































Figure 4.2.12 Generation of miRVec plasmids containing Scramble sequence or sponges 
for miR-222 and their validation in HEK-293T cells. A. miRNAsong output for sponge 
sequence of Scramble and miR-222. Most scored on-targets are showed for both 
sequences. B. Schematic representation of miRVec vectors: miRVec-eGFP-miR-222-S (left) 
and miRvec-eGFP-Scramble (right). C. Visualization of eGFP expression by fluorescence 
microscope 48 hours after transfection of miRVec-eGFP-Scramble or miRVec-eGFP-miR-
222-S in HEK-293T cells. Scalebar 100μM. D. Quantification of eGFP intensity by flow 
cytometry 48h after plasmids transfections in HEK-293T cells. Left panel shows curves of 
fluorescence intensity, quantified in right panel (MFI). E. Quantification of eGFP expression 
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by qRT-PCR. Values are represented as fold change compared to miRVec-eGFP-Scramble. 
F. Quantification of miR-221 and miR-222 after miRNA sponges transfection. Values are 
represented as fold change compared to miRVec-eGFP-Scramble. N>4, data are 
represented as mean ± SEM. *p<0.05, **p<0.01, Non parametric Mann-Whitney U test. 
 
4.2.5 Generation of AdNuPAR-E-miR-222-S and evaluation 
of its potency in vitro and in vivo in PDAC models 
To evaluate the potential translational application of miR-222-
Sponges in adenoviral activity, we inserted miR-222 sponges in the 
oncolytic viral backbone AdNuPARmE1A. The whole fragment of 
CMV-eGFP-miR-222-S or the scramble counterparts were cloned 
in the region between E4 and R-ITR and viruses were generated 
190,205 (Fig 4.2.13). 
 
E1A L1 L2 L3-Hexon L4 L5 
MLP 




E1A L1 L2 L3-Hexon L4 L5 
MLP 







Figure 4.2.13 Schematic representation of AdNuPAR-E-miR-222-S and AdNuPAR-E-miR-
Scramble backbones. AdNuPARmE1A backbone was modified by the insertion of a 
construct comprising the CMV promoter with the eGFP and the sponge sequences, 




PANC-1 cells were infected with 10 IFU of both AdNuPAR-E-
miR-Scramble and AdNuPAR-E-miR-222-S and mRNA eGFP 
expression was quantified. AdNuPAR-E-miR-222-S infected cells 
displayed reduced eGFP expression in line with miR-222 sponge 
control (Fig 4.2.14 A). Moreover, confirming the sponge activity, 
we observed a reduction of 25% and 30% for miR-221 and miR-
222 expression, respectively, quantified at 24h, when compared to 










































































Figure 4.2.14 Functional validation of sponges in AdNuPAR-E-miR-222-S infected PANC-
1 cells. A. 150000 c/w were seeded in 12 MW plate, and the day after infected with 10 
IFU. Cells were collected at the indicated time points and eGFP expression was analyzed 
by qRT-PCR. Values are represented as fold change from the value at 6h for each virus. B. 
miRNAs quantification at 24 hours PI. MiR-221 and miR-222 were analyzed by qRT-PCR 
using TaqMan specific probes. Results are represented as FC with AdNuPAR-E-Scramble-
infected cells. N>3, data are represented as mean ± SEM. *p<0.05, Non parametric Mann-
Whitney U test. 
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Then, we challenged adenoviral potency of AdNuPAR-E-miR-222-
S and AdNuPAR-E-miR-Scramble in the PDAC cell lines PANC-1, 
MIA PaCa-2 and CP-15 Luc. Cells were treated with different viral 
dilutions and 7 days later viability was assessed by MTT assay. In 
all the cell lines, the viability curves for AdNuPAR-E-miR-222-S 
showed a shift to left, indicating increased sensitivity resulting in 
significantly lower ID50 with respect to Scramble-infected cells 
(Fig 4.2.15 A, B, C). Enhanced potency of AdNuPAR-E-miR-222-S 
was corroborated in a viral yield assay. We infected PANC-1, MIA 
PaCa-2 and CP-15 Luc with 1, 5 or 10 IFU respectively, and 72 h PI 
we collected cell supernatant containing viral particles.  
Quantification of AdNuPAR-E-miR-222-S virions released from 
PANC-1 and MIA PaCa-2 cells showed a 1.5-fold increase in viral 
production of AdNuPAR-E-miR-222-S compared to AdNuPAR-E-
Scramble. No significative differences were observed in CP15-Luc 




























































































































































Figure 4.2.15 Cytotoxicity effects of AdNuPAR-E-miR-222-S in PDAC cell lines. A, B, C. 
5000 cells of PANC-1, MIA PaCa-2 or CP15-Luc were seeded and the day after infected 
with serial doses of Ad5wt. Results were visualized 7 days later by MTT assay. Viability 
curves are represented by the panels on the left, ID50 values on the right. ID50 values 
were extrapolated from viability curves by non-linear regression with the help of 
GraphPad prism v5. N>4, data are represented as mean ± SEM. *p<0.05, Non parametric 






















































































































































Figure 4.2.16 Viral release from AdNuPAR-E-Scramble and AdNuPAR-E-miR-222-S-
infected PDAC cells. 50000 (PANC-1) or 100000 (MIA PaCa-2 and CP15-Luc) c/w were 
seeded and the day after infected with 1 (PANC-1), 5 (MIAPaCa-2) or 10 (CP15-Luc) IFU of 
both viruses. Four hours later, cells were washed three times with PBS and 500 μL of fresh 
medium were added to each well. Seventy-two hours after infection supernatants were 
collected and the amount of viral particles present were detected by qRT-PCR with 
adenoviral hexon specific primers. N =4, data are represented as mean ± SEM. *p<0.05, 
Non parametric Mann-Whitney U test. 
 
We also explored AdNuPAR-E-miR-222-S activity in PDAC 
derived organoids.  We selected three different patients and first we 
analyzed miR-222 expression, confirming high miR-222 levels in 
all of them (2^-∆Ct mean values: 35, 64 and 19 for IDIT4, IDIT5 and 
IDIT6, respectively). IDIT4, IDIT5 and IDIT6 PDOs were infected 
with 3 different doses of both OVs. Fluorescence intensity 
monitored during infections revealed no differences between viruses 
in terms of eGFP expression (Fig 4.2.17 A, B, C left panels). 
However, AdNuPAR-E-miR-222-S triggered highest cytotoxic 
effects than the Scramble OV, which was statistically significant at 
the 105 IFU/well doses in IDIT5 and IDT6 organoids (Fig 4.2.17 A, 


















































































































Figure 4.2.17 AdNuPAR-E-miR-222-S cytotoxicity in PDOs. A, B, C. IDIT4, 5 and 6 
organoids were infected with the indicated doses of viruses. Infection was monitored via 
eGFP detection in a fluorescence-inverted microscope 24, 48h and 5 days after infection. 
Cytotoxicity of the two viruses was measured on day 5 via an MTT assay. *p<0.05 Non 
parametric Mann-Whitney U test. N=5, data are represented as mean ± SEM. 
 
Altogether these results highlight that miR-222 sequestration by a 




To evaluate the therapeutic effects of the AdNuPAR-E-miR-222-S 
in vivo, athymic nude mice bearing PANC-1 tumors received 
intravenously administrations of either saline solution or 
AdNuPAR-E-Scramble or AdNuPAR-E-miR-222-S (51010 
vp/animal) and tumor growth was monitored twice a week.  Both 
oncolytic viruses controlled tumor progression. Interestingly, 
AdNuPAR-E-miR-222-S displayed increased potency and the 
inhibition of tumor growth was consistently higher than that exerted 
with the Scramble virus (Fig 4.18 A, B). 
These results highlight the therapeutic potential of arming 
adenoviruses with miR-222 sponges as a strategy to enhance viral 
































































Figure 4.2.18 In vivo antitumor effects of AdNuPAR-E-miR-222-S. Athymic nude mice 
were subcutaneously injected in both flanks with 2·106 c/flank of PANC-1 cells. When 
tumors reached 100mm3 animals were assigned to a group and treated either with Saline, 
AdNuPAR-E-Scramble or AdNuPAR-e-miR-222-S. A. Tumor growth follow-up. ***p<0.001 
Tukey’s Multiple comparison test. B. Tumor volumes at end point. The panel shows tumors 
mean volumes at the moment of sacrifice Number of tumors ≥8, data are represented as 
mean ± SEM. *p<0.01, ***p<0.001, Non parametric Mann-Whitney U test. 
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4.2.6 Mechanistic insights of miR-222 on adenoviral activity 
To elucidate the molecular mechanisms related to miR-222 
modulation and adenoviral boosting, we analyzed miR-222 target 
genes by the PANTHER-GO software, based on gene ontology 
principles. We considered processes with p-values lower than 10-5, 












161 84.05 1.66E-16 
Molecular 
Function 
RNA binding 94 36.95 1.30E-15 
Cellular 
Component 






203 124.9 1.40E-14 
Cellular 
Component 







289 228.3 5.29E-9 
Biological 
Process 
Cell cycle 75 39.39 1.69E-5 
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Table 4.2.2. Pathways of hsa-miR-222 targets with potential effects on adenoviral infection 
 
Using data extracted from Reyes and collaborators we selected 5 
genes with miR-222 target sites whose expression was 2-fold higher 
during an adenoviral infection (data available from 223): 
 
• BPTF (Bromodomain PHD Finger Transcription Factor) 
• DDX21 (Nucleolar RNA Helicase 2) 
• KPNA2 (Karyopherin Subunit Alpha 2) 
• NOLC1 (Nucleolar and coiled-body phosphoprotein 1) 
• TCOF1 (Tetracle Ribosome biogenesis factor 1). 
 
The interactions between miR-222 and the targets were 
bioinformatically predicted, but no experimental validation was 
performed, and no data were available from the literature. 
Nevertheless, we evaluated whether the depletion of miR-222 was 
associated with changes in any of the candidate target genes.  For 
this, we analyzed the expression of each gene in PANC-1 and MIA 
PaCa-2 miR-222 KO cells. Interestingly, we observed that all the 
targets genes displayed higher expression in miR-222 KO than in 
the Ctrl cells reaching values up to 2/3-fold higher, suggesting miR-
222 regulation (Fig 4.2.19 A). Next, we analyzed their expression in 
AdNuPAR-E-miR-222-infected PANC-1 cells and observed 





162 114.9 5.55E-5 
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infected cells when compared to Scramble infected cultures, 
suggesting that miR-222 sponge rescued the expression of the target 
genes. (Fig 4.2.19 B left graph). Similar studies in MIA PaCa-2 
cells showed a tendency to rescue the expression of the target genes, 
although no statistical significance was achieved (Fig 4.2.19 B right 
panel). 




















































































































































Figure 4.2.19 Identification of miR-222 molecular targets suspected to be implicated in 
oncolysis. A. RNA from PANC-1 and MIA PaCa-2 cells KO for hsa-miR-222 was analyzed via 
qRT-PCR to evaluate expression of indicated targets. Values are represented as FC 
compared to level of expression in Ctrl cells. B. Expression of identified targets in PANC-1 
cells infected with AdNuPAR-E-miR-222-S. Values are represented as FC comparing 
expression levels when infecting with AdNuPAR-E-Scramble. N>4, data are represented as 
mean ± SEM. *p<0.05, **p<0.01, Non parametric Mann-Whitney U test. 
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NOLC1 and TCOF1 are proteins related to ribosomal biogenesis 
with a role on protein production 229. BPTF is a chromatin 
remodeler, modulating gene transcriptional activity, and DDX21 
helps RNA loops resolution during transcription acting as a 
transcriptional co-activator 230,231. KPNA2 is a nuclear importin, 
favoring translocation of molecules to the nucleus 232. 
Considering the molecular functions of the described targets, we 
hypothesized that changes in their expression could impact the 
virus, probably at several levels. We speculated that the protein VII 
of the adenovirus, strongly associated with the viral DNA, could 
bind KPN2A through any of the three NLS motifs and, as a 
consequence, facilitate the nuclear import of viral DNA 233.  
KPN2A could also facilitate the nuclear translocation of other viral 
proteins needed for viral replication and or viral assembly.  Thus, 
we decided to analyze the intracellular viral DNA content at 
different times PI in PANC-1 cells infected either with AdNuPAR-
E-Scramble or AdNuPAR-E-miR-222 (2.5 IFU). Cells were 
harvested at 4, 8, 16, 20, 24 and 30h PI, and the intracellular viral 
DNA quantified.  We observed a tendency to increased viral DNA 
content in AdNuPAR-E-miR-222-S infected cultures at 24h and 30h 



























































Figure 4.2.20 Intracellular viral DNA content of cells infected with AdNuPAR-E-miR-222-
S and AdNuPAR-E-Scramble.  Monitoring of intracellular viral particles production during 
an infection with AdNuPAR-E-Scramble and AdNuPAR-E-miR-222-S. 50000 PANC-1 cells 
were seeded in 24MW plate. The day after, cells were infected with 2.5 IFU of both viruses 
and samples collected at the indicated time points. Cells were harvested and lysed to 
quantify viral genome by qRT-PCR using specific primers for adenoviral hexon. Results are 
represented as amount of viral genomes/cell, relativized to 4h values. Left panel 
represents the time course-follow up of the experiment, in right panel the last 3 time 
points are represented. *p<0.05, Non parametric Mann-Whitney U test. N=4, data are 
represented as mean ± SEM. 
 
Further studies are definitively needed to fully elucidate the miR-
222 molecular mechanisms impacting adenoviral fitness, and it is 
likely that several of the identified targets could mediate in different 













4.3 Effects of miRNA reactivation on oncolytic 
adenovirus activity. 
Modulation of miRNAs in malignancies demonstrated a critical role 
in the management of adenoviral potency (94,190; section 4.2). We 
wondered whether broadening the restoration of miRNA activity in 
cancer cells with the use of specific drugs could generate benefits 
on adenoviral oncolysis. THZ1, is a recently discovered drug with 
inhibitory effects on cyclin dependent kinase 7 (CDK7) and super 
enhancer driven genes, such as the MYC oncogene 234. Particularly, 
THZ1 has been described to markedly downregulate MYC 
expression, leading to massive reprogramming of MYC-
transcriptional regulation 234,235. Since MYC-activation has been 
related to the repression of miRNAs as a consequence of MYC-
binding to miRNA promoters, treatment with THZ1 could restore 
miRNAs expression. 
We decided to investigate whether miRNA-modulation by THZ1 
treatment could impact on adenoviral oncolysis and evaluate 
whether this strategy could have any advantage over miRNA-




4.3.1 THZ1 cytotoxicity in PDAC cells and its effects in 
modulating miRNA expression 
Treatment of PDAC in in vitro models with THZ1 has been poorly 
described 236. To evaluate its effects, we screened its cytotoxicity in 
a battery of PDAC cell lines: ASPC-1, CAPAN-1, MIA PaCa-2 and 
PANC-1. Cells were treated with serial dilutions of the drug, and 
the effects were visualized 3 days later by MTT assay.  Apart from 
ASPC-1, all the remaining cell lines showed relevant sensitivity to 
the drug, with ID50 at the micro (CaPan-1) and nanomolar (MIA 
PaCa-2 and PANC-1) order (Fig 4.3.1 A, B). 
 
 
Figure 4.3.1 Cytotoxic effects of THZ1 in PDAC cell lines. A. Viability Curves summarizing 
THZ1 effects at escalating doses 3 days after treatment. 5000 cells/well were seeded and 
the day after administered with serial dilution of THZ1. Results were visualized 72 hours 
later by MTT assay. B. ID50 values of the 4 different PDAC lines relative to THZ1 
administration. Data were extrapolated from viability curves by non-linear regression with 
the help of GraphPad prism v5.0. N=4, data are represented as mean ± SEM. *P<0.05 
Kruskal-Wallis test, with individual differences calculated via Dunn's Multiple Comparison 
Test. 
Next we analyzed the effects of THZ1 on MYC expression and 
consistent with previous data 235,237, we confirmed that THZ1 was 
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inhibiting MYC expression both in MIA PaCa-2 and PANC-1 cells 
( Fig 4.3.2 A). 
MYC binding sites have been identified in the promoter regions of 
at least 10 pri-miRNAs, correlating their widespread repression to 
MYC-promoted tumorigenesis 75. MiR-29c/b cluster’s promoter 
was one of the genomic regions to which MYC directly associated 
75. We performed a bioinformatic study to reveal other miRNAs 
potentially repressed by MYC. Analyzing miRNA promoters in 
Genecard, we identified binding sites for MYC in the regulatory 
region of miR-99b and miR-485, two miRNAs previously reported 





































































































































Figure 4.3.2 THZ1 effects over MYC and MYC-regulated miRNAs expression. A. MYC 
Expression after 6 hours of treatment with THZ1. 150000 cells/well were seeded in a 
12MW plate. The day after, medium was replaced with DMEM 10% containing 500nM 
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THZ1 or DMEM 10% alone (500μL/well). 6 hours later cells were harvested by 
trypsinization and cellular pellet used for RNA extraction. MYC expression was quantified 
in MOCK and THZ1 treated cells via qRT-PCR. B,C,D. miR-29c (B), miR-99b (C), miR-485 (D) 
expression after 6 hours of treatment with THZ1. Experiment was performed as in A. 
miRNAs quantification was performed by qRT-PCR using specific TaqMan probe assays. 
N≥4, data are represented as mean ± SEM. *p<0.05, **p<0.01, non-parametric Mann-
Whitney U test. 
Considering these findings, we studied whether THZ1 treatment 
had any impact on the expression of MYC-repressed miRNAs. We 
analyzed the cellular content of miR-29c, and the potential MYC 
targets miR-99b and miR-485 in THZ1-treated cells. Interestingly, 
we observed that miR-29c expression was restored both in MIA 
PaCa-2 and PANC-1 cells, whereas miR-485 was only rescued in 
MIA PaCa-2 cells. Increased expression of miR-99b upon treatment 
was also observed in both cell lines although it did not reach 
statistically significance (Fig 4.3.2 B, C, D). 
 
4.3.2 Cytotoxic effects of THZ1 and virotherapy combined 
treatment in PDAC cells 
Considering the rescue observed in oncolytic sensitizer miRNAs 
after THZ1 treatment (Fig 4.3.2 B, C, D), we hypothesized that the 
drug could have positive effects on adenoviral oncolysis. Thus, we 
explored the impact of a combination treatment of THZ1 and Adwt 
adenovirus. MIA PaCa-2 and PANC-1 cells were treated with a 
battery of THZ1 and Adwt doses, alone or in combination. 
Cytotoxic effects were visualized 3 days later, revealing the 
presence of a moderate synergism in MIA PaCa-2 cells (Table 
4.3.1). In these cells the combination treatment benefits Adwt and 
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THZ1 effects, resulting in ID50s significantly decreased when 
compared to unimodal treatment (Fig 4.3.3 A, B, C upper panel). A 
synergistic analysis by analyzing the combination index (CI) 
revealed that the combined treatment was synergistic. In contrast, 
PANC-1 cells did not benefit from the combination, showing 
individual or combined treatment with THZ1 analogous 
cytotoxicity effects (Fig 4.3.3 A, B, C lower panel). 
 
These results suggested that the synergistic effects of Adwt and 
THZ1 treatment observed in MIA PaCa-2 cells could be at least 
partially explained by the restoration of the MYC-repressed miR-
29c and miR-485. 





































































































































Figure 4.3.3 Cytotoxic effects of combination treatment of THZ1 and Adwt in PDAC cell 
lines. A. Viability Curves for two different PDAC cell lines. Upper panel represents MIA 
PaCa-2 cells, lower panel represents PANC-1. B. ID50 relative to THZ1, calculated for both 
cell lines when the drug is used alone or in combination with Ad5wt. Upper panel 
represents MIA PaCa-2, lower panel PANC-1 C. ID50 relative to Ad5wt, alone and in 
combination with THZ1. Upper panel represents MIA PaCa-2, lower panel PANC-1. N=4, 






CI2 Ad5wt CI+C2 
Synergy 
CI<0.8 
MIAPaCa-2 0,56 0,21 0,77 YES 
PANC-1 0,79 0,058 0,85 NO 
Table 4.3.1. Evaluation of synergism between THZ1 and Ad5wt. 
4.3.3 Comparative efficacy study of ICOVIR15-miR-29c with 
the combination regimen THZ1 and ICOVIR-15 in PDAC in 
vitro models 
Interestingly, in our group Maria Rovira performed an in vitro 
library screening of miRNA-engineered adenoviruses, challenged in 
PDAC cells. This study identified an adenovirus expressing miR-
29c being strongly enriched at the end of the bioselection strategy 
(data not published). 
This observation, together with the results showing restored 
expression of miR-29c after THZ1 treatment associated to improved 
adenoviral oncolysis, prompted us to investigate whether miR-29c 
could be a sensitizer of adenoviral oncolysis. To that end, we 
introduced the ICOVIR15-E-miR29c previously generated in the 
laboratory and ICOVIR15-E (same of section 4.1) was used a 
control (Fig 4.3.4 A). 
 
To test the OV functionality, we assessed miR-29c levels induced 
after ICOVIR15-E-miR-29c infection. Detection of miR-29c 24h PI 
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in PANC-1 cells revealed increased expression in a dose dependent 
manner (Fig 4.3.4 B). 
E1A-∆24 L1 L5 - RGD 
MLP 
L-ITR R-ITR 
L… eGFP E4 
E1A-mod-P 
E1A-∆24 L1 L5 - RGD 
MLP 
L-ITR R-ITR 



































































Figure 4.3.4 Evaluation of effects induced after miR-29c introduction in an oncolytic 
viral backbone. A. Schematic representation of ICOVIR15-E-miR29c and its parental 
backbone ICOVIR15-E. Upper backbone represents ICOVIR15-E-miR29c, in which the 
genetic sequence of pre-miR-29c under a CMV promoter was inserted in the region 
between E4 and R-ITR. Lower backbone represents ICOVIR15-E, introduced in section 4.1. 
B. Quantification of miR-29c expression in PANC-1 cell line after infection with ICOVIR15-
E-miR29c. 150.000 c/w were seeded in 12MW plate and the day after infected with the 
indicated doses of virus. Twenty-four hours later cells were harvested and miR-29c 
quantified by qRT-PCR using specific TaqMan probe assays. Values are represented as fold 
change values compared to MOCK condition. C. Infective Units in A549 cells coming from 
previously infected PANC-1 cell extract. 80.000 cells/well of PANC-1 were seeded in a 
24MW plate and infected with 25 IFU. 24, 48, 72 hours post-infection cells and 
supernatant were harvested and submitted to freeze and thaw cycles. Lysates were 
centrifuged and supernatant used to infect A549 cells, previously seeded at 200.000 
cells/well. 4 hours PI, A549 cells were washed three times with PBS and collected. Cellular 
Results 
173
pellets were collected to quantify viral particles inside the cells by qRT-PCR using 
adenoviral hexon specific primers. N≥3, data are represented as mean ± SEM. *p<0.05,  
non parametric Mann-Whitney U test. 
Next, we studied whether miR-29c expression was triggering any 
effects on viral production. For this, PANC-1 cells were infected 
with 25 IFU of ICOVIR15-E or ICOVIR-15-E-miR29c and total 
cell extracts were collected 24, 48 and 72h PI. To estimate the 
number of infective virions produced, all the extracts were used to 
re-infect naïve A549 cells. After 4 hours of incubation, A549 cells 
were harvested and the content of viral genomes was measured. 
Interestingly, ICOVIR15-E-miR29c adenovirus produced the 
double amount of viral particles when compared to the parental 
virus ICOVIR15-E at 72 hours PI (Fig 4.3.4 C). 
 
To further estimate the potency of ICOVIR15-E-miR29c, we 
designed an experiment that could illustrate the effects of 
consecutive infections, simulating what occurs during in vivo 
treatment. For this, PANC-1 cells were infected with a dose of 
either ICOVIR15-E or ICOVIR15-E-miR29c for 72 hours. Then, 
the supernatant was collected (I1) and used to re-infect naïve 
PANC-1 cells in 4 consecutive steps (I2, I3, I4) (represented in fig 
4.3.5 A). The staining of viable cells with a dye revealed 
accumulating cytotoxic effects of ICOVIR15-E-miR29c at every 
round of infection (Fig 4.3.5 B). For every step, we collected the 
cell supernatant and quantified the virions released from cells. After 
4 round of infections ICOVIR15-E-miR29c produced 30-fold more 
viral particles than ICOVIR15-E, calculated with respect of the viral 
particles released at I1 (Figure 4.3.5 C). 
Results 
174
These preliminary results confirm the role of miR-29c in boosting 
adenoviral oncolysis, although the mechanism supporting miR-29c 
adenoviral sensitization remains to be elucidated. 






































Figure 4.3.5. In vitro tumor-like model to further evaluate improved cytotoxicity of 
ICOVIR15-E-miR29c in comparison to the parental backbone. A. Schematic 
representation of the experiment. Fresh PANC-1 cells were infected with 1 IFU of both 
ICOVIR15-E and ICOVIR15-E-miR29c. 72 hours later supernatant was collected (I1). Part of 
I1 was used to further infect naïve PANC-1 cells and 200μL went for viral particle 
quantification. The same procedure was repeated up to I4. B. Results obtained from the 
experiment. Left panel show methylene blue staining performed at the end of every round 
of infection. Bars graph on the right shows quantification of viral particles in I4 compared 
to the ones in I1 for each of the two viruses. **p<0.01, Non parametric Mann Whitney U 
test. N≥3, data are represented as mean ± SEM. 
To evaluate whether the combined THZ1 and ICOVIR15-E 
treatment had any advantage with respect to the restoration of miR-
29c through ICOVIR15-E-miR-29c, we designed an experiment to 
compare the treatments. MIA PaCa-2 cells were exposed for 72 
hours to serial doses of THZ1, THZ1 + ICOVIR15-E, ICOVIR15-E 
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alone and ICOVIR15-E-miR-29c. Results were visualized 3 days 
later by MTT colorimetric assay. 
Both ICOVIR15-E-miR-29c and the THZ1 + ICOVIR15-E 
treatments improved the cytotoxicity of the parental ICOVIR15-E 
virus, although the combination of THZ1 plus ICOVIR15-E showed 
a tendency to higher cytotoxicity. This is not surprising since THZ1 
cytotoxicity may also respond to mechanisms independent of miR-
29c (Fig 4.3.6 A, B, C). 



















































































Figure 4.3.6. Evaluation of the cytotoxic effects exerted by ICOVIR15-E in combination 
with THZ1 compared to ICOVIR15-E-miR29c. A. Viability curves at increasing doses of 
drug and/or adenoviruses, showing cytotoxicity 72 hours after treatment. 5000 cells/well 
were seeded and the day after administered with serial dilution of THZ1 and/or indicated 
adenoviruses. Results were visualized 72 hours later by MTT assay. B, C. ID50 values 
relative to THZ1 administration (B) and adenovirus treatment (C). Data were extrapolated 
from viability curves by non-linear regression with the help of GraphPad prism v5.0. N =4, 
*p<0.05, Two tailed non parametric Mann Whitney U test. 
 
Current studies are insufficient to identify the optimal treatment and 
further evaluations are required, in particular in in vivo studies. 
However, the presence of a sensitizing miRNA in an oncolytic virus 
backbone has the advantage to self-boost its own expression and 
propagate the infection. In contrast, the combination treatment will 
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probably require continuous administration of the drug what could 








































PDAC is a neoplastic malignancy with a very dismal prognosis. The 
majority of patients already presents with unresectable carcinomas 
at the time of diagnosis. Available therapies contribute very little to 
increase patients’ survival, and surgical removal of the tumor 
remains the only available cure 7. 
 
Predictivity of 2D cell lines for the screening of therapies in PDAC 
is extremely poor. PDXs, in which freshly resected human tumors 
are implanted into immunosuppressed mice, recapitulate various 
elements of tumor biology and can be more predictive of tumor-
response to different treatments. The use of humanized PDX models 
in the presence of an intact human immune system is a very 
attractive strategy. However, all these models are complex and very 
time consuming for a broad preclinical testing of personalized 
treatments 95,105,238. The advent of organoids introduced a revolution 
in the study of cancers, permitting the analysis of patients-derived 
tissues and their response to treatments in a simpler model within a 
short time frame. Organoids maintain genomic and histopathologic 
similarities with their tumor of origin and several studies have 
shown its predictive value in terms of response to therapies. These 
characteristics are converting the organoids system in a valuable 
tool for the study of PDAC in vitro.  
 
Genetic heterogeneity of PDAC tumors makes this malignancy less 
suitable for treatment with conventional chemotherapies. Oncolytic 
virotherapy is showing promising results in clinical trials for the 
treatment of solid tumor. However, oncolytic adenoviruses as 
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monotherapy are not strong enough to completely ablate tumor 
mass, and they are often co-administered with chemotherapy or 
immune modulators 132,139.  
Improvement of oncolytic adenoviral potency is investigated by 
arming adenoviruses with transgenes to provide additional 
antitumor functions. More recently, our group showed that the 
introduction of miRNAs sensitizers of adenoviral oncolysis can also 
improve adenoviral antitumor efficacy in vivo in PDAC xenografts 
190.  
Considering the state of art, this thesis focused on the development 
of organoids technology to evaluate its utility for predicting patient-
specific responses to oncolytic adenoviruses in PDAC. Moreover, 
we explored different strategies to modulate the deregulated 
miRNome in PDAC to boost adenoviral oncolysis.  
 
 
5.1 Organoids as a predictive translational model 
to screen for personalized oncolytic adenoviral 
therapies 
In the current work, for the first time, we demonstrate the feasibility 





The capacity of adenoviruses to transduce organoids was already 
described in intestinal organoids, and in this study the authors 
showed with a replication-deficient adenovirus the expression of a 
transferred transgene up to 7 days 211. Our data supports the 
infectivity of organoids cultures in a different model, the PDAC 
organoids. With the use of a replication-competent adenovirus 
armed with eGFP, we were able to show that adenoviruses not only 
infect organoids, but also replicate and spread to adjacent cells, as 
we demonstrated by monitoring eGFP and viral production after 
several organoid passages. These results suggested the potential of 
PDAC organoids to study oncolytic virotherapy.  
 
One of the concerns of oncolytic adenoviral treatments is safety, 
mostly associated to limiting viral lysis to cancer cells, leaving 
healthy cells unharmed 240. The availability of non-transformed 
pancreatic tissues allowed us to demonstrate the utility of organoids 
in the study of adenoviral oncoselectivity. Low eGFP spread in the 
infected IDIS0 and IDIS6 over time suggested impaired viral 
replication of AdNuPARmE1A and ICOVIR15.  In the cytotoxicity 
studies some mortality was observed in healthy organoids when 
infected at at 105 pfu/well, likely due to the high presence of viral 
DNA and proteins inside the cells, generating cytotoxicity. In 
AdNuPARmE1A-infected normal organoids, some of the residual 
activity, observed with eGFP monitoring or with the cytoxicity 
effects, could also be linked to the expression of stemness and 
embrionary genes in the pancreatic progenitors giving rise to 
healthy organoids 210. Notch activation levels regulate pancreatic 
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development and the fate of pancreatic progenitors 241,242. It is 
highly probable that the active Notch signaling in these cells could 
stimulate AdNuPARmE1A, resulting in viral production. The fact 
that AdNuPARmE1A and ICOVIR15 activity in IDIS0 and IDIS6 
was diminished with respect to that of Adwt, was in line with the 
good safety profile of both viruses in immunocompetent mice 172,173. 
Of course, organoids screening will not substitute the toxicity 
studies in animals, but they might offer a first analysis to select for 
optimal candidates. 
 
One of the attractive interests of organoids is their potential 
predictivity in terms of therapeutic-response to treatments. Besides 
general sensitivity of the five studied PDAC organoids to 
adenoviral infections, we identified inter-patient diversity in the 
response to adenoviruses. The dissimilarity was aligned with the 
variable expression of genes encoding cellular factors that regulate 
viral activity. For instance, the Notch-sensitive uPAR-regulated 
oncolytic adenovirus AdNuPARmE1A was more effective in PDOs 
with upregulated Notch signaling pathway and uPAR 
transcriptional activity. Although we did not investigate further 
mechanisms behind ICOVIR15 activity, it is likely that the study of 
RB mutational status and its pathway could help in this direction. 
Moreover, ICOVIR15 has a fiber characterized by the insertion of 
an RGD motif, lacking in AdNuPARmE1A, permitting adenovirus 
entry both via integrin and CAR recognition. Considering the 
gradual loss of CAR observed in gastro-intestinal tumors165, 
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expression profiles of integrins and CAR in PDOs could help to 
explain the different grades of cytotoxicity observed.  
 
Our study also showed the utility of the well-defined model of 
PDOs to screen for armed oncolytic viruses that bear inserted 
transgenes that provide enhanced viral fitness.  The increased viral 
cytotoxicity of ICOVIR15-miR-99b and AdNuPAR-E-miR-222-S, 
with respect to their corresponding parental virus in different PDOs, 
supports this notion.  
 
However, the lack of stromal elements from the tumor 
microenvironment in the current organoids system limits the 
evaluation of novel oncolytic adenoviruses engineered with 
transgenes modulating TME to facilitate viral oncolysis.  The 
generation of more complex patient-derived models including 
CAFs, immune cells and organoids would expand the number of 
oncolytic adenoviruses to test, and thus enlarge the merits of this 
approach. 
Studies in a higher number of PDAC organoids and with an 
extended battery of viruses will increase the robustness of 
validating the organoids model for virotyping. In this study all the 
organoids were originated from patients undergoing surgical 
operation. In the future we aim to incorporate organoids from 
PDAC biopsies obtained by EUS-guide fine needle aspiration, as 
has been lately demonstrated to successfully generate organoids 
with high efficiency 115,243. This new paradigm would allow the 
therapeutic testing at the time of initial tumor diagnosis. 
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The possibility to establish a correlation between organoids-
sensitivity to oncolytic viruses with patient-responses to the 
treatment would be a step forward to position organoids as a clinical 
meaningful platform to predict patient-oncolytic response. 
Unfortunately, we could not perform this correlation since the 
studied viruses were not in clinical trials. The concordance between 
PDOs and patient-response to treatment has been nicely studied in a 
pharmacotyping study in PDOs, in which chemorefractory PDOs 
showed sensitivity to alternative therapeutic agents 115. 
 
The heterogeneous nature of cancer highlights the need of joining 
forces to develop combination therapies. Oncolytic viruses 
undergoing clinical trials showed better response rate when 
administered in combination regimens. The oncolytic adenoviruses 
LOAd703 244 and VCN-01 185 are currently administered with the 
combination of gemcitabine and nab-paclitaxel for the treatment of 
local and advanced PDAC 126,132. Our results validated the benefit 
of combining the standard chemotherapeutic regimen of 
gemcitabine + nab-Paclitaxel with oncolytic adenoviruses using the 
preclinical models of PDOs, recapitulating the synergism already 
observed in pancreatic cancer cell lines, 3D spheroids and PDXs 
172,245.  
 
The high metastatic ability of PDAC makes this malignancy to be 
already a systemic disease at the moment of diagnosis 246. Systemic 
administration of oncolytic adenoviruses can be a valuable strategy 
to reach both primary tumors and metastatic foci. However, 
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availability of metastases from PDAC patients is very limited, and 
generally obtained post mortem, restricting organoids generation to 
a very small number of patients 115. In this study, we addressed the 
study of oncolytic adenoviruses in metastasis-derived organoids 
with the generation of a model of metastasis induced by the 
orthotopic implantation of PDOs in mice. The formation of 
metastatic foci in diaphragm and liver, recapitulating common 
features of PDAC metastatic evolution, supported the model 247. 
Interestingly, the small metastases showed extreme propensity to 
form organoids, probably due to a strong amount of CSC in the 
invasive front of pancreatic tumors, populating metastasis in a high 
number and thus facilitating organoids generation 248.  
 
Our metastatic model evidenced a significant degree of aneuploidy 
in line with the genomic complexity and instability of PDAC 
tumors. Higher chromosomal alterations were present in the 
metastatic foci confirming a parallel evolution of chromosomal 
instability with the invasive phenotype 249,250. Interestingly, 
AdNuPARmE1A and ICOVIR15 tested in organoids derived from 
primary tumors and metastases showed similar responses and 
matched PDO sensitivity. However, this might not be the case for 
any oncolytic adenovirus, since preferential killing of high-
metastatic versus low metastatic cells have been reported for the 
replication-selective adenovirus vector OBP-401 251.  Ideally, to 
elucidate the optimal adenoviral activity in metastatic nodules, OA 
screening should be performed in PDOs derived from patient 
metastases. However, in the absence of metastatic biopsies, our 
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results provide an indication that OA screening in PDOs derived 
from primary tumors still reflects their activity in metastatic foci. 
 
All together, these results show that virotyping in organoids is 
feasible and inter-patient sensitivities can be identified, suggesting 
that PDOs may represent in the future an easy-to-handle platform to 
help on virotherapy-based, personalized treatment decisions. 
 
Personalized treatment 






















Figure 5.1 PDOs can help on virotherapy-based, personalized treatment decisions. T 




5.2 miRNAs impact adenoviral infection. 
Enhanced adenoviral oncolysis in PDAC can be 
achieved by inhibition of miR-222 content or 
reestablishment of miR-29c activity. 
MiRNAs were shown to play a role in the replication and 
propagation of viruses, including the activation of cellular antiviral 
responses or the promotion of viral infections. In fact, normal 
miRNA profiles are profoundly altered during an adenoviral 
infection in the context of normal cells. The adenovirus manipulates 
miRNAs to propagate, whereas the cells reshape miRNAs to 
counteract the viral infection, generating a complex crosstalk 
between miRNA pathways and viral infections 93,252. In PDAC cells 
there is an important deregulation of miRNA levels 253,254. This 
perturbed miRNome might either favor adenovirus infection or, on 
the contrary, interfere with viral propagation. Deciphering the role 
of miRNAs in adenovirus infection can contribute to the 
development of more efficacious oncolytic viral therapies. 
 
In this work, we broadened the concept of miRNAs in oncolysis, 
showing that miRNAs expression impacts adenoviral fitness in 
different directions. We explored the consequences provoked by the 
removal of upregulated miRNAs in PDAC or by the restoration of 
miRNAs whose expression is gradually lost in PDAC and observed 
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that their modulation could impact positively or negatively the 
adenoviral life cycle.  
 
With the generation of miRNA KOs, we evaluated the role of 
upregulated miRNAs in PDAC during adenoviral infections. In 
contrast, by the treatment with the transcriptional regulator THZ1, 
we rescued miRNAs poorly expressed in PDAC, what helped us to 
study their effects on oncolysis.  
We showed how miR-21 and miR-93 might have a key role for 
adenoviral propagation, since KOs of either miRNAs strongly 
interfered with adenoviral activity. Opposite effects were observed 
with miR-222 since its removal facilitated oncolysis. On the other 
hand, THZ1 treatment mediated the rescue of miR-99b and miR-
485 and confirmed their role as adenoviral sensitizers 190. 
Furthermore, this treatment facilitated the discovery of miR-29c as 
a novel miRNA that promotes adenoviral infection.  
 
The impaired adenoviral activity observed in miR-21 and miR-93 
KO cells could be, at least partially, related to the role of this 
miRNAs in repressing cells’ innate immune response. Both 
miRNAs act by repressing the interferon response. In the case of 
miR-93 it regulates the c-GAS/STING pathway, inhibiting the 
production of type I interferon, thus creating the conditions to 
facilitate viral propagation (Wu et al., 2017). MiR-21 targets 
MyD88 and IRAK1, two components of the Toll-like receptor 
signaling pathway that leads to type I interferon production. The 
downregulation of these two molecules by miR-21 has been shown 
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to repress type-I interferon and promote Hepatitis C viral infections 
255,256. 
Moreover, miR-21 exerts anti-apoptotic effects, inhibiting tumor-
suppressor molecules, and induce proliferation, actions probably 
required by the virus to complete its lytic cycle 257. 
 
Among the intricate networks of interactions that occur between the 
virus and the host cell upon an infection there are important changes 
in the miRNAs profile. Studies monitoring miRNA levels during an 
adenoviral infection evidenced miR-93 as s stable miRNA at early 
time points and upregulated at later phases of infections. This 
suggests that miR-93 would be important to complete viral 
infection, in line with our observation that its KO hampered 
adenoviral fitness 93. In the same study, the authors observed that 
miR-21 was highly downregulated only at 12h PI but no changes 
were observed at later time-points 24h and 36h PI, suggesting the 
need of fluctuating levels of this miRNA during the course of an 
infection, and that the presence of miR-21 particularly at late phases 
should be important to complete the adenoviral cycle. Thus, a 
scenario of steady-state KO of miR-21 will hamper viral fitness, 
whereas a minimal expression would be sufficient to maintain good 
viral activity This support the results obtained with miR-21 KO, in 
which residual levels of miR-21 in pools of PANC-1 and MIA 
PaCa-2 were sufficient to maintain normal adenoviral activity. On 
the contrary, adenoviral activity was strongly impaired in PANC-1 




Our data supports miR-222 as a miRNA that, at least in excess, can 
interfere with adenoviral replication. In fact, miR-222, KO both in 
PANC-1 and MIA PaCa-2 cells boosted adenoviral activity. 
Interestingly, the modulation of miR-222 content in the cells, by 
miR-222 sponges, after infection with AdNuPAR-E-miR222-S 
resulted in enhanced sensitization of adenoviral oncolysis.  
The finding that miR-222 inhibition can favor viral fitness is not 
new. Screening in prostate cancer cells showed that miR-222 
downregulation by miR-inhibitors favored adenoviral propagation 
94. Reduced levels of miR-222 were also observed upon Epstein Bar 
Virus (EBV) and Herpes Simplex Virus (HSV) infections, favoring 
their viral activity 258,259. Both EBV and HSV are also dsDNA 
viruses and it could be speculated that miR-222 acts over 
mechanisms commonly exploited by the three viruses. In fact, a 
recent work comparing proteomes associated with replicated DNA 
of three DNA viruses Ad5, HSV1 and Vaccinia Virus (VACV) 
provides information about host factors and cellular pathways 
potentially exploited by the viruses during infections (Reyes 2017). 
The same study identified enriched host factors that aid adenoviral 
replication during an adenoviral infection. Interestingly, through a 
bioinformatic analysis we identified that five of these genes: BPTF, 
DDX21, KPNA2, NOLC1 and TCOF1 contain in their 3’UTR miR-
222 target sites, indicating their susceptibility to be regulated by 
miR-222. If so, it can be speculated that in PDAC cells some of 
those genes would be maintained at low levels limiting viral 
infection, as a consequence of the high upregulation of miR-222. 
These would be in line with the increased oncolysis triggered by 
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AdNuPAR-E-miR222-S, and with the rescued expression of these 
genes when miR-222 was inhibited, either by KO or by miR-222 
sponges. 
The infection of AdNuPAR-E-miR222-S cultures resulted in higher 
amounts of mature virions released when compared to the Scramble 
virus, accompanied by increased viral DNA inside the infected 
cells. Since viral DNA replication does not seem to be a limiting 
factor during an infection, it is likely that the potential role of the 5 
identified molecules would facilitate AdNuPAR-E-miR222-S 
through the whole course of infection: by favoring both DNA 
synthesis, viral genes expression and viral protein translation. 
By analyzing the function of these proteins, we can speculate some 
comprehensive mechanisms to explain the improved AdNuPAR-E-
miR-222-S activity.  After virion disassembly, the naked viral DNA 
enters to the nucleus by the nuclear pore complex. Viral DNA 
arrives at the pore complex associated to protein VII. Through its 
three potent nuclear localization signals (NLS) protein VII binds 
multiple import proteins and translocate into the nucleus together 
with the viral DNA233. KPNA2 recognizes NLS on proteins, 
mediating their translocation to the nucleus 232.  Then, protein VII 
could bind KPNA2 and promote the efficient nuclear entry of the 
viral genome 233. Inside the nucleus, the expression of adenoviral 
genes happens gradually, starting with the early genes codifying for 
viral polymerase 260. However, viral gene transcription is still 
dependent on the host cell machinery to transcribe viral mRNAs 
and translate them to proteins 261. The cellular factors BPTF and 
DDX21 can help the adenovirus in the processes involving gene 
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expression. BPTF has chromatin remodeler activity and might re-
direct cell chromatin conformation in favor of a permissive 
adenoviral lytic cycle 260,262. DDX21 has a RNA/DNA helicase 
activity that might be helping in the transcription of the viral genes, 
resolving eventual conformational problems 263. Interestingly, 
DDX21 activity is necessary for expression of CMV genes, 
resolving R-loop formation during viral genes transcription 264, 
exerting a similar role in HIV gene expression 265. Finally, changes 
in the expression of TCOF1 and NOLC1 might also contribute to 
adenoviral infection. TCOF1 regulates ribosomal DNA 
transcription and processing, forming with NOLC1 a scaffold that 
recruits the ribosomal polymerase RNA POL I. Adenoviral 
infection of TCOF1 KO cells, impacted the localization of NOLC1 
away from sites of Ad replication, reduced viral genome 
accumulation and diminished viral yield, suggesting a relevant role 
for TCOF1 in viral infections 223.  To sum up, the re-expression of 
these factors, by miR-222 downregulation, either individually or in 
combination, can facilitate adenoviral replication. However, to fully 
understand the position of these proteins as mediators of adenoviral 

















Figure 5.2. Molecular mechanism proposed for the improved adenoviral activity 
observed in AdNuPAR-E-miR222-S infected PDAC cells. 
 
Apart from the cellular effects of AdNuPAR-E-miR222-S infection 
leading to superior viral yield and enhanced oncolysis, our data also 
showed a remarkable control of tumor progression when 
AdNuPAR-E-miR-222-S was administered in vivo in mice bearing 
tumors. Contributing to this antitumor effect there are probably the 
tumor suppressor effects of reducing miR-222 in the cells. The 
cluster miR-221/222 inhibits Cip/Kip family of cyclin dependent 
kinases (CDK) p27 and p57, resulting in uncontrolled proliferation 
193,225. Indeed, the good antitumoral activity observed with 
AdNuPAR-E-miR-222-S in vivo is probably the combination of 
enhanced oncolysis and the sequestration of the pro-tumorigenic 




Treatment with THZ1 suppressed MYC expression, in line with 
previous results 235. Interestingly, we could demonstrate that this 
treatment rescued the expression of miRNAs with binding sites in 
their promoter region for MYC transcription factor, the miR-99b, 
miR-485 and miR-29c.  Moreover, our data showed that THZ1 
treatment was synergistic with adenoviral lysis, suggesting 
cooperating mechanisms. Although there might be several 
possibilities, we considered that the re-expression of miRNAs 
facilitating oncolysis, such as miR-99b and miR-485 could 
contribute to these effects.  Interestingly, we could also demonstrate 
that miR-29c, when expressed from the virus, strongly boosted its 
fitness, achieving ICOVIR15-E-miR29c a viral yield 30 times 
higher than the parental ICOVIR15-E virus. 
 
The mechanisms behind miR-29c sensitization have not been 
explored yet. However, data from the literature helped to formulate 
some hypothesis. Several studies demonstrated that miR-29c 
protected the expression of the deubiquitination enzyme A20, 
essential for the homeostasis of the immune system and inhibiting 
NFKβ activity, mechanism observed to reduce the antiviral 
response in cells infected by influenza virus 87.Other studies have 
shown that miR-29c indirectly inactivates STAT1 signaling, 
required by the cells to react against the virus 266–268. 
Thus, similarly to what we observed with miR-93 and miR-21, 
miR-29c could act to counteract cell immune response to the virus, 
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emphasizing the idea that deregulation of miRNAs impacting on the 
host antiviral response can influence adenoviral oncolysis. 
 
The ICOVIR15-E- miR29c could be a very good candidate for in 
vivo administration, since, in addition to the effects favoring 
adenoviral oncolysis, many tumor suppressor activities have been 
associated to this miRNA, with emphasis on its anti-proliferative 
role. Moreover, miR-29c tightly regulates ECM remodeling factors, 
such as MMP2 and SPARC, impairing tumor progression and 
formation of metastasis 84,86,269. Considering the desmoplatic 
reaction taking place in PDAC tumors, the re-introduction of miR-
29c could help to reduce ECM production, thus facilitating viral 
spread in the tumor. 
 
Altogether, these results highlight the strong impact exerted by 
miRNAs on adenoviral infections. Different outcomes were 
observed depending on the miRNAs and on its targets, although in 
all the cases miRNA modulation impacted adenoviral fitness. 
Interestingly, we managed to boost adenoviral activity in PDAC 
cells with an altered miRNome by either inhibiting miR-222 or re-
expressing miR-29c. We propose two novel oncolytic adenoviruses 
with increased potency, the AdNuPAR-E-miR-222-S and 







ICOVIR15-E + THZ1 
 
Figure 5.3 Re-expression of miR-29c favor adenoviral oncolysis, and its introduction in 









































1) Organoids can be successfully generated from patients’ 
healthy pancreas and PDAC, and from primary tumors and 
metastases established in nude mice. 
 
2) Adenoviruses infect and propagate in patient-derived 
organoids (PDOs). 
 
3) PDOs can be used as a platform to identify patients’ 
sensitivity to OVs and evaluate their effects in combination 
with chemotherapy. 
 
4) Metastatic response to OV in mouse models, mirrored 
patients’ response in PDOs primary tumors, suggesting that 
sensitivity to OV in primary tumors can predict metastases 
response to OV treatment. 
 
5) Deregulation of miRNAs in PDAC has a strong impact on 
adenoviral oncolysis. 
 
6) miRNA-222 sponges engineered in the AdNuPAR-E-miR-
222-S downregulate miR-222 and improve adenoviral 
fitness, probably facilitating adenoviral DNA replication and 
viral particles production. 
 
7) AdNuPAR-E-miR-222-S triggers high cytotoxic effects in 




8) THZ1 treatment restores the expression of MYC-regulated 
miRNAs and synergizes with adenovirus activity to enhance 
cytotoxicity of PDAC cells. 
 
9) ICOVIR15-E-miR29c, by restoring miR-29c in PDAC cells, 
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Appendix 8.1. Sequencing and sequence alignment of 
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Appendix 8.2 Molecular targets of new miRNA candidates in c-
GAS/STING pathway or in mechanisms of adenoviral biology 
 
 
miRNA c-GAS/STING Pathway Adenoviral biology 
miR-222 
No targets among the 
genes analyzed 
ERCC4 – PRKAB2- 
PRKAA2 – BPTF – 
DDX21 – KPNA2 – 
NOLC1 – TCOF1 
miR-761 
TTLL4 - PRKAA2 - 
PRKAG2 – PRKAB1 
POLR1A – NAT10 – 
POU2F1 – MSH3 
miR-3714 
ENPP1 – ULK1 – ULK2 
– PRKAA2 
HEATR1 – NOLC1 – 
POLR1A – AP15 – 
NF1 - ATM 
miR-4713 
No targets among the 
genes analyzed 














Appendix 8.3 Analysis of miR-222 molecular targets. 
Genes target of miR-222 have been grouped for gene onthology and 
functions by the prediction software miRDB and PANTHER GO, which 
were used for the prediction. Only the top 25 - scored are listed. The 
pathways selected for further analysis have been highlighted. 
 
Pathway Expected hits P-value 
Nucleic Acid binding 84.05 1.99E-16 
RNA binding 36.95 1.30E-15 
Nucleus 153.9 2.59E-15 
Organic cycling compound 
binding 
124.9 1.40E-14 
Cytosol 111.6 1.37E-11 
Nuclear lumen 112.1 1.43E-11 




Intracellular organelle 261.3 2.38E-8 
Protein binding 247.8 5.03E-8 
Cadherin binding 7.27 1.52E-6 




Organelle organization 76.65 3.61E-6 
Molecular function 340 1.44E-5 
Cell cycle 39.39 1.69E-5 
Negative Regulation of gene 
expression 
39.94 1.69E-5 
Nitrogen Compound metabolic 
process 
205.7 2.06E-5 
Enzyme binding 45.13 2.18E-5 
Protein-containing complex 96.04 2.74E-5 
Metabolic process 253.3 3.10E-5 
Cell adhesion molecule binding 10.44 3.5E-5 
Cellular metabolic process 221.4 4.64E-5 
Gene expression 114.9 5.55E-5 







Appendix 8.4 Scientific Publications 
 
The results introduced in the section 4.1 of this thesis have been 
submitted for publication the journal EBioMedicine (currently 
under second review): 
 
• Patient-derived pancreatic tumor organoids identify 
therapeutic response to oncolytic adenoviruses. 
G. Raimondi, A. Mato-Berciano, S. Pascual-Sabater, M. 
Rovira-Rigau, M. Cuatrecasas, C. Fondevila, S. Sánchez-
Cabús, Harry Beghtel, S.F. Boj, H. Clevers, C. Fillat. 
 
Additional scientific publications deriving from collaborations 
established during this PhD thesis are detailed as follow: 
 
• Germline mutations in FAF1 are associated with hereditary 
colorectal cancer.  
L. Bonjoch, S. Franch-Expósito, P. Garre, J. Muñoz, C. 
Arnau-Collell, M. Díaz-Gay, A. Gratacós-Mulleras, G. 
Raimondi, C. Esteban-Jurado, Y. Soares de Lima, M. 
Cuatrecasas, T. Ocaña, A. Castells, C. Fillat, F. Balaguer, T. 
Caldés, L. Valle, S. Castellví-Bel. Gastroenterology 
(currently under second review). 
 
• miR-93 is related to poor prognosis in  pancreatic cancer 
and promotes tumor progression by modulating targets 
involved in microtubule dynamics. E. Vila-Navarro, M. 
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Rovira-Rigau, E. Fernandez-Castañer, G. Raimondi, M. 
Vila-Casadesus, J.J. Lozano, P. Soubeyran, J. Iovanna, A. 
Castells, C. Fillat, M. Gironella. Oncogenesis (currently 
under second revision). 
 
• Bioselection reveals mir-99b and miR-485 as enhancers of 
adenoviral oncolysis in pancreatic cancer.  
M. Rovira-Rigau, G. Raimondi, M.A. Marín, M. Gironella, 
R. Alemany, C. Fillat. Molecular Therapy, 2019. 
 
• Deciphering microRNA targets in pancreatic cancer using 
miRComb R package.  
M. Vila-Casadesús, E. Vila-Navarro, G. Raimondi, C. 
Fillat, A. Castells, J.J. Lozano, M. Gironella. Oncotarget, 
2018. 
 
• A NOTCH-sensitive uPAR-regulated oncolytic adenovirus 
effectively suppresses pancreatic tumor growth and triggers 
synergistic anticancer effects with gemcitabine and nab-
paclitaxel. 
Mato-Berciano, G. Raimondi, M.V. Maliandi, R. Alemany, 
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ABSTRACT
MiRNAs are small non-coding RNAs that post-transcriptionally regulate gene 
expression. They play important roles in cancer but little is known about the specific 
functions that each miRNA exerts in each t ype of cancer. More knowledge about their 
specific targets is needed to better understand the complexity of molecular networks 
taking part  in cancer. I n this study we report the miRNA-mRNA interactome occurring 
in pancreatic cancer by using a bioinformatic approach called miRComb, which 
combines t issue expression data with miRNA-target  prediction databases ( TargetScan, 
miRSVR and miRDB) . MiRNome and transcriptome of 12 human pancreatic tissues ( 9 
pancreatic ductal adenocarcinomas and 3 controls)  were analyzed by next-generat ion 
sequencing and m icroarray, respectively. Analysis confirm ed different ia l expression 
of both miRNAs and mRNAs in cancerous tissue versus control, and unveiled 17401 
relevant miRNA-mRNA interactions likely to occur in pancreat ic cancer. They were 
sorted according t o the degree of negative correlation between miRNA and mRNA 
expression. Results highlighted the importance of miR-148a and miR-21 interactions 
among others. Two components of the Notch signaling pathway, ADAM17 and 
EP300, were confirmed as miR-148a targets in MiaPaca-2 pancreatic cancer cells 
overexpressing miR-148a. Moreover, a CRI SPR-Cas9 cellular model was generated 
to knock-out the expression of m iR- 21  in PANC-1  cells. As expected, the expression 
of two miRComb miR-21 predict ed targets, PDCD4 and BTG2, was significant ly 
upregulated in these cells in com parison to control PANC- 1 .
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the 
fourth leading cause of cancer death in occidental countries 
and has the worst prognosis of all major malignancies 
with just a 6% five-year survival rate [1]. By the time of 
diagnosis, most patients present with locally advanced 
or metastatic disease that precludes curative resection 
and have a mean survival of less than 1 year [2, 3]. This 
fatal scenario is due, in part, to the high aggressiveness of 
the tumour and the lack of ef fective treatments. In order 
to overcome this dire problem, new and more ef ficient 
therapeutic targets are urgently needed. To achieve this 
goal is highly necessary to increase the knowledge about 
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ABSTRACT
Notch signaling pathw ay is an em bryonic program  that  becom es react ivated in 
pancreatic cancer and cont ributes to cancer stem cell ( CSC)  maint enance. We explored 
the concept of oncolytic adenoviral act ivity in response to Notch activation signaling, 
in the context of a chimeric promoter with uPAR regulatory sequences, as a strategy 
to drive its act ivity in neoplastic and CSC. We explored the advant ages of a chemo-
virotherapy approach based on synergistic combinat ions. Regulatory sequences 
recognized by the transcriptional factor CSL upstream a minimal uPAR promoter were 
engineered in adenoviral vectors and in the oncolytic adenovirus AdNuPARmE1A. Viral 
response to Notch signaling, and viral potency in cell lines and pancreatic cancer st em 
cells ( PCSC)  was tested. Preclinical toxicity and antitumor efficacy in xenografts and 
Patient-derived xenografts ( PDX)  mouse models was evaluated, as unimodal or in 
combination with gemcitabine+ nab-paclit axel. Mechanistic studies were conducted 
to explore the synergism  of com bined therapies.
We demonstrate that CSL-binding sit e optimized-engineered sequences respo nd 
to Notch activat ion in AdNuPARmLuc and AdNuPARmE1A. AdNuPARmE1A showed 
strong lytic effects in pancreat ic cancer cell lines and PCSC. AdNuPARmE1A displayed 
at tenuated act ivity in norm al t issues, but  robust  ant itum or effects in xenograft  and 
PDX m odels, leading to a reduced capacity of t reat ed tum ors to form  tum orspheres. 
Chem o- virotherapy t reatm ent enlarged therapeut ic response in both tum or m odels. 
Synergistic effects of the combination resulted from viral sensitization of apoptotic 
cell death t r iggered by chem otherapy.
I n sum m ary w e present a novel effect ive oncolyt ic adenovirus, AdNuPARm E1 A 
that reduces PCSC and presents synergistic effects wit h gemcitabine and nab-
paclitaxel, supporting further clinical developm ent .
INTRODUCTION
Reactivation of embryonic programs is a common 
characteristic of human malignancies. In pancreatic  cancer 
reactivation of Hedgehog, Wnt and Notch signaling 
pathways is well define d [1–4]. Notch signaling acts as a 
mediator of growth regulatory pathway and as a regulator 
of the balance between self-renewal and dif ferentiation 
in the developing pancreas [5]. In pancreatic cancer 
Notch activity has been shown to syner gize with K-ras, 
promoting PanIN initiation and progression, and to 
contribute to the maintenance of the pancreatic CSC 
population [6, 7]. The Notch pathway initiates when a 
cell expressing the appropriate ligand (jagged or delta) 
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